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An understanding of the characteristics and regulation of mammary stem cells 
(MaSCs) is needed to gain insight into normal gland development and carcinogenesis. 
Previous profiling of MaSCs relied upon immunophenotypic selection of enzymatically 
dispersed cells by flow cytometry. However, these approaches involved the selection of 
cells that are removed from their tissue location and cellular microenvironment. In this 
study, I have utilized an alternative approach called laser mic odissection, to excise 
putative MaSCs, based upon their ability to retain bromodeoxyuridine labeled DNA for 
an extended period, and control cells from their in situ locations in prepubertal bovine 
mammary cryosections. First, I established a protocol to immunostai putative MaSCs in 
tissue cryosections and isolate RNA of high quality. Next, I excis d putative MaSCs and 
control cells from immunostained cryosections using laser microdissect on. Global gene 
  
expression analysis by microarray provided evidence that MaSCs were located in the 
basal epithelium and progenitor cells located in suprabasal layers. A number of genes that 
were up-regulated in MaSCs and progenitor cells were identified and these are potential 
biomarkers. Analysis of the expression pattern of four genes (NR5A2, NUP153, HNF4A 
and FNDC3B) by immunohistochemistry showed that the protein expression profile was 
consistent with microarray data. Detailed immunohistochemical analyses of NR5A2, 
NUP153, HNF4A and FNDC3B in calf and cows (at various stages of lactation) revealed 
that their frequency and distribution were consistent with stem/progenit r cell 
characteristics. Finally, I attempted to manipulate stem/progenitor cells number using 
cultures of primary mammary epithelial cells. Expansion of stem/progenitor cell is a 
prerequisite for stem cell therapeutics and facilitates stem c ll research. The effect of 
xanthosine on bovine mammary epithelial cells (MEC) was evaluated. The result of this 
study showed that xanthosine treatment increased cell proliferation, promoted symmetric 
cell division and increased expression of telomerase and a novel stem cell arker 
(FNDC3B). Together, these studies identified novel, potential markers for MaSCs and 
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Chapter 1: Introduction 
 
Stem cells are nonspecialized cells that generate more differentiated cells within 
an organism and are capable of self-renewal throughout the lifespan of that organism. 
There are two broad categories of stem cells, namely embryonic stem cells and adult stem 
cells (also referred to as somatic stem cells). Embryonic stem cells ar  pluripotent, 
derived from the inner cell mass of the embryonic blastocyst, and differentiate to form all 
the tissues present in an organism. Adult stem cells can be multipotent, bipotent, or 
unipotent and are named based on the tissue or organ in which they reside and populate. 
Mammary stem cells (MaSCs) are the adult stem cells present within the mammary 
gland.  
An essential property of adult stem cells is their ability to undergo asymmetric 
and symmetric cell division.  Asymmetric stem cell division permits renewal of 
mammalian tissues while maintaining a constant tissue mass, through the production of 
one daughter stem cell and one more differentiated progenitor cell. Symmetric cell 
division facilitates exponential growth kinetics by yielding two daughter cells with 
equivalent stem cell capacity. Clonal expansion of mammalian adult stem cells is 
hindered by the predominance of asymmetric cell division in vivo. Xanthosine, a purine 
nucleoside, has been found to suppress asymmetric cell division kinetics and to promote 
exponential growth of adult stem cells in culture (Lee et al., 2003). 
The main goal of this dissertation research was to expand our knowledge of 
bovine mammary stem cells.  Specific aims  were to: (1) characterize the global gene 




potential protein biomarkers of MaSCs and progenitor cells and (3) confirm the utility of 
xanthosine for  increasing expansion of MaSCs using an in vitro model system.  
Characterization of MaSCs and progenitor cells are important steps towards 
understanding their regulation, expansion and proliferation. In dairy animals, appropriate 
regulation of the expansion and proliferation of MaSCs and progenitor cells can likely 
lead to increased milk production and lactation persistency, improved dry period
management, and enhanced repair of damaged tissue in the event of injury or infectin. 
Additionally, knowledge of MaSCs will enhance understanding of tissue homeostasis and 
facilitate investigations of mammary tumorigenesis.  Most research attempts to provide 
molecular profiles of MaSCs in mice, human and bovine species have utilized 
fluorescence-activated cell sorting or in vitro cultivation of cells from enzymatically 
dissociated tissues. However, the microenvironments encountered by MaSCs and 
progenitor cells are lost prior to analysis using these approaches. Data suggest that 
bromodeoxyuridine label retaining epithelial cells (LREC) represent mammary stem and 
progenitor cells. In this thesis research, these putative MaSCs and progenitor c lls 
(LREC) were excised from their in situ locations in tissue cryosections using laser 
microdissection, and their transcriptome profiles were evaluated using microarray 
analysis. The overall hypotheses of this research was that LREC are MaSCs and that 
comparison of the molecular profile of these cells with that of control cells can provide 
potential MaSCs biomarkers, which can then be evaluated by immunohistochemistry.  In 
liver hepatocyte culture, xanthosine appears to be a regulator of stem cell karyokinesis 
(Lee et al., 2003).  Similarly, intramammary infusion of xanthosine appears to lead to 




objective of my thesis research was to confirm that xanthosine enhances expansion of the 
MaSC population.  To this end, the ability of xanthosine to enhance cell proliferation by 
promoting symmetric division of MaSCs was investigated using cultures of primary 




Chapter 2: Literature review 
 
2.1  Bovine mammary gland structure and development 
The mammary gland is composed of two major tissue compartments, epithelium 
and stroma, which are separated by a basement membrane. The epithelium is a single 
tissue that is the primary component of the mammary ducts and alveoli. The stroma is the 
connective tissue matrix in which the ducts and alveoli develop, and includes many cell 
types such as fibroblasts, adipocytes, endothelial cells, mast cells, leukocytes and neural 
cells.  
In cattle, mammary ducts develop as highly arborescent structures called terminal 
ductal units (TDU), which resemble the terminal ductal lobular units (TDLU) of the 
human breast. TDU are the predominant histological feature of the mammary glands of 
prepubertal heifers.  Ductal elongation occurs by the coordinated growth, branching and 
extension of the TDU (Capuco et al. 2002).  The TDU of the prepubertal gland typically 
consists of 2-3 layers of epithelial cells and contains 5-10 ductular outgrowths arranged 
around a central epithelial cord (Figure 1). Layers of epithelial cells within the TDU may 
be designated as basal, embedded and lumenal (Figure 2). The basal layer of cells is 
adjacent to the basement membrane.  The lumenal layer of epithelium is located most 
apically from the basement membrane and cells of this layer are in contact with the ductal 
lumen. The embedded layer(s) of cells are sandwiched between the basal and lumenal
































Figure 1. Histological structure of the prepubertal bovine mammary gland. 
Mammary ducts develop as a highly arborescent structure called a terminal ductal unit 
(TDU) in which there are 5-10 separate ductal outgrowths, with 2-3 layers of epithelial 
cells in each ductal growth. Epithelial cells (EPI) of the elongating ducts are surrounded 
by intralobular loose connective tissue (ICT) and adipocytes (ADP). Adipocytes are not 












Figure 2. Epithelial cell arrangement in the prepubertal bovine mammary gland.  
Epithelial cells (EPI) are arranged in 2-3 distinct layers (basal and lumenal or basal, 
embedded and lumenal) around a clearly defined central lumen. However, immature 
ducts may not contain a clear lumen. Cells in the basal layer are hypothesized to contain 



















The microanatomy of the peripubertal bovine mammary gland differs from that of 
the murine mammary gland.  Adipose tissue is generally more abundant in the 
peripubertal murine mammary gland than it is in the bovine gland, in which the amount 
of adipose tissue varies between animals and by location (periphery vs. internal 
structures) of the TDU within the gland. In contrast to the bovine mammary gland, ducts 
of the murine gland grow with minimal branching. At the distal end of each murine 
mammary duct is a mass of proliferating cells within a bulbous structure called the 
terminal end- bud (TEB).  At the distal end of the TEB, a layer of proliferating cells 
called cap cells contact the surrounding stroma mainly composed of adipocytes (Williams 
and Daniel, 1983). There is little to no basement membrane present between the cap cells 
and the stroma. With the exception of the TEB, murine mammary ducts are typically 
composed of two layers of epithelium, a single basal layer of myoepithelium and an i ner 
layer of lumenal epithelium. Thus, a developing ruminant mammary gland is different 
from a murine mammary gland in terms of number of epithelial cell layers, absence of a 
definitive layer of myoepithelium, composition of the stroma, and the nature of ductal
elongation.  
During early postnatal life, the mammary gland grows at an impressive rate that is 
faster than that of the rest of the body (allometric growth); this rate declines after puberty 
when its rate of growth equals that of the rest of the body (isometric) (Sinha and Tucker, 
1969). During pregnancy, there is extensive proliferation of the mammary epithelium, 




under the influence of hormones of pregnancy and serve as the basic epithelial structure 
responsible for milk secretion. 
2.2  Existence of mammary stem cells and their identification 
In the mouse mammary gland, the first evidence for the existence of MaSCs cme 
from the work of DeOme and coworkers (DeOme et al, 1959), who demonstrated that 
small pieces of mammary tissue could expand and differentiate into a fully functional and 
reconstituted mammary gland when transplanted into the cleared fat pad (devoid of 
endogenous epithelium) of recipient mice. Other experiments have provided evidence for 
the existence of MaSCs. In the human breast, clonal expansion of cells from stem cells 
has been suggested to explain the presence of entire lobules and ducts with the sameX-
chromosome inactivation patterns (Tsai et al., 1996). In murine mammary gland, Kordon 
and Smith (1998) employed retroviral tagging to demonstrate the existence of multipotent 
MaSCs capable of regenerating a functional mammary gland.  
Based on biological and morphological features, investigators have identified 
putative MaSCs/progenitor cells in human, murine and bovine mammary glands. In mice, 
mammary epithelium stained with Blue-Azure II dye identified a distinct population of 
pale-staining mammary epithelial cells and hypothesized to represent MaSCs.  These pale 
cells were characterized by light staining of cytoplasm, presence of a large round nucleus, 
sparse cytoplasmic organelles and presence of tight junctions (Smith and Medina, 1988). 
The more darkly staining cells were considered more differentiated cells. These pale 
staining cells were refractory to differentiation signals, evidenced by their lack of casein 
immunostaining in mammary explants that were cultured in the presence of lactogenic 




shape, staining characteristics, organelle distribution, and nuclear morphology), Chepko 
and Smith developed a model for epithelial cell lineage in mouse and rat mammary 
glands (Chepko and Smith, 1997). Pale staining cells were subdivided into small light 
cells (SLC) and large light cells (LLC). The abundance of SLC was unaltered ac oss 
physiological developmental stages and these were concluded to be stem cells. These 
SLC (putative MaSCs) were characterized by morphological features includi g, small 
cell size, high nucleus to cytoplasm ratio, condensed chromosomes and unspecialized 
cytoplasmic organelles.  In human breast, a study of proliferating cells provided evidence 
for the existence of cells that are morphologically similar to the pale staining cells in 
mouse and rat mammary gland (Ferguson, 1985).  In mammary glands of calves, Ellis 
and Capuco found similar morphologically distinct populations of epithelial cells and 
categorized them as light, intermediate and dark cells based upon intensity of their 
cytoplasmic staining (Ellis and Capuco, 2002). The difference in nomenclature from that 
used to describe analogous cells in rodents reflected differences in parenchymal 
architecture, cellular morphology and location of cells within the multiple epithelial 
layers (basal, embedded and lumenal) of bovine mammary tissue. In prepubertal bovine 
mammary gland, the frequency of light staining cells were reported to be approximately 
10% of total mammary epithelial cells (Ellis and Capuco, 2002). 
Using a different approach, investigators have identified potential MaSCs based
on increased expression of membrane transporter proteins like breast cancer resistanc  
protein (BCRP) (Zhou et al., 2001). Increased expression of these ATP binding cassette 
transporters in cells effectively excludes dyes like rhodamine from their cytoplasm, 




population (SP), by flow cytometry.  In various studies, the SP fraction was demonstrated  
to possess an enriched capacity to regenerate a murine mammary gland upon 
transplantation (Welm et al., 2002; Alvi et al., 2003). The SP fraction averaged 0.2% to 
1% in human (Dontu et al., 2003), 0.5% to 3% in murine (Welm et al., 2002) and 0.5% in 
bovine (Motyl et al., 2011) mammary glands. A recent review discusses the importance 
of cell-cell interactions in dictating stem cell behavior and the value of in vivo 
transplantation studies in elucidating this aspect (Smith and Medina, 2008). 
A population of mammary epithelial cells enriched with MaSCs, based on 
expression of a combination of cell surface protein markers, was identified by use of a 
multiparameter cell sorting in mouse mammary gland (Shackleton et al., 2006; Stingl et 
al., 2006). The Shackleton and Stingl groups carried out independent research in which 
they enriched the MaSCs population by selecting cells for CD29 (β1-integrin) and/or 
CD49f (α6-integrin), and CD24 (heat stable antigen). This enrichment followed the 
exclusion of cells that were of endothelial and hematopoietic lineage, so-called Lin+ cells 
(CD31+, CD45+ and TER119+).  CD31, a platelet cell adhesion molecule, is expressed 
by endothelial cells.  CD45, a transmembrane tyrosine phosphatase, is expresd in 
hematopoietic cells with the exception of erythrocytes.  TER119 is exclusively expressed 
on cells in the erythrocyte lineage. Hence, CD31 was used as a marker to exclude 
endothelial cells and CD45 and TER119 were used as markers to exclude hematopoietic 
cells. In contrast, CD29 (β1-integrin) and CD49f (α6-integrin) are integrin adhesion 
proteins that are expressed by mammary epithelial cells and mediate interactions with 
stroma (Streuli, 2009).  Expression of β1-integrin along with α2-integrin has been used to 




as it has been used as a neuronal stem cell marker (Rietze et al., 2001) and as a marker of 
aggressive breast cancer (Kristiansen et al., 2003). Using the aforementioned surface 
markers, Lin- CD24+CD29high cells (Shackleton et al., 2006) and Lin- CD24+CD49high 
cells (Stingl et al., 2006) were shown to be enriched for MaSCs. These marker-sorted 
cells displayed increased capacity, compared to unsorted cells, to generate a functional 
mammary gland when transplanted into genetically identical mice.   
Another approach to characterize MaSCs has employed use of anchorage 
independent culture systems. Under these conditions, human, mouse and bovine 
mammary epithelial cells produce spherical colonies called “mammospheres” (Dontu et 
al., 2003; Morrison and Cutler, 2009; Riley et al., 2010).  Mammospheres are solid 
spheres of cells that are hypothesized to originate from a single MaSCs and appear to be 
enriched in stem cell/progenitor cell populations. This approach was based upon the use 
of neurospheres to study neural stem cells (Reynolds et al., 1992). Typically, 
mammospheres are 200-250 µm in diameter and contain approximately 150-300 cells 
(Dontu et al., 2003) in human cell suspension culture. In Matrigel, a single cell isolated 
from mammospheres was demonstrated to develop a complex functional structure, with 
ductal and alveolar cells (Dontu et al., 2003). Because the efficiency of human 
mammosphere formation was 0.4%, it was inferred that each mammosphere contains 
approximately one sphere-initiating cell (1/250 cells per mammosphere = 0.4%). In a 
recent study, mammosphere initiating cells were reported to be CD44highCD24low and 
their ability to form next generation mammospheres was exhausted after five generations 
(Dey et al., 2009). Thus mammosphere culture conditions will need further improvement 




community may be due to the inability to maintain mammosphere for a long time and the 
difficulty in separating cell aggregates and quantifying different types of cells within the 
mammosphere. 
Another approach to identify putative stem cells is based on the observation that 
many somatic stem cells retain label in their DNA for a prolonged period after initial 
labeling with tritiated thymidine or bromodeoxyuridine (BrdU) (Bickenbach, 1981; 
Potten et al., 1978).  In mice, intestinal crypt cells (Potten et al. 2002), muscle satellite 
cells (Conboy, et al., 2007) and putative mammary stem cells (Smith, 2005) retained the 
label. In bovine mammary gland, Capuco and coworkers (Capuco, 2007; Capuco et al., 
2009) proposed that these label-retaining epithelial cells (LREC) are putative stem cells. 
However, the phenomenon of label retention by adult stem cells does not appear to be a 
universal marker for these cells. In hematopoietic tissue, label retaining cells are not stem 
cells (Kiel et al., 2007). There are two schools of thought as to why stem cells may retain 
label; one school of thought says that MaSCs (not progenitor cells) are quiescent cells 
and the other school of thought says that MaSCs retain label due to asymmetric 
segregation of DNA strands (immortal strand hypothesis).  In mammary gland, label 
retaining epithelial cells were suggested to be the result of asymmetric seg egation of 
DNA stands (Smith, 2005; Capuco, 2007). A schematic representation of the immortal 
strand hypothesis to explain the retention of labeled DNA is depicted in Figure 3.  
2.3  Important signals in the mammary microenvironment 
Mammary epithelial cells are regulated by a complex network of communicatio  
between basement membrane, basal cells, embedded cells, lumenal cells, stromal cells, 




















Figure 3. Concept of retention of labeled DNA strands in stem cells by asymmetric 
division. Retention of label (e.g. BrdU) by putative adult stem cells may be due to 
selective segregation of labeled DNA strands during asymmetric division giving rise to 
cells that retain label (LRC) despite multiple cell divisions. Random segregation of DNA 
after initial labeling would cause dilution of label by ~50% in each division and the label 




1. Initial BrdU labeling  
2.    Subsequent mitotic divisions of 
BrdU labeled cells 













which are necessary for mammary gland development, a variety of other hormones and 
factors These structures, along with cell-cell communication and soluble factors, direct 
cellular activity through direct contact or paracrine signaling. The role of endocrine 
hormones as master coordinating regulators of mammary gland development is well 
established (Brisken and O'Malley, 2010). including physical factors such as cell-cell 
contact, cell-stoma interactions (Muschler and Streuli, 2010; Wiseman and Werb, 2002) 
and diffusible factors such as growth factors, growth suppressors and cytokines provide 
for regulation and development of the mammary gland. The number of regulators and 
interactions is enormous.  Only those deemed most relevant to this investigation of 
bovine mammary stem cells will be discussed. 
Local signals generated from the epithelial and stromal compartments of the gland 
have important roles in controlling development of the mammary gland. These signals
are growth factors, hormones and soluble factors that direct gland development 
(Silberstein, 2001). In a recent study, loss of adipocytes resulted in loss of TEB formation 
and fewer ductal branching in mouse mammary gland, suggesting an important role of 
adipocyte secreted factors in maintaining lobular architecture (Landskroner-Eiger et al., 
2010).  Adiponectin, a protein secreted by adipocytes has been demonstrated to influence 
proliferation and differentiation of mammary epithelial cells via estrogen receptor 
dependent and independent mechanisms (Rahal and Simmen, 2011). An additional 
stromal factor that is secreted by mammary macrophages, is colony stimulating factor -1 
(CSF1), which promotes mammary gland development during pregnancy (Pollard and 
Hennighausen, 1994) and plays a role in mammary stem cell function in mice (Gyorki et 




Numerous growth factors of the epidermal growth factor (EGF), insulin-like 
growth factor (IGF) and fibroblast growth factor (FGF) families regulate the proliferation 
of MaSCs in coordination with activated endocrine pathways (Hynes and Watson, 2010). 
The EGF family of growth factors, amphiregulin, and transforming growth factor-α 
(TGFα) are expressed during all phases of mammary gland development and a 
collaborative role of EGF and TGFα has been suggested in mammopoiesis and 
lactogenesis (Luetteke et al., 1999).  Amphiregulin serves as a mediator of estrogen 
signaling and is necessary for ductal development and the formation of TEB in murine 
mammary gland (Booth et al., 2010). FGF-mediated signaling is initiated by dimerization 
of the receptor tyrosine kinase upon ligand binding, which ultimately promotes cell 
growth, differentiation and functions that are important for normal development and 
tissue maintenance (Katoh and Katoh, 2006). Expression of  FGF1 protein and mRNA 
has been demonstrated during mammogenesis, lactation and involution stages suggesting 
the possible role of  FGF1 in changing morphological and functional properties of the 
bovine mammary gland (Sinowatz et al., 2006).  
Considerable evidence suggests that IGF1 has an important role in mediating 
ductal growth. IGF1-null mice have diminished ductal growth and TEB formation (Ruan 
and Kleinberg, 1999) and locally implanted IGF1 induced development of TEB and 
formation of alveolar structures (Ruan, et al., 1992).  Similarly, IGF1 and IGF-binding 
proteins are produced locally and regulate growth and development of the bovine 
mammary gland peripubertally (Akers et al., 2000).  
The nuclear receptors for ovarian steroids, estrogen receptor-alpha (ERα) and 




Proliferation of mammary epithelial cells is mediated in paracrine fashion, and these 
paracrine factors are derived from estrogen receptor (ER)-positive and progeste n  
receptor (PR)-positive cells of the epithelial or stromal compartments of the mammary 
gland (Capuco et al., 2002; Hovey and Aimo, 2010; Li and Capuco, 2008; Mallepell et 
al., 2006). Without these essential ER-positive and PR-positive cells in the 
microenvironment, the MaSCs and progenitor cells do not function properly. A recent 
report on ovariectomized mice reported a decreased number and diminished self-renewal 
capacity of MaSCs (Asselin-Labat et al., 2010). Loss of ERα in the mammary epithelium 
resulted in impaired ductal branching and elongation in estrogen receptor null pubertal 
mice (Feng, et al., 2007; Mallepell et al., 2006).  Current evidence indicates that MaSCs 
are ERα-negative and PR-negative in mouse (Asselin-Labat et al., 2006), human 
(Anderson and Clarke, 2004) and cow (Capuco et al., 2002). 
The Wnt signaling pathway is one of the most complex pathways in multicelllar 
organisms. This complexity is due to the large number of Wnt protein ligands (Wnt 1-16) 
and proteins that regulate the production of Wnt, the interactions with receptors on target 
cells and the resulting signaling cascade and physiological responses (Katoh and Katoh, 
2006). The canonical Wnt/β-catenin pathway is the best-characterized Wnt pathway. The 
signaling pathway includes Wnt ligands, cell surface fizzled receptor and β-catenin. Upon 
ligand binding, cytoplasmic protein disheveled is activated and destroys the second 
complex of proteins that includes glycogen synthase kinase-b (GSK-3b), axin, and 
adenomatous polyposis coli (APC).  Destruction of GSK3b/axin/APC spares destruction 
of β-catenin in the cytoplasm and promotes β-catenin translocation into the nucleus.  In 




transcription factor (LEF/TCF) family of transcription factors and activ tes Wnt target 
genes. Non-canonical Wnt pathways are independent of β1-catenin. Among various non-
canonical pathways, planar cell polarity (PCP) and Wnt/calcium are well known. In the 
mammary gland, various Wnt proteins (Wnt-2, Wnt-4, Wnt-5a, Wnt-5b, Wnt-6 and Wnt-
7b) appear to be synthesized in the epithelium and stroma based upon localization by in 
situ hybridization, and an essential role of Wnt proteins in breast development has been 
suggested (Weber-Hall, et al., 1994).  Wnt-5a ligand binds with Frizzed receptor and has 
been shown to regulate intercellular calcium level through a non-canonical Wnt/calcium 
pathway. In mouse, transcriptome analysis of mammary epithelial subpopulations 
revealed that expression of Wnt-4, Wnt-5a, and Wnt-7b was enriched in lumenal ERα 
positive cells (Kendrick et al., 2008). A role for Wnt-4 in progesterone-induced ductal
side-branching (Brisken et al., 2000) and Wnt-1 and Wnt-10b in alveolar development 
(Robinson, et al., 2000) have been suggested. Musashi-1 (MSI1), a neuroglial stem cell 
marker and proposed MaSCs marker, has been demonstrated to promote proliferation of 
progenitor cells (CD24 highCD29+) by activating the Wnt pathway in a mouse mammary 
epithelial cell line (Rezza et al., 2010; Wang et al., 2008). In a recent study, Wnt 
responsive cells were shown to be enriched for MaSCs and exogenous exposure of Wnt 
protein promoted clonal expansion of stem cells and the ability to generate a functional 
mammary gland for many generations in transplantation studies (Zeng and Nusse, 2010). 
The TFG-β pathway has a variety of roles that are pertinent to mammary 
development, including regulation of cell differentiation, cell growth and epith lial-
mesenchymal transition. The signaling pathway consists of ligands (TFG super family 




type 2 receptor dimer, which recruits and phosphorylates type 1 receptor dimer, forming 
a heterotetramer complex with ligand.  This results in phosphorylation of SMAD proteins 
(SMAD 1-9) in the cytoplasm, and dimers of SMAD proteins translocate into the nucleus 
and mediate transcription of target genes. In the mammary gland, TFG-β1 has been 
recognized as a negative regulator of mammary proliferation, regulator of mammary stem 
cells, promotor of apoptosis and inducer of epithelial-mesenchymal transition. In vivo 
studies using slow releasing implants of TGF-β1 in mouse mammary gland have 
demonstrated that growth of the mammary ductal network is reduced by TGF-β1 (Daniel, 
et al., 1989; Silberstein and Daniel, 1987). Other studies in mice have established a role 
for TGF-β1 in regulation of stem cells (Kordon et al., 1995) and induction of apoptosis 
during post-lactation involution of the mammary gland (Nguyen and Pollard, 2000). 
Recent studies demonstrated a role for TGF-β1 in epithelial-mesenchymal transition and 
maintenance of stem cell states in breast tissue (Fuxe et al., 2010; Scheel et al., 2011). 
The Notch signaling pathway is a highly conserved pathway in multicellular 
organisms. It regulates cell fate during development and determines differentiation of 
MaSCs and progenitor cells. The Notch pathway is mediated by juxtacrine signaling 
among adjacent cells, wherein ligand (Notch 1 to 4) presenting cells send the signal to 
receptor (Jagged family-JAG1,2 and Delta-like family-DLL1, 2 and 4) presenting cells.  
Ligand binding to the extracellular domain of the receptor induces proteolytic cleavage 
and release of the intracellular domain, which then translocates into the nucleus and binds 
with its partner of the CSL family (CBF1, Su, Lag-1) of transcription factors and 
mediates transcription of target genes like Myc and p21. In mammary gland, the Notch 




specification and progenitor cell expansion. In vitro, increased expression of Notch 
activating DSL peptides promoted stem cell self-renewal, which was evidenced by a 10-
fold increase in the number of mammospheres and increased ductal branching in 3D 
Matrigel upon differentiation; whereas blocking the Notch 4 signal blocked 
mammosphere formation  in human mammary epithelial cells (Dontu et al., 2004).  In 
vivo, knock-down of the canonical Notch effector gene CBF1 led to an increase in the 
stem cell (CD29hiCD24+) population and aberrant ductal morphogenesis, suggesting a 
role for Notch in restricting stem cell expansion (Bouras et al., 2008). Conversely, 
constitutive activation of the pathway led to an expansion of lumenal progenitor cells 
(CD29loCD24+CD61+) (Bouras et al., 2008).  
The Hedgehog (Hh) signaling pathway is a well-studied and conserved pathway 
in multicellular organisms. The Hh pathway is mediated in autocrine and paracrine 
fashion. The signaling pathway includes secreted glycoprotein ligands (SonicHh, Desert 
Hh, and Indian Hh), receptors (Patched 1 and 2, PTCH), an effector (Smoothened, SMO), 
and transcription factors (Gli 1 to 3). Paracrine mode of action requires another protein 
called ‘dispatched’. In absence of ligand, PTCH and SMO form a receptor complex and 
SMO activity remains inhibited. Upon ligand binding, the receptor complex dissociates 
and relieves SMO inhibition causing activation of transcription factors Gli 1, 2 (activator) 
and Gli 3 (repressor). The transcription factors translocate into the nucleus and regulate 
transcription of target genes (e.g. myc, cyclin D, cyclin E, components of the EGF 
pathway). Hh signaling components (Sonic Hh, PTCH1, Gli 1, 2) are highly expressed in 
human mammospheres and their expression is associated with an increase in 




important role of Hh signaling in mediating epithelial-stromal interaction has been 
demonstrated in mouse mammary gland by genetic analysis (Lewis et al., 2001). 
Likewise, activation of the Hh signaling pathway in vivo increases the number of 
mammary progenitor cells by increasing the mitotic activity of MaSCs (Li et al., 2008). 
This pathway regulates multiple phases of mammary gland development, including 
ductal development and lactation (Lewis and Veltmaat, 2004). These results suggestthat 
Hh signaling plays a role in the regulation and self-renewal of mammary progenit r cells. 
2.4  Manipulations of stem cells and uses 
Techniques to induce stem cell de-, re-, or transdifferentiation into tissue-specific 
cell lineages and to promote proliferation require an understanding of tissue
microenvironment wherein cell-to-cell and cell to environment interactions occur (Figure 
4).  Recent efforts have focused on the manipulation of adult stem cell differentiation 
using soluble factors, chemicals and hormones to produce a suitable physiological 
environment that mimics tissue microenvironment for the stem cells to renew, divide or 
differentiate depending upon the need. A role of progesterone in expansion of MaSCs has 
been demonstrated (Joshi et al., 2010). In a model experiment with mammary cance 
stem cells, cytotoxicity targeted towards differentiated cells enhanced proliferation of 
stem cells (Agur et al., 2010). Earlier I discussed various signaling pathways that regulate 
expansion and differentiation of MaSCs and progenitor cells. Manipulation of these 
signaling pathways could alter cell division kinetics to achieve expansion, propagation  
and finally differentiation of MaSC. Indeed, a role of the β-catenin pathway in regulation 






















Figure 4. Possible sources of tissue specific stem cells (e.g. MaSCs) and their 
proliferation. The dairy industry, MaSCs and their proliferative population of cells are 
likely to help in mammary gland development, increasing the persist ncy of lactation, 
and management of dry period. Knowledge of bovine embryonic stem cells (ESC) and 







study, protein p53 mediated the down-regulation of inosine-5’-monophosphate 
dehydrogenase (IMPDH) and promoted symmetric proliferation of hepatic stem cells 
(Sherley and Johnson, 1995). Exogenous treatment with xanthosine overcame this down 
regulation of IMPDH, increased guanine ribonucleoside concentration in the cell and 
promoted symmetric division of stem cells and expansion of the stem cell population 
(Lee et al., 2003) (Figure 5). Analogously, intra-mammary infusion of xanthosine in 
prepubertal heifers increased the abundance of BrdU label-retaining epithelial cells i.e. 
MaSCs (Capuco et al., 2009). Conversely, natural compounds such as curcumin and 
piperine, which have been used as cancer preventative agents, have been shown to 
abolish mammosphere formation and Wnt signaling (Kakarala et al., 2010).  Taken 
together, manipulation of MaSCs and progenitor cells may be a feasible means of 
promoting mammary growth, cell turnover and tissue regeneration, with the ultimate 
































Figure 5. Exogenous administration of xanthosine promotes symmetric cell division. 
Xanthosine enters the ribonucleoside biosynthesis pathway and forms xanthosine 
monophosphate (XMP), which promotes synthesis of guanosine monophosphate (GMP). 
Xanthosine circumvents the inosine monophosphate dehydrogenase (IMPDH) -mediated 
conversion of IMP to XMP, a rate limiting enzymatic step in XMP synthesis. This 























Chapter 3: Development of a protocol for rapid  5-bromo-2′-
deoxyuridine (BrdU) immunostaining 
 
Abstract 
A rapid method of immunostaining was developed for 5-bromo-2′-deoxyuridine 
(BrdU) -labeled cryosections of bovine mammary tissue while preserving RNA quality of 
the stained section. BrdU is a thymidine analog that is incorporated into the DNA of 
proliferating cells, and serves as a proliferation marker. Immunostaining of BrdU-labeled 
cells within a histological section requires heat, enzymatic or hemical-mediated antigen 
retrieval to open double stranded DNA, and exposure of the BrdU antigen. Although 
these established treatments permit staining, they preclude use of cells within the tissue 
section for further gene expression experiments. Additionally, long a tibody incubations 
and washing steps lead to extensive RNA degradation and elution. A protocol was 
developed for immunolocalization of BrdU-labeled cells in cryosections of bovine 
mammary tissue. The protocol does notrequire harsh DNA denaturation and it preserves 
RNA integrity and quantity. This protocol comprised an initial acetone:polyethylene 
glycol 300 [9:1 (vol/vol)] fixation (2 min) followed by staining with methyl green (0.5% 
aqueous; 2 min) to stabilize macromolecules, antigen retrieval with deionized formamide 
(70% in nuclease-free phosphate buffered saline; 4 min incubation), antibody incubation 
in the presence of RNase inhibitors (5 min), and minimal washing to facilitate recovery 
of RNA from cells from the stained sections. Applicability of this protocol to other 
nuclear antigens was evaluated by testing its suitability for staining estrogen receptor-




immunostaining and tissue morphology. The RNA quality of estrogen receptor α- and Ki-
67- stained sections was not evaluated. Quality of the isolated RNA from BrdU-stained 
sections was evaluated by micro-fluidic electrophoresis and its utility was confirmed 
using quantitative reverse transcription-PCR. Staining intensity obtained with this 
labeling protocol was similar to that obtained using conventional immunohistochemistry 
protocols. When coupled with laser microdissection and RNA or cDNA amplification, 
this immunostaining protocol will provide a means for future transcriptome analysis of 
BrdU-labeled cells within acomplex tissue. 
 






3.1  Background 
5-Bromo-2′-deoxyuridine (BrdU) has been used extensively to identify 
proliferating cells, study cell lineages, and identify putative stem clls (Capuco, 2007; 
Conboy et al., 2007; Plickert and Kroiher, 1988). A thymidine analog, BrdU is 
incorporated into DNA during the S-phase of the cell cycle and can be detected by 
standard immunohistochemical procedures. These procedures have limitations for 
subsequent transcriptome analysis of BrdU-labeled cells. Antibodies against BrdU can 
access only the antigen in single-stranded DNA (Gratzner, 1982), so staining procedures 
require DNA denaturation before antibody incubation. These procedures typically 
involve high heat (~100°C) in sodium citrate buffer or treatment with harsh chemicals 
(e.g., HCl; (Tang et al., 2007)). Such treatments affect RNA integrity and c  affect cell 
morphology. Establishing a procedure that could identify BrdU-labeled cells without 
damaging cellular RNA would facilitate subsequent in situ hybridization or isolat on of 
cells by laser microdissection for subsequent analysis of gene expression in these cells. In 
this study, a novel strategy was developed whereby good-quality RNA was extr ct d 
from BrdU-immunostained cryosections of bovine mammary gland. Our future 
application will be to use this protocol to identify putative bovine mammary stem cells 
for laser excision and subsequent downstream analyses. Putative bovine mammary ste  
cells can be identified on the basis of their ability to retain BrdU for extended periods of 
time after initial labeling (Capuco, 2007), because of selective segregation of parental 





3.2  Materials and Methods 
Tissues were obtained from an experiment that was performed in compliance with 
the Beltsville Agricultural Research Center’s Animal Care and Use Committee. Five 
Holstein heifers (3 mo of age) were injected with BrdU (Sigma-Aldrich Co., St. Louis, 
MO) intravenously once daily for 5 d as described previously (Capuco, 2007). Forty-five 
d after the last BrdU injection, heifers were humanely killed at the Beltsville Agricultural 
Research Center abattoir. Animals were stunned with a captive bolt pistol and 
exsanguinated, udders were removed and mammary tissue was collected from 
parenchymal regions within rear mammary glands (i.e., quarters) of the udder. Individual 
tissue samples (5 × 5 × 5 mm3) were immediately embedded in optimal cutting 
temperature (OCT) compound (Sakura, Torrance, CA), frozen in liquid nitrogen vapor, 
transported on dry ice, and stored at −80°C. Serial sections (8 µm thick) were thaw-
mounted on glass slides, UV-irradiated previously to destroy potential nuclease activity, 
and stored at −80°C until the time of microdissection (~2 wk maximum storage). These
glass slides were covered with a membrane (2 µm thick) of polyethylene naphthalate 
(PEN slides, Leica AS, Wetzlar, Germany). Testing and evaluation of vari us protocols 
was performed as a linear process.  Different parameters were tested and chained together 
to evolve the final and effective protocol.  If a parameter was found to be ineffective, it 
was not repeated.  However, successful tests were repeated and used as the basis for 
chaining additional steps in the protocol.  The final protocol was tested repeatedly and 




Tissue cryosections were fixed with a variety of noncrosslinking fixatives 
including alcohols and acetone. Crosslinking fixatives, such as formalin, severely impair 
the ability to extract quality RNA from tissue (Lewis et al., 2001) and were not used. A 
list of fixatives evaluated is provided in Table 1. Sections were treated with these 
fixatives to optimize morphology and BrdU staining while maintaining good RNA 
quality. Sections fixed in acetone: polyethylene glycol (ACEPEG) 300 [9:1 (vol/vol); 
Sigma-Aldrich], our newly developed fixative, at -20°C for 2 min possessed good 
morphology and consistent immunostaining and yielded RNA of highest quality. This 
fixative was prepared on the day of use.  Preliminary experiments with acetone alone as a 
fixative yielded acceptable tissue morphology. These results were much iproved with 
the addition of polyethylene glycol (PEG) 300 to acetone. This fixative was derive from 
the composition of universal molecular fixative (UMFIX) (Vincek et al., 2003), which is 
a combination of methanol and PEG [9:1 (vol/vol)]. Further, PEG is a component of OCT 
compound, so it was thought that adding it to the fixative would aid in the preservation of 
morphology by providing a more gradual transition from OCT compound to acetone 
fixative.  
Different methods were evaluated for their ability to retain the quality of RNA 
extracted from the tissue sections. These methods included 1) the use of methyl gre n to 
precipitate RNA in aqueous solution without affecting immunostaining and RNA 
isolation procedures; 2) use of RNase inhibitors in antibody incubation buffer (RNasin 
Plus RNase inhibitor, Promega, Madison, WI); and 3) the use of small volumes of wash 




Table 1.  Fixatives and antigen retrieval agents, their modes of action, and effects on 
morphology, BrdU staining, and RNA quality in bovine mammary cryosections. 
 
 
1 Companion slides were processed and used to quality of BrdU staining and the quality of RNA obtained 
from the stained slides. RNA quality is expressed as the RNA integrity number (RIN), The RIN is 
automatically generated from the electrophoretic data obtained by the microfluidic analysis of RNA with 
the Agilent Bioanalyzer (Agilent Technologies, Wilmington, DE). The algorithm used for calculating the
RIN uses several features commonly used for assessing RNA quality, e.g. area under rRNA bands, ratio of 
18S and 28S rRNA peaks, height of the lower marker peak (Schroeder et al., 2006). RIN is expressed on a 
scale of 1-10. Lower RIN corresponds to degraded RNA and high RIN corresponds to high quality RNA. 
2 Quality graded as bad (–), poor (+), moderate (+ +), or good (+ + +). RNA integrity numbers 
corresponded as follows: – = RIN 1 to 3; + = RIN 3 to 4; + + = RIN 4 to 6;  + + + = RIN 6 to 8. 
3 Methanol + chloroform + glacial acetic acid [6:3:1 (vol/vol)]. 
4 Universal molecular fixative: a mixture of methanol and polyethylene glycol 300 [9:1 (vol/vol)]. 
5 A mixture of acetone and polyethylene glycol 300 [9:1 (vol/vol)]. 
 
 
Item Mode of action Morphology2 Staining RNA 
quality1 
Fixatives 
Methacorn3  Nonprecipitating + 
precipitating 
+ + + + - 
75% ethanol  Precipitating + + + + 
Acetone  Precipitating + + + + + + 
UMFIX 4  Precipitating + + + + + + + 
ACEPEG5  Precipitating + + + + + + + + + 
Antigen retrieval agents 
2 N HCl  Denatures DNA + + + + + - 
DNase1  Cleaves DNA + + + - - 
0.01 N NaOH  Denaturing and 
hydrolysis 
Destroyed - - 
U.V. irradiation Crosslinks double 
stranded DNA 
     Destroyed - - 
Formamide 
100% 
Lowers DNA melting 
temperature 
+ + + - 
Formamide 10% Lowers DNA melting 
temperature 
Destroyed - - 
Formamide 70% Lowers DNA melting 
temperature 




The effects of different antigen retrieval agents on immunostaining, tissue 
morphology, and RNA quality were evaluated. Most treatments were time consuming 
and yielded unsuitable morphology and unacceptable RNA quality (Table 1). 
Denaturation of DNA with 70% deionized formamide (Amresco, Solon, OH) in nuclease 
free PBS (nfPBS) for 4 min at 60°C maintained tissue morphology and facilitated 
immunostaining. This approach was an application of results obtained by Mayer et al. 
(2006), who successfully used deionized formamide for BrdU antigen retrieval in an in 
situ hybridization experiment. Formamide lowers the melting temperature of DNA by 
destabilizing its helical structure (Blake and Delcourt, 1996). 
The final protocol developed to rapidly detect BrdU-labeled cells and retain RNA 
quality is described below.  In all cases, slides were processed singly in RNase-free 
LockMailer microscope slide jars (Ted Pella Inc., Redding, CA). The optimized short 
method for immunostaining started with ACEPEG fixation at -20°C for 2 min followed 
by air drying for 1 min. Air drying was essential for best fixation and adherenc  of the 
tissue to the slide during subsequent steps. Drying of the slide was followed by 
incubation of  the section with 200 µL of 0.5% aqueous methyl green (Vector 
Laboratories Inc., Burlingame, CA) for 2 min at RT. After a brief (10 s) wash with 
nfPBS, the slide was incubated with 400 µL of prewarmed 70% deionized formamide at 
60°C for 4 min, on a metal block placed in a dry bath. Immediately after formamide 
treatment (antigen retrieval), the section was washed twice with ice-ch ll d antibody 
dilution buffer at 4°C using 200 µL of buffer for 30 s/wash.. Antibody dilution buffer 
consisted of nfPBS with 1% normal goat serum and 0.1% Triton X-100 (Sigma-Aldrich) 




the tissue. Washing the section with ice chilled buffer immediately after formamide 
treatment was essential to prevent re-annealing of denatured DNA. One-step 
immunostaining was performed using mouse monoclonal anti-BrdU antibody conjugated 
to Alexa 488 fluorophore (Clone PRB-1, Invitrogen, Carlsbad, CA) at 1:10 dilution in 
antibody dilution buffer for 5 min at RT in the dark. The section was then briefly washed 
with 200 µL of nfPBS (twice for 10 s each), counterstained with 100 µL of propidium 
iodide (2.5 µg/µL in nfPBS) for 20 s, and rinsed in 200 µL of nuclease-free water twice 
for 10 s each (counter staining with propidium iodide permitted visualization of all nuclei 
in the tissue section). The slide was dehydrated in freshly prepared ascen ing 
concentrations of ethanol: 70% for 10 s, 95% for 10 s, 100% for 10 s and 100% for 1 
min. The slide was air dried at RT in the dark for 5 min before sample acquisition and 
total RNA isolation.  
To assess RNA quality, whole immunostained tissue sections were lysed with the 
manufacturer’s lysis buffer and total RNA was isolated using an RNeasy micro kit 
according to the protocol for the purification of total RNA from microdissected 
cryosections (Qiagen, Valencia, CA). The optional on-column DNase digestion was 
performed as described by manufacturer (Qiagen). Quality and quantity of RNA were 
evaluated using a Bioanalyzer (Agilent Technologies, Wilmington, DE), and a 
comparison was made between the RNA isolated from immunostained versus unstained 
cryosections. The RNA integrity number (RIN) generated by analysis (Agilent 
Bioanalyzer) of the RNA electropherogram provided an objective measure of RNA 




Applicability of the protocol to other nuclear antigens (not specifically DNA) was
tested using indirect immunolabeling and bright field microscopy in the presence and 
absence of 70% formamide, our antigen retrieval agent. Test antibodies were estrog n 
receptor α (ERα) and Ki-67. Because of the preliminary nature of this test, an indirect (2-
step) immunostaining protocol was used and RNA quality was not evaluated after 
staining. For ERα labeling, slides were incubated with mouse ERα antibody (Clone c-
311, Santa Cruz Biotechnology, Santa Cruz, CA) used at a concentration of 0.01 µg/µL in 
antibody dilution buffer for 10 min at RT. Similarly, for Ki-67 labeling, slides were 
incubated with prediluted mouse Ki-67 antibody (Clone MIB-1,Invitrogen) for 10 min at 
RT. Slides were then incubated with horseradish peroxidase conjugated broad spectrum 
secondary antibody (SuperPicture HRP Polymer Conjugate Broad Spectrum, Invitrogen) 
after brief washings with PBS. Positively labeled cells were visualized with the 3,3’-
diaminobenzidine (DAB) reaction (2-3 min incubation) and then rinsed in water. Slides
were counterstained with hematoxylin for 30 s and washed briefly with waterand then 
PBS (Counter staining with hematoxylin permitted the visualization of all cells in the 
tissue section; immunostained nuclei appear brown and non-labeled nuclei appear blue). 
Finally, slides were dehydrated in ascending grades of ethanol and viewed by bright field 
microscopy. 
3.3  Results and Discussion 
Identification and isolation of immunophenotypically different cells from 
morphologically indistinguishable cell populations and subsequent characteriz tion of 
their transcriptome profiles requires successful immunostaining and isolation of good 




optimized to ensure acceptable tissue morphology, consistent BrdU staining, and good 
RNA quality. Because the immediate application of this protocol was for isolation of 
BrdU-labeled cells using laser microdissection and subsequent transcriptome analysis, the 
slides were viewed without coverslips and digital micrographs were captured using a 
Leica AS-LMD laser microdissection system (Leica Microsystems, Bannockburn, IL). 
The initial fixatives tested resulted in tissue morphology of variable quality and low RNA 
quality and quantity (Figure 6A and B; only representative micrographs are pres nted 
among all fixatives tried). Similarly, several antigen retrieval agents were evaluated and 
resulted in morphology and RNA quality that varied according to the retrieval agent 
tested (Figure 6C; only 1 micrograph from all antigen retrieval agents initially tested is 
depicted). The newly developed ACEPEG fixative and 70% formamide in nfPBS as 
antigen retrieval agent yielded good morphology and immunostaining (Figure 6D). Use 
of a fluorescently conjugated primary antibody simplified immunostaining, and 
minimized protocol time and RNA degradation. The BrdU-labeled cells were id ntified 
using an Alexa 488-conjugated mouse monoclonal anti-BrdU antibody and 
counterstained with propidium iodide (Figure 6E). The 4’,6-Diamidino- 2-phenylindole 
(DAPI) or Hoechst stains were not used as nuclear stains because the polyethylene 
naphthalate membrane fluoresced with excitation–emission characteristis that were 
similar to those for these stains.  
Retention of RNA quality (assessed by increase in RIN value) was achieved by 
addition of RNase inhibitors to the antibody incubation buffer (Figures 7A, B, C, and D) 
and exposure to aqueous buffers was limited to a total of 15 min. Antibody incubation 
























Figure 6. Effects of selected fixatives and antigen-retrieval agents on tissue morphology 
and bromodeoxyuridine (BrdU) staining.  
A) Acetone-fixed cryosection permitted good BrdU staining (arrows) when coupled with 
70% deionized formamide as antigen retrieval agent.  B) Methanol-polyethylene glycol 
(UMFIX)-fixed section resulted in good BrdU staining when coupled with 70% 
deionized formamide as antigen retrieval agent; UMFIX provided better preservation of 
stromal tissue compared with acetone-fixed sections.  C) Deoxyribonuclease 1 failed to 
expose BrdU in the current protocol, contrary to expectation.  D) Acetone-polyethylene 
glycol (ACEPEG) fixation and formamide antigen retrieval provided an effective fixative 
and antigen retrieval agent, yielding good morphology. Section was counterstained with 
hematoxylin to stain all nuclei blue.  E) Cryosection, fixed with ACEPEG and treated 
with 70% formamide, was labeled with Alexa 488-conjugated anti-BrdU (green; arrow
indicates labeled nucleus of epithelial cell) and counterstained with propidium iodide (red 
nuclei). This was the optimal protocol, providing good morphology, immunostaining and 
best RNA quality (see Figure 7F for RNA quality). Inset shows the highlighted BrdU-










resulted in inconsistent immunostaining. The adverse effect of longer incubation times on 
RNA quality was consistent with the findings of Fend and coworkers (Fend et al., 1999).
To successfully utilize a short incubation time, a high concentration of antibody was 
employed as suggested for staining tissues for laser microdissection (Murakami, et al., 
2000). The dilution used for BrdU antibody (1:10) was titrated for our system. Finally, 
the quality of RNA from tissue sections that were immunostained using the op imized 
protocol (outlined in Materials and Methods) was analyzed and compared with the RNA 
from fixed but unstained tissue sections (Figure 7E and F; Figure 7F corresponds to 
micrograph in Figure 6E).  RNA quality was high for both the stained and unstained 
sections. Furthermore, the utility of the isolated RNA for gene expression analysis was 
tested using quantitative reverse transcription-PCR. Successful amplification of genes 
with reverse transcriptase quantitative PCR (RT-qPCR) using gene specific rimers 
confirmed good quality of RNA (data not shown). To obtain a preliminary evaluation of 
the efficacy of the antigen retrieval with 70% formamide for detection of other cellular 
antigens, tissue cryosections were stained for ERα or Ki-67, with or without formamide 
treatment. 
The ERα staining was restricted to mammary epithelium, consistent with previous 
results (Capuco et al., 2002), and Ki-67-labeled cells were primarily seen in mammary 
epithelium (Figure 8). Convincingly, more ERα-labeled cells were seen in formamide-
treated slides (Figure 8A) than in PBS-treated slides (Figure 8B). In addition, formamide 
enhanced overall tissue morphology of cryosections with clear nuclear staining. Similar 
findings were observed with Ki-67 staining; with formamide increasing detection of Ki-































Figure 7. Electropherograms of total RNA obtained from stained serial tissue sections.   
Effect of incorporating RNase inhibitor in incubation buffer on RNA quality was tested 
and is depicted in comparison with fixed, unstained sections and sections stained with the 
final optimized protocol.  
A) No RNase inhibitor; RNA integrity number (RIN) = 2.1.  
B) One unit of inhibitor (RNasin plus)/µL; RIN = 4.7.  
C) Two units of inhibitor/µL; RIN = 5.0.  
D) Three units of inhibitor/µL; RIN = 5.7.  
E) RNA isolated from acetone-polyethylene glycol (ACEPEG)-fixed, unstai ed 
slide from different serial sections yielded a maximum RIN = 7.2. 
 F) Optimized protocol with ACEPEG-fixed, stained sections yielded RIN = 7.1 
(micrograph provided in Figure 1D).  
Both panels E and F had similar RIN, indicative of good-quality RNA. 
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Figure 8. Serial cryosections of bovine mammary gland stained with estrogen receptor α 
(ERα) and Ki-67 antibody.  
A) Immunostaining with ERα antibody in formamide-treated cryosection. Good tissue 
morphology and improved ERα labeling (more intensely labeled nuclei in terminal ductal 
units) were evident in formamide-treated sections.  
B) Immunostaining with ERα antibody in PBS treated cryosection.  
C) Immunostaining with Ki-67 antibody in formamide-treated cryosections. Good tissue 
morphology and more Ki-67-labeled cells were noted in formamide-treated section .  
D) Immunostaining with Ki-67 antibody in untreated cryosections.  
Scale bar = 100 µm.  Arrows indicate examples of labeled nuclei in each panel.  
 





treatment (Figure 8D). This provided suggestive evidence for the applicability of our
protocol to other non-DNA-specific nuclear antigens.  The RNA integrity within these 
stained sections was not evaluated. 
In conclusion, a rapid nuclear immunostaining method was developed with BrdU 
as the main antigen of study for bovine mammary cryosections. The method resulted in 
clear localization of BrdU-labeled cells and retention of good-quality RNA in the stained 
sections. This was achieved by fixation in ACEPEG, antigen retrieval with 70% 
formamide, and brief antibody incubation in the presence of RNase inhibitors. This 











Chapter 4: Mammary stem cells: Molecular profiling to 
identify novel biomarkers and the stem cell niche 
 
Abstract 
Mammary stem cells (MaSCs) account for the cell lineage of mammary epithelia 
and provide for mammary growth, development and tissue homeostasis. Previous 
molecular characterizations ofMaSCs have utilized fluorescence-activated cell sorting or 
the in vitro cultivation of cells from enzymatically dissociated tissue to enrich for MaSCs. 
However, utilization of these approaches necessitates the loss of histological information 
encoding the in vivo locale of MaSCs and their more committed progenitor cell progeny. 
Here we report use of an alternative approach, laser microdissection, to excise putative 
MaSCs and control cells from their in situ locations in cryosections and to characterize 
the molecular properties of these cells. We identified MaSCs based upon their ability to 
retain bromodeoxyuridine for an extended period. Using laser microdissection, we 
isolated four categories of cells from mammary epithelium of female calves: 
bromodeoxyuridine label retaining epithelial cells (LREC) from basal (LRECb) and 
embedded layers (LRECe), and epithelial control cells from basal (ECb) and embe ded 
layers (ECe). Enriched expression of genes in LRECb was associated with stem cell 
attributes and with Wnt, Notch and MAPK pathways of self-renewal and proliferation. 
Genes expressed in LRECe revealed retention of some stem-like properties along with 
up-regulation of differentiation factors and the Notch pathway involved in lineage 
commitment. The basal epithelium provided for the stem cell niche, characterized as a 




growth suppressors and chromatin modifiers. Our data suggest that LREC in the basal 
epithelial layer are MaSCs, as these cells showed enriched expression of genes that 
impart stem cell attributes; whereas LREC in suprabasal epithelial layers re more 
committed progenitor cells, expressing some genes that are associated with stem cell 
attributes along with those indicative of cell differentiation. Our results provide a 
molecular profile and novel candidate markers, evaluated by immunohistochemistry, for 
bovine MaSCs. Insights into the biology of stem cells will be gained by further 
confirmation of candidate MaSCs markers identified in this study. Genes encoding cell 
surface markers may prove useful for future isolation and investigation of MaSCs 
properties and their regulation. 
 





4.1  Background 
In female mammals, growth and development of mammary glands occur 
primarily postnatally, with mammary function in the mature animal being tightly coupled 
to reproductive strategy. This dictates cycles of mammary growth, differentiation, 
lactation and regression, during which MaSCs provide for the lineages of lumenal and 
basal (myoepithelial) epithelial cells in the ducts and alveoli. Although mice have 
provided the primary model for study of mammary growth and development, a single 
model species cannot provide comprehensive knowledge. Because mammary glands of 
prepubertal calves have a tissue architecture resembling that of the prepubertal human 
breast more closely than does mouse (Capuco et al., 2002), cows provide an alternative 
experimental model for human breast development and a viable model for other specis. 
Increased knowledge of MaSCs is directly applicable to agriculture and the development 
of management schemes to enhance the lifetime productivity of dairy cows.   
A method that has been used to identify MaSCs is based upon the capacity of 
these cells to retain bromodeoxyuridine (BrdU) labeled DNA for an extended perio  
(Capuco, 2007; Smith, 2005). We previously reported that label retaining epithelial cells 
(LREC) in the mammary epithelium of calves were localized in the basal layer (LRECb) 
or in the embedded (LRECe) layers between the basal and  lumenal cells of a 
multilayered epithelium (Capuco, 2007; Capuco et al., 2009). LRECb were estrogen 
receptor-α (ESR1) negative and hypothesized to be MaSCs, whereas ESR1-positive 
LRECe were hypothesized to be progenitor cells. The estrogen receptor status of MaSCs 




mammary ductal growth, and tumorigenesis. MaSCs of mouse and human are ESR1-
negative (Anderson and  Clarke, 2004; Sleeman et al., 2007).   
Morphological evidence suggests that MaSCs are basally localized within the 
mammary epithelium, typically underlain by cytoplasmic extensions of epithelial cells 
and in close  proximity to ESR1-positive epithelial cells (Brisken and Duss, 2007; Smith 
and Chepko, 2001). However, MaSCs have not been fully characterized due to technical 
limitations inherent in stem cell identification and in isolation of cells from known 
locations within the mammary epithelium. Based on fluorescence-activated cell sorting 
with multiple biomarkers and use of mammary transplantation methods to evaluate  
multi-lineage potency, Shackleton, Stingl and colleagues obtained and characterized a 
population of cells, from enzymatically dispersed mammary tissue, that was enriched for 
MaSCs (Shackleton et al., 2006; Stingl et al., 2006). Critical to success of this approach 
was use of markers to deplete the population of hematopoietic (CD45 and TER119) and 
endothelial cells (CD31), as well as markers to select epithelial cells (CD29, CD24), 
likely from a basal location. Another approach involved characterization of mammary 
epithelial cells that possess multipotency potential (MaSCs) in vitro (Dontu et al., 2003). 
These previous studies evaluated MaSCs after removing them from their stem cell niche, 
i.e. the microenvironment of surrounding signaling molecules and other noncellular 
components that support stem cell function and survival. We have taken an approach that 
retains histological information by characterizing gene expression in putative MaSCs 
directly after their in situ excision. 
In the present study, putative stem and progenitor cells (LREC) were identified 




epithelial control (non-LREC) cells were excised from two different locati ns: basal and 
embedded layers of the mammary epithelium. We hypothesized that LRECb are MaSCs 
and LRECe are more committed progenitor cells, and that by comparing the 
transcriptomes of these cells with neighboring control cells we would obtain molecular 
profiles and biomarkers for MaSCs and progenitor cells. Results support these hypotheses 
and provide novel candidate markers for MaSCs. 
4.2  Materials and Methods 
Experimental animals and mammary tissue 
Use of animals for this study was approved by the Beltsville Agricultural 
Research Center’s Animal Care and Use Committee. A flow chart of methodology for 
identification, isolation and characterization of LREC is provided in Appendix Figure 1. 
Tissues were obtained from five Holstein heifers, 3 months of age. Heifers were inject d 
intravenously with BrdU (Sigma-Aldrich Co., St. Louis, MO) for 5 consecutive d. BrdU 
was administered in a saline solution containing 20 mg BrdU/mL (0.9% sodium chloride; 
pH 8.2) at a dosage of 5 mg/kg body weight, as described previously (Capuco, 2007). 
Heifers were sacrificed humanely (stunning with captive bolt and exsanguination) t the 
Beltsville Agricultural Research Center abattoir forty-five d after th  last BrdU injection. 
Mammary tissue (~5x5x5 mm3) was collected from the outer parenchymal region (region 
in close proximity to the border with mammary fat pad) of a rear mammary gland. 
Individual samples were immediately embedded in OCT compound (Sakura, Torrance, 
CA, USA), frozen in liquid nitrogen vapor and stored at -80°C until use. Cryosections of 
8 µm thickness were thaw-mounted on ultraviolet-irradiated PEN slides (Leica AS, 




microdissection within 8 d. Mammary tissues harvested for histological validation of 
microarray data were fixed overnight in 10% neutral buffered formalin at 4°C and then 
stored in 70% ethanol until further processing. Tissues were then dehydrated and 
embedded in paraffin according to standard techniques, sectioned at 5 µm thickness and 
placed onto Superfrost–plusTM slides (Erie Scientific Co., Portsmouth, NH, USA). 
BrdU immunostaining to identify putative MaSCs 
Putative MaSCs were identified as those cells in cryosections that retained BrdU 
label, visualized using an optimized method for BrdU immunostaining that retains RNA 
quality in tissue cryosections (Choudhary et al., 2010a). Sections were individually 
processed immediately before laser microdissection. The cryosections were fixed in 
acetone/polyethylene glycol 300 (9:1 v/v) at  -20°C for 2 min and air dried for 1 min and 
then incubated with 0.5% methyl green for 2 min at RT. After a brief wash (10 s) with 
nuclease-free phosphate buffered saline (nfPBS), 400 µL of a pre-warmed solution of 
70%, deionized formamide in nfPBS was pipetted onto the tissue and the section 
incubated at 60°C for 4 min. The section was washed with antibody dilution buffer 
(nfPBS with 1% normal goat serum and 0.1% triton-X 100) at 4°C on a metal plate kept 
on ice to prevent re-annealing of DNA strands and then incubated with mouse 
monoclonal anti-BrdU antibody conjugated to Alexa 488 (Clone PRB-1, 1:10 dilution, 
Molecular Probes, Carlsbad, CA, USA) for 5 min at RT in the dark. The section was 
washed briefly before counterstaining with propidium iodide (2.5 µg/µL in nfPBS). 
Finally, the slide was washed with nuclease-free water (10 s), dehydrated in ascending 





Laser microdissection and cDNA amplification 
 
Immediately after staining, sections were examined and cells excised with a laser 
microdissection system equipped for epifluorescence microscopy (Leica AS-LMD, 
Mannheim, Germany). The laser setting was determined empirically and dissection 
performed using the 40X objective. We dissected 6 to 13 cells (equivalent to 3 to 7 cells 
by volume) per category per heifer. For each animal, cells in a given category were 
collected into the cap of a 0.2 mL thin walled PCR tube (Biozyme Scientific GmbH, Hess 
Oldendorf, Germany). Total processing time for immunostaining and microdissection 
was less than one hour, and only one slide was processed at a time. Four categories of 
cells were dissected: LREC from basal (LRECb) and embedded layers (LRECe), and 
epithelial control cells from basal (ECb) and embedded layers (ECe). Cells within the cap 
were dissolved in 2 µL of lysis buffer (WT-Ovation™ One-Direct RNA Amplification 
System; NuGEN Technologies, Inc. San Carlos, CA, USA). The tube was capped and 
centrifuged for one min at 13000 rpm, after which the tube and contents were vortexed 
gently for 30 s and centrifuged briefly before placing on ice. First strand cDNA synthesis 
and amplification reaction was carried out using Ribo-SPIA-based methodology 
according to the manufacturer’s recommendations (NuGEN). Concentrations of 
amplified cDNA were determined spectrophotometrically (ND-1000, NanoDrop 
Technologies, Rockland, DE, USA). A known amount of high quality RNA (250 pg) was 
used as positive control for cDNA amplification. Nuclease-free water was used as a no-
template control for cDNA amplification. The amplified cDNA was evaluated using 
RNA Nano-chips to estimate the median fragment size (Agilent Technologies, Palo Alto, 




control and fell within the expected range of 100-300 bp, whereas products for the no-
template control were <50 bp. 
Microarray analysis 
Oligonucleotide microarray analysis was performed using a custom bovine 
microarray (Nimblegen, Inc., Madison, WI, USA) as described previously (Li et al., 
2006). The bovine microarray consisted of 86,191 unique 60-mer oligonucleotides, 
representing 45,383 bovine sequences. After hybridization, scanning, and image 
acquisition, the data were extracted from the raw images using NimbleScan software 
(NimbleGen).  A total of 21 microarrays (5 animals × 4 categories of cells, and no-
template amplification control) were used. Relative signal intensities (log2) for each 
feature were generated using the robust multi-array average algorithm (Irizarry et al., 
2003) and data were processed based on the quantile normalization method (Bolstad et 
al., 2003). Fold-change >2 and P ≤ 0.05 were used to identify transcript abundance that 
differed among cell categories. Use of fold change and less stringent P-value cutoff has 
been reported to provide for consistent results and relevant biological pathway analysis 
(Guo et al., 2006). Genes that were differentially expressed were subjected to Ingenuity 
pathway analysis (IPA, Ingenuity Systems, www.ingenuity.com). IPA is biological data 
analysis software in which expression data differentially expressed gens, after 
preliminary background corrections and statistical analysis, are fed into the Ingenuity 
knowledge-based systems. IPA uses its knowledge base to build a network of genes with 
their interactions and identifies significant molecular and biological relationships. Known 
gene interactions are derived from curated literature. Significance of a bi logically 




indicates likelihood of the focused genes in a network being found together due to 
random chance. The IPA score is expressed as the negative log of the P-value. The data 
discussed have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) 
and are accessible through GEO Series accession number GSE31541 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31541). 
Brightfield immunohistochemistry 
Paraffin sections were dewaxed in xylene and hydrated in a graded series of 
ethanol to phosphate buffered saline (PBS, pH 7.4). Tissue sections were quenched with 
3% H2O2 in PBS for 10 min and then washed in PBS. Antigen retrieval was performed by 
incubation with 70% formamide in PBS at 60°C for 5 min, or microwave heating in 10 
mM Tris containing 1 mM EDTA, pH 9.0 (5 min heat, 5 min rest, 5 min heat, 25 min 
cooling). Sections were blocked with casein (CAS-blockTM, Invitrogen, Carlsbad, CA, 
USA). Primary antibodies NR5A2, NUP13 and HNF4A (Abcam Inc. Cambridge, MA, 
USA) were used at 1:200 dilution and FNDC3B (Santa Cruz, Santa Cruz, CA, USA) at 
1:50. Sections were incubated with primary antibody for 2 h at RT or overnight at 4°C. 
After washing in PBS, sections were incubated with horseradish peroxidase-conjugated 
broad spectrum secondary antibody (ImmPRESS anti-mouse/anti-rabbit, Vector Labs, 
Burlingame, CA, USA). Positively labeled cells were visualized brown or purple sing 
3,3’-diaminobenzidine or ImmPACT VIP (Vector Labs), respectively. Slides were 
washed and then counterstained with hematoxylin or methyl green.  
To determine if cells expressing FNDC3B were LREC, dual antigen labeling was 
performed. Tissue sections were processed as described earlier and incubated with mouse 




Indianapolis, IN, USA) for 2 h at RT. Sections were then incubated with vector 
ImmPRESS anti-mouse polymer detection reagent (Vector Labs) for 20 min, followed by 
washing in PBS. BrdU was detected by incubation for 10 min with the chromagen 3,3’-
diaminobenzidine. Sections were then washed in deionized water. Peroxidase activity 
was quenched for a second time with 3% H2O2 in PBS, followed by washings with water. 
Sections were blocked with casein and then incubated overnight at 4°C with FNDC3B 
rabbit polyclonal antibody (1:50 dilution), washed and then incubated with ImmPRESS 
anti-rabbit polymer detection reagent (Vector Labs) for 20 min. Sections were washed 
with PBS and FNDC3B staining was visualized after incubation with a contrast purple 
chromogen, ImmPACT VIP peroxidase substrate (Vector Labs). Sections were washed in 
deionized water, counterstained with 0.5% aqueous methyl green (Vector Labs), 
differentiated in 0.05% acetic acid/acetone, washed and dehydrated in ethanol, cleared in 
xylene and mounted in DPX (Sigma). Sections in which primary antibodies were omitt d 
served as negative controls. 
4.3  Results and Discussion 
Transcriptomes of LRECb versus ECb 
 
To evaluate the hypothetical stem cell nature of LRECb, we compared the 
transcript profiles of LRECb vs. neighboring control cells (ECb). Out of 611 genes, 592 
identified and mapped to corresponding genes of IPA database (Appendix Table 1). 
Enriched expression of 387 genes in LRECb were involved in pathways linked to cancer, 
cell growth and proliferation, organism survival, cell cycle, and post-translational 
modifications (Appendix Table 5). A number of genes with documented relevance to 




aldehyde dehydrogenase 3B1 (ALDH3B1) in LRECb were consistent with MaSC 
character. Similar to the situation in mouse and human, bovine MaSCs appear to be 
ESR1-negative (Capuco et al., 2009), and aldehyde dehydrogenase activity has been used 
as a stem and progenitor cell marker in several tissues, including mammary gland 
(Douville et al., 2009). Increased abundance of HNF4A, NR5A2, NUP153 and FNDC3B 
mRNA and decreased abundance of X-chromosome inactivation factor (XIST) in LRECb 
are noteworthy (Appendix Table 1). Hepatocyte nuclear factor (HNF4A) is a liver stem 
cell transcription factor (Battle et al., 2006; Delaforest et al., 2011), and NR5A2 is a 
pluripotency transcription factor analogous to OCT4 (Heng et al., 2010). Lack of XIST in 
LRECb is consistent with MaSCs identity, as absence of XIST expression and low XIST 
expression have been associated with hematopoietic stem and progenitor cells, 
respectively (Savarese et al., 2006). Transcripts of several genes that are involved in 
epigenetic modification of chromatin were also enriched in LRECb. Relative to ECb, 
LRECb expressed a greater number of transcription regulators, zinc fingers a d nuclear 
transporters (e.g., NUP153, IPO13). Overall, the transcriptome profile of LRECb is 
consistent with expectations for MaSCs. Further evidence in support of the stem cell 
nature of LRECb comes from biological pathway analysis of differentially expressed 
genes. Ingenuity Pathway Analysis of genes that were differentially expressed in LRECb 
and ECb revealed biological processes and networks that were highly significant. The 
most significant networks associated with LRECb related to cellular growth and 
proliferation (Figure 9A, IPA score = 58), and cell cycle and posttranslational 







Figure 9A. Network of cellular growth and proliferation: Ingenuity Pathway Analysis 
(IPA) on genes differentially expressed in LRECb vs. ECb.Genes that were differentially 
expressed in LRECb vs. ECb were imported into IPA software, which revealed the 
involvement of several networks pertinent to LRECb. Network (A) pertains to cellular 
growth and proliferation and shows a single module with HNF4A at its hub. Red color 
denotes up-regulation in LRECb and green color denotes down-regulation in LRECb 




























Figure 9B. Network of cell cycle and post-translational modification: Ingenuity Pathway 
Analysis (IPA) on genes differentially expressed in LRECb vs. ECb.Genes that were 
differentially expressed in LRECb vs. ECb were imported into IPA software, which 
revealed the involvement of several networks pertinent to LRECb. Network (B) relates to 
cell cycle and post translational modification. Red color denotes up-regulation in LRECb 
and green color denotes down-regulation in LRECb relative to control cells. The IPA 





proliferation (Figure 9A) contains a single module with HNF4A, up-regulated in LRECb, 
as the hub. Down-regulation of developmental genes like SIX2 and XIST suggests that 
LRECb are undifferentiated cells. KEGG pathway analysis using DAVID (Huang et al., 
2009) revealed that genes which were differentially expressed in LRECb vs. ECb (FGF, 
BRAF, ATF4, CREB3, GLK, HSPA8,TAOK3, CDC25B) were components of the 
MAPK pathway, a pathway involved in cellular growth and proliferation, and 
components of the Wnt (Dvl,  PPP2R5E, SMAD4) and TGF-β ( ST and SMAD4) 
pathways, which are associated with stem cell renewal (Esmailpour and Huang, 2008; 
Mazumdar et al., 2010). 
Transcriptomes of LRECe versus ECe 
 
Comparison of transcriptome profiles of LRECe and neighboring ECe identified 
101 functionally identifiable genes that were differentially expressed (Appendix Table 2) 
and supported classification of LRECe as progenitor cells. The most significant network 
associated with these genes was related to cancer (Figure 10A, IPA score = 51), followed 
by a network associated with DNA replication, recombination and repair (Figure 10B, 
IPA score = 36) that contained an HNF4A module. Conservation of the HNF4A module 
in LRECe and LRECb suggests a hierarchical similarity between LRECe and LRECb; 
although HNF4A transcripts were not significantly up regulated in LRECe and genes 
involved in this module differed between the two categories of LREC. Enriched 
expression of NR5A2, NUP153 and FNDC3B in both LRECe and LRECb (vs. ECe and 
ECb, respectively) provides another line of evidence for the similarity of LREC in basal 






Figure 10A. Network of cancer: Ingenuity Pathway Analysis (IPA) on genes 
differentially expressed in LRECe vs. ECe. Genes that were differentially expressed in 
LRECe vs. ECe were imported into IPA software, which revealed th  involvement of 
several networks pertinent to LRECb. Network (A) relates to cancer. Red color denotes 
up-regulation in LRECe and green color denotes down regulation in LRECe relative to 





Figure 10B. Network of DNA replication, recombination and repair: Ingenuity Pa hway 
Analysis (IPA) on genes differentially expressed in LRECe vs. ECe.Genes that were 
differentially expressed in LRECe vs. ECe were imported into IPA software, which 
revealed the involvement of several networks pertinent to LRECb. Network (B) pertains 
to DNA replication, recombination and repair and contains a HNF4A module. Red color 
denotes up-regulation in LRECe and green color denotes down regulation in LRECe 





FNDC3B have been characterized as markers of proliferation and cell migration. KEGG 
pathway analysis of transcripts that were up-regulated in LRECe vs. ECe using DAVID 
(data not shown) identified upregulation of Wnt pathway (Dvl, PP2A, CaMKII) and actin 
cytoskeleton pathway (GPCR, CALMKII). 
Transcriptomes of LRECb versus LRECe 
 
To evaluate the relative characteristics of LRECb and LRECe, transcript profiles 
for these cells were compared. We identified 274 genes that were differentially expressed 
in LRECb vs. LRECe (Appendix Table 3). The molecular profile of LRECb included 
increased abundance of transcripts for stem cell markers (NR5A2, NES), cell survival 
and proliferation factors (IGF2, FGF2, FGF10, HSPB6, LAMC1) and DNA repair 
enzymes (EXO1, MSH60, MDC1). Relatively high expression of stem cell markers, 
growth and survival factors, DNA repair enzymes and low expression of apoptotic genes 
and differentiation markers supported greater “stemness” of LRECb vs. LRECe. In 
addition, enriched expression of cell adhesion molecules (CADM3, NCAM, AOC3), 
growth factors (CSF3, FGF2, FGF10, FST, IGF2, IL33, MESDC2, AGT), and a number 
of cell surface markers (ANX46, CPRC5, CXCR4, DRD2, GNB4, GRB14, SDPR, 
THY1/CD90, TRIB2) were noted in LRECb. The LRECe were characterized (Table 2) 
by increased expression of XIST, splicing factor arginine/serine-rich 5 (SFRS5), THAP 
domain containing apoptosis associated protein 3 (THAP3), and calcium/calmodulin-
dependent protein kinase II delta (CAMK2D).  Increased expression of glucose metabolic 
enzymes, glucose phosphate isomerase (GPI) and UDP-glucose pyrophosphoryla e 2 
(UGP2) were also characteristics of LRECe. Additionally, KEGG pathway an lysis 





Table 2. Top 10 up-regulated and down-regulated genes in LRECb vs. LRECe  
Gene 
Symbol 
Chromosome Gene summary 
 
Up-regulated in LRECb 
FBXO34 14 Members of F-box proteins, act as protein-ubiquitin ligase 
USP15 12 Ubiquitin, a highly conserved protein involved in the regulation of 
intracellular protein breakdown, cell cycle regulation, and stress 
response, is released from degraded proteins by disassembly of the 
polyubiquitin chains.  
RPS7 2 This gene encodes a ribosomal protein that is a component of the 40S 
subunit. The protein belongs to the S7E family of ribosomal proteins.  
CFL1 11 Cofilin is a widely distributed intracellular actin-modulating protein 
that binds and depolymerizes filamentous F-actin  
COLIA2  This gene encodes the pro-alpha2 chain of type I collagen whose triple 
helix comprises two alpha1 chains and one alpha2 chin.  
RRN3 16 Biogenesis, proliferation, apoptosis, survival 
HSPB6  HSPB6 is associated with actin, response to heat 
TRIB2 2 An oncogene that inactivates the transcription factor C/EBPalpha 
(CCAAT/enhancer-binding protein alpha) and causes acute 
myelogenous leukemia.  
NUP153 6 Epigenetic role in modifying chromatin structures 
LAMC1 1 Laminins, has a wide variety of biological processes including cell 
adhesion, differentiation, migration, signaling, neurite outgrowth and 
metastasis.  
 
UP-regulated in LRECe 
XIST X The XIST gene is expressed exclusively from the XIC of the inactive X 
chromosome.  
C17ORF49 19 Unknown 
SFRS5 14 Nuclear mRNA splicing, via spliceosome; mRNA splice site selection; 
RNA splicing; regulation of cell cycle 
THAP3  An apoptosis associated protein 3, Function unknown 
STK11IP 2 Serine/threonine kinase 11 interacting protein, Function unknown 
UGP2 2 The enzyme transfers a glucose moiety from glucose-1-phosphate to 
MgUTP and forms UDP-glucose and MgPPi. In liver andmuscle 
tissue, UDP-glucose is a direct precursor of glycogen; in lactating 
mammary gland it is converted to UDP-galactose which is then 
converted to lactose.  
SLC3A2 11 This gene is a member of the solute carrier family and encodes a cell 
surface, transmembrane protein  
EIF4E3 3 EIF4E3 belongs to the EIF4E family of translational i itiation factors 
that interact with the 5-prime cap structure of mRNA and recruit 
mRNA to the ribosome 
CAMK2D 4 The product of this gene belongs to the serine/threonine protein kinase 
family and to the Ca(2+)/calmodulin-dependent protein kinase 
subfamily.  
CPEB1 15 Members of this protein family regulate translation of cyclin B1 during 




significant network associated with genes that were differentially expressed in LRECb vs. 
LRECe was related to tissue development, cell growth and proliferation (Figure 11A, IPA 
score = 43). This network showed up-regulation inLRECb of HIP1, which may be 
required for differentiation or survival of somatic progenitors, and TRIB2, which 
modulates signal transduction pathways and may promote growth of mouse myeloid 
progenitors. This was followed by a network associated with tissue injury (Figure 11B, 
IPA score = 34), featuring up regulation of a heat shock protein module in LRECb. The 
top three canonical pathways associated with LRECb vs. LRECe pertained to the mito ic 
roles of polo-like kinases, cleavage and polyadenylation of pre-mRNA, and chemokine 
signaling. Polo-like kinases are key centrosome regulators. Asymmetric localization of 
polo-kinase promotes asymmetric division of adult stem cells (Rusan and Peifer, 2007). 
Transcriptomes of ECb versus ECe 
 
Epithelial cells isolated from basal and embedded layers exhibited transcriptome 
profiles that were consistent with their location. Analysis identified 318 genes that were 
differentially expressed (Appendix Table 4), 267 of which were functionally identifiable. 
Among these, ECb expressed increased transcript levels for cell structural and motility 
genes, including actin (ACTA2), myosin (MYL12A, MYO6), tropomyosin (TPM4), 
catenin, tubulin, titin (myosin head adaptor protein), spectrin (actin cross linking scaffold 
protein) and tetraspanin 31. Transcripts for JAG-1 (a ligand of Notch pathway) fibroblast 
growth factors (FGF1, FGF2, FGF10), insulin like factor-2 (IGF2), follistatin (FST), and 
IGF2 were enriched in basal epithelial cells. The enriched expression of integrin-β1 
within ECb was consistent with its use as a marker to isolate MaSCs (Shackleton et al., 






Figure 11A. Network of tissue development, cell growth and proliferaton: Ingenuity 
Pathway Analysis (IPA) on genes differentially expressed in LRECb vs. LRECe. 
Genes that were differentially expressed in LRECb vs. LRECe were imported into IPA 
software, which revealed the involvement of several networks pertinent to LRECb. 
Network (A) pertains to tissue development, cell growth and proliferation. Red color 
denotes up-regulation in LRECb and green color denotes down-regulation in LRECb 






Figure 11B. Network of tssue injury featuring heat shock proteins (HSPs): Ingenuity 
Pathway Analysis (IPA) on genes differentially expressed in LRECb vs. LRECe.   
Genes that were differentially expressed in LRECb vs. LRECe were imported into IPA 
software, which revealed the involvement of several networks pertinent to LRECb. 
Network (B) is associated with tissue injury and contains a heat shock protein module 
that was up-regulated in LRECb. Red color denotes up-regulation in LRECb and green 
color denotes down-regulation in LRECb relative to control cells. The IPA legend is 





a number of heat shock proteins (HSAA8, HSPA4, HSP90AB1,  HSP90A1), peptidases 
(USP4, USP16, USP54, PRSS3, TTN, PSMD14, MME, PDIA3), ribosomal proteins, 
translational regulators, components of the ECM and its regulators (collagens, MFAP5, 
FBN, FSTL1, CHAD, ERBB2IP, SPARC), and tumor suppressors (MTSS1, Myc binding 
proteins) were also up-regulated in ECb. However, transcripts of membrane transporters 
(AP1M1, APOE, AQP7, SLC13A3, SLC38A3, TMED3, CLCN3) were more highly 
expressed in ECe than ECb. Thus, control cells harvested from basal and embedded 
layers within the mammary epithelium possess different character and represent two 
distinct cell populations. To understand key biological processes occurring in basal and 
embedded epithelium, we utilized Ingenuity pathway analysis (IPA) to generat  gene 
networks and canonical pathways for genes that are differentially expressed between ECb 
and ECe. All identified networks (Networks of endocrine system development and 
function, cancer, cell cycle, tissue development) were highly significant as me ured by 
IPA score (ranges from 35 to 42). The identified network for endocrine development and 
function, lipid metabolism (Figure 12A) features an estrogen signaling module, 
peptidase, ubiquitination and ubiquitin modules. The identified network for cancer 
(Figure 12B) contains two heat shock protein modules. The canonical pathways identified 
by IPA analysis were protein ubiquitination, hypoxia signaling and clathrin mediated 
endocytosis. Consistent with expression in the basal epithelium, specific cell adhesion 
molecules, extrinsic growth factors and regulators, and hypoxia-inducing fator have 









Figure 12A. Network for endocrine development and fuction: Ingenuity Pathway 
Analysis (IPA) on genes differentially expressed in ECb vs. ECe.  
Genes that were differentially expressed in ECb vs. ECe were imported into IPA 
software, which revealed the involvement of several networks pertinent to ECb. Network 
(A) pertains to endocrine development and function, lipid metabolism.. Red color denotes 
up-regulation in LRECb and green color denotes down-regulation in LRECb relative to 






Figure 12B. Network for cancer: Ingenuity Pathway Analysis (IPA) on genes 
differentially expressed in ECb vs. EC. Genes that were differentially expressed in ECb 
vs. ECe were imported into IPA software, which revealed the involvement of several 
networks pertinent to ECb. Network (B) is associated with cancer and contains two heat 
shock protein modules. Red color denotes up-regulation in LRECb and green color 
denotes down-regulation in LRECb relative to control cells. The IPA legend is shown in 






















Figure 13. Schematic representation of characteristics of bovine putative MaSCs 
(LRECb) and progenitor cells (LRECe). Putative MaSCs (LRECb) are localized in the 
basal epithelium in a stem cell niche characterized as an environment enriched for 
extracellular growth factors, tumor suppressors for regulating MaSCs function. LRECb 
exhibit enriched expressions of adhesion molecules and a variety of potential MaSCs 
biomarkers including HNF4A and the pluripotency marker, NR5A2.  Putative progenitor 
cells (LRECe) also express NR5A2 but at a reduced level along with increased 




Immunohistochemical evaluation of LRECb and LRECe markers 
Genes that are highly expressed in LRECb and LRECe may provide novel 
markers for MaSCs and progenitor cells. Those that were evaluated by 
immunohistochemistry were: NR5A2, NUP153, FNDC3B and HNF4A. NR5A2 is a 
pluripotency gene that aids in inducing somatic cells into pluripotency (iPSC) (Heng et 
al., 2010). NUP153 is a nuclear basket protein that can cause chromatin modification 
(Vaquerizas et al., 2010), and FNDC3B is a regulator of adipogenesis and cell 
proliferation, adhesion, spreading and migration (Nishizuka et al., 2009). HNF4A may 
serve as a stem cell regulator (Koh et al., 2010; Douville et al., 2009; Battle et al., 2006) 
and was identified as a key pathway component by IPA analysis of expression data for 
LRECb and LRECe. Transcripts for NR5A2, NUP153, FNDC3B and HNF4A were more 
abundant (> log2 fold change) in LRECb than in control cells, with the greatest 
expression in LRECb (LRECb>LRECe>EC).  
Immunohistochemical analysis showed that a small number (1-6%) of epithelial 
cells expressed these potential markers. In agreement with transcript abundance, positive 
cells in the basal epithelium appeared intensely stained than those in suprabasal locations. 
The abundance and localization of NR5A2, NUP153 FNDC3B and HNF4A-positive cells 
(Figure 14A-D) were similar to that of LRECs. Co-localization studies showed that 
LREC expressed these markers. Surprisingly, expression of FNDC3B was not limited to 
the cytoplasmic compartment of the cell. Expression of FNDC3B was found to be 
cytoplasmic (arrows) and nuclear (arrowheads) and co-expressed with BrdU in 






Figure 14. Immunohistochemical localization of potential mammary stem/ progenitor cell 
markers.  
A-D- Consistent with transcriptome data, cells that were positive for thesenovel markers 
were more strongly labeled (brown nuclei) in the basal layer of mammary epithelium 
than in the embedded layers. Solid arrows designate labeled nuclei of basal cells and 
arrowheads designate labeled nuclei of embedded epithelial cells. NR5A2.(A), NUP153 
(B), FNDC3B (C), HNF4A (D), FNDC3B (E) expression by LREC. Localiz tion of 
FNDC3B (purple) to the nucleus (arrow) and cytoplasm (arrowhead) of LRECb (brown) 
is depicted (E). F- Identification of LREC in cryosections used for laser microdissection. 
Basal and embedded cells retaining BrdU label are designated, along with the location of 





sorting, we also identified transcripts that encoded surface proteins and were up- 
regulated in LRECb. These included SAT2,CXCR4, SDPR, RTP3, CASR, GNB and 
DRD2. However, we have not evaluated the suitability of these membrane markers fo 
identifying and enriching stem cell populations by flow cytometry. 
Discussion 
To address our hypothesis that LRECb represent MaSCs and that LRECe more 
committed progenitors, we performed transcriptome analyses on four populations of 
bovine mammary epithelial cells obtained by laser microdissection of LREC and EC 
from different epithelial layers (basal and embedded layers). Microarray nalysis 
revealed distinct gene signatures for the four categories of mammary epithelial cells: 
LRECb, LRECe, ECb and ECe. Comparison of LRECb vs. ECb and LRECe vs. ECe 
suggested that LRECb are enriched for MaSCs and LRECe for progenitor clls. 
Furthermore, factors that are important for maintenance of the stem cell nich  were 
evident in the basal epithelium.  
The ECb and ECe were distinguishable by the increased abundance of transcripts 
in the basal cells for genes encoding structural and motility proteins, extrac llul r growth 
factors, extracellular matrix (ECM) proteins and ECM regulators. Additionally, increased 
expression of transcripts for heat shock proteins, peptidases, ribosomal proteins, 
ubiquitins, proteins that provide interaction between the cell and the ECM (caveolin-1, 
β1-integrin), tumor suppressors, and epigenetic modifiers (JARID2, JMJD1C) are also 
characteristic of ECb. Myoepithelial cells, present in the basal layer of mature mammary 
epithelium, may be a part of the stem cell niche and their paracrine factors may regulate 




2005). However, the precise nature of the ECb in a calf is uncertain. Expression of 
markers for myoepithelial cells in mammary tissue from prepubertal heifers is absent or 
expressed in a limited fashion (Ballagh et al., 2008; Capuco et al., 2002). 
Transcriptome analysis of LRECb vs. ECb showed that LRECb possess 
characteristics of MaSCs. Our mRNA data were consistent with the lack of expression of 
ESR1 and increased expression of ALDHB1 in LRECb. As in mouse (Sleeman et al., 
2007) and human (Anderson and Clarke, 2004) bovine MaSCs appear to be ESR1-
negative (Capuco et al., 2009). Further, ALDH1 activity has been used as an effective 
stem and progenitor cell marker in several tissues including blood, lung, prostate, 
pancreas and breast (Douville et al., 2009). However, 17 isoforms of ALDH have been 
identified (Sladek, 2003) with different cellular and species expression patterns (Hess et 
al., 2004). ALDHB1 is expressed by bovine MaSCs. Increased abundance of HNF4A, 
NR5A2, NUP153 and FNDC3B mRNA and decreased abundance of XIST transcripts 
(noncoding) in LRECb are noteworthy. HNF4A is a hepatic stem cell transcription factor 
whose associated network was highly up-regulated in LRECb, suggesting a key role in 
these cells. It is noteworthy that HNF4A has recently been implicated as a regulator of 
mesenchymal stem cells (Koh et al., 2010). Lack of expression or low expression of 
XIST has been associated with stem and progenitor cells, respectively, in hematopoietic 
tissue (Savarese et al., 2006). Subsequently, we evaluated four potentially novel markers 
for stem/progenitor cells (NR5A2, NUP153, FNDC3B, HNF4A) immunohistochemically 
and found protein expression profiles that were consistent with the observed transcript 




Because of their potential utility for cell sorting, we identified transcripts that 
encoded surface proteins and were up-regulated in LRECb. Among the cell surface 
markers, THY1/CD90 is a proposed marker for mesenchymal, liver, keratinocyte, 
endometrial and haematopoietic stem cells. TRIB2 is an oncogene shown to prolong 
growth of mouse myeloid progenitors (Keeshan et al., 2010). CXCR4 is a receptor for 
stromal derived factor 1 (SDF-1) and its activation was associated with breast cancer 
invasiveness (Kang et al., 2005). SAT2 is the target of DNA methyltransferse 1 
(DNMT1) and an epigenetic modifier, whose methylation status may serve as a m rker 
for cancer prognosis (Jackson et al., 2004).  CXCR4 is a proposed marker of non-
hematopoietic stem cells and regulator of neural stem cell trafficking and tumor 
metastasis (Ratajczak et al., 2006). SDF-1 is positively regulated by HIF1α and 
negatively regulated by CXCR4 receptor, which in turn is regulated by G-protein 
signaling (RGS) proteins. RGS4, which was up regulated in LRECb, is likely to be an 
RGS protein regulating SDF-1 responsiveness to CXCR4 in the mammary gland.  
Up-regulation of growth factors such as fibroblast growth factors (FGF1, FGF2, 
FGF10), insulin-like factor-2 (IGF2) and plasminogen (PLG) in the basal epithelial layer 
suggest a function of these molecules as regulators of MaSCs. Role of FGFs in mammary 
gland development and growth has been demonstrated (Mailleux et al., 2002; Sinowatz et 
al., 2006).  
Further evidence in support of LRECb being mammary stem cells comes from 
biological pathway analysis of differentially expressed genes. A number of differentially 
expressed genes (LRECb vs. ECb) were involved in MAPK, Wnt and TGF-β pathways. 




pathways are both involved in mechanism of mammary stem cell renewal. A theme 
emerging from a variety of data is that stem cells exhibit characteristics of cells under 
stress (Covello et al., 2006; Mazumdar et al., 2010). An up-regulation of chaperones, 
ubiquitin/proteosome, DNA repair and chromatin remodeling in LRECb are consistent 
with this characteristic and support identification of these cells as MaSCs.  
Comparison of the transcript profiles of LRECe with those of ECe and LRECb 
supports classification of LRECe as progenitor cells. As with LRECb, presenc  of an 
HNF4A network and BrdU label retaining ability suggest that LRECe possess ome stem 
cell attributes. However, up-regulation of metabolic enzymes and differentiation factors 
suggest that LRECe are more differentiated than LRECb.  XIST is a non-coding RNA 
that inactivates one of the X-chromosomes in the early embryo, initiates gene repression, 
and defines epigenetic transitions during development. Pluripotency genes (NANOG, 
OCT4 and SOX2) cooperate to repress XIST (Navarro et al., 2008). Our mRNA data 
revealed no expression of XIST in LRECb, moderate expression in LRECe and greatest 
expression in control cells, consistent with classification of LRECb as MaSCs nd 
LRECe as progenitor cells (Savarese et al., 2006). Finally, comparison of tra script 
abundance in LRECb vs. LRECe revealed upregulation of the Notch signaling pathway 
in LRECe. The Notch pathway plays a critical role in cell fate determination in human 
mammary stem and progenitor cells (Dontu et al., 2004). We hypothesize that the Notc 
pathway regulates the generation of progenitor cells from MaSCs.  
Our study provides evidence that the stem cell niche lies in the basal layer of 
mammary epithelium. In this study, LREC and control cells were isolated from known 




microenvironments. LREC and control cells were adjacent or in close proximity to allow 
evaluations of potential cross talk between stem cells and neighboring cells. Microarray 
analyses of LRECb and LRECe identified features of LRECb that are reflective of 
mammary stem cells residing in a stem cell niche. Distinct features of a tem cell niche, 
as discussed by Li and Xie (Li and Xie, 2005), are the presence of (1) cell adhesion 
molecules that provide anchorage for stem cells within the niche, (2) extrinsic factors 
within the niche that regulate stem cell behavior and (3) factors that cause asymmetric 
cell division of stem cells, that is upon cell division, one daughter cell is maintained in 
the niche as a stem cell (self-renewal) and the other daughter cell leaves the niche to 
proliferate and differentiate. A very recent study also suggested that a stem cell niche is 
hypoxic, resulting in the induction of proteins of the family of hypoxia inducible 
transcription factor (HIF), such as HIFA1 and targets Wnt, OCT4, IGF2 and Notch 
signaling molecules (Kaufman, 2010; Mazumdar et al., 2010). In our study, we identifie 
specific cell adhesion molecules, extrinsic growth factors and regulators, factors that 
promote asymmetric cell division, and hypoxia inducing factor as molecules that are 
prevalent in the stem cell niche of the basal epithelium (Figure 13). 
In summary, transcriptome analysis of mammary epithelial cell subpopulations 
has provided a framework for future studies of normal mammary epithelial cell 
development and homeostasis, and for the pathobiology of breast cancer. First, we 
provided the evidence that LRECs represent MaSCs and progenitor cells, with LRECb 
being MaSCs and LRECe more committed progenitor cells. Second, we showed the 




provide the first transcriptome profile of MaSCs and progenitor cells excised from their 
in situ locations and identified potential novel biomarkers for these cells.  
Insights into the biology of stem cells will be gained by further confirmaton of 
candidate MaSCs markers identified and evaluated in this study.  Appropriate biomarkers 
will provide means to identify MaSCs and facilitate our understanding of their functions 
in mammary development and homeostasis and cancer. Specific cell surface markers will 



















Chapter 5: Expression of NR5A2, NUP153, HNF4A and 
FNDC3B is consistent with their use as novel biomarkers for 
mammary stem/progenitor cells 
 
Abstract 
Mammary stem cells (MaSCs) are essential for growth and maintenance of 
mammary epithelium. Previous studies have utilized morphological characteristi s or 
retention of bromodeoxyuridine (BrdU) label to identify MaSCs, but these approaches 
may not be feasible or may not identify all resident stem cells. Alternatively, MaSCs may 
be identified by expression of appropriate protein markers. The focus of this study was to 
evaluate staining patterns of four novel candidate markers for bovine MaSCs, in 
mammary tissue from prepubertal and lactating Holsteins. These proteins were identified 
as candidate MaSCs markers because their transcripts were highly express d in laser-
microdissected cells, identified as putative MaSCs by their retention of BrdU label and 
their basal location within the mammary epithelium. The four candidate markers for 
MaSCs were: nuclear receptor subfamily 5 group A member 2 (NR5A2), nucleoporin 
153 (NUP153), hepatocyte nuclear factor 4-alpha (HNF4A) and fibronectin type III 
domain containing 3B (FNDC3B). We also evaluated presumptive MaSCs markers 
[aldehyde dehydrogenase 1 (ALDH1) and Musashi 1 (MSI1)] and notch 3 receptor 
(Notch3), which have been used in other species. We found that NR5A2, NUP153 and 
HNF4A -labeled cells represented 2.5-6% of epithelial cells prepubertally and were 
distributed in a fashion consistent with the location and abundance of MaSCs/progenitor 




FNDC3B was localized mainly in the nucleus prepubertally and in the cytoplasm of 
myoepithelial cells and nuclei of a limited number of alveolar cells during lactation. 
Abundant expression of ALDH1 precludes its use as a marker for bovine MaSCs, 
whereas MSI1 staining was consistent with MaSCs localization. Onset of lumen 
formation in mammary ducts of prepubertal gland was associated with Notc3 
expression in the apical surface of lumenal cells. Nuclear expression of NR5A2, 
NUP153, HNF4A and FNDC3B are likely markers for bovine MaSCs and progenitor 
cells.  
 





5.1  Background 
Mammary stem cells (MaSCs) provide for mammary growth and cell 
replacement.  Accordingly, they provide a biological target for increasing milk 
production, persistency of lactation and tissue repair. Several approaches have been used 
to identity, isolate and enrich MaSCs in order to characterize their molecular properties. 
Among these, the long-term retention of bromodeoxyuridine (BrdU) to identify putative 
MaSCs has been of considerable interest. The long-term retention of labeled DNA by 
somatic stem cells is based on the following hypotheses: (1) stem cells are relatively 
quiescent and (2) stem cells retain the original DNA strands and transfer newly 
synthesized stands to daughter cells. Although the precise mechanism for label retention 
remains obscure, studies have demonstrated that asymmetric DNA segregation is  
common property of somatic stem cells (Shinin et al., 2006). Using this technique, we 
have identified label-retaining epithelial cells (LREC) that are present in low abundance 
in mammary glands of prepubertal heifers (Capuco, 2007; Capuco et al., 2009). We 
suggested that LREC in the basal epithelium (estrogen receptor-negative) are MaSCs and 
those in suprabasal layers (estrogen receptor-positive) are progenitor clls (Capuco, 2007; 
Capuco et al., 2009).  However, application of label retention as a means for identifying 
MaSCs is limited by of the minimal labeling of relatively quiescent cells and its use in 
large animals is constrained by cost and logistical concerns.  As a result, there is a need 
for other types of markers for MaSCs identification. An alternative approach to identify 
resident MaSCs is based on detection of appropriate protein markers by 
immunohistochemistry. Although a single reliable marker for MaSCs has been difficult to 




combination to study MaSCs/progenitor cells in other species.  Among those used for 
investigations in mouse and human are aldehyde dehydrogenase 1 (ALDH1), Musashi 1 
(MSI1) and Notch 3 receptor.  Based upon microarray analysis of LREC, which were 
excised from mammary tissue of prepubertal bovine mammary glands using laser 
microdissection, we recently identified novel, potential MaSCs markers (NR5A2, 
NUP153, FNDC3B and HNF4A).   
Notch signaling components are conserved proteins that have been associated in 
lineage commitment, cell proliferation, differentiation and apoptosis (Bray, 2006). Over-
expression of the Notch pathway has been associated with breast cancer developm nt 
(Shi and Harris, 2006). Notch signaling has also been found to direct bipotent mammary 
progenitors to lumenal lineages (Raouf et al., 2008). In agreement with previous 
morphological data, we have molecular profiling data demonstrating that mammary stem 
cells are localized in the basal layer of the mammary epithelium whereas p ogenitor cells 
are more apically localized (Choudhary et al, 2010b). We anticipate that evaluating the 
expression pattern of the Notch 3 protein will facilitate our understanding of lineage 
specification in the epithelium of the bovine mammary gland.  
Our objective was to evaluate the expression patterns of novel MaSCs markers 
and additional putative MaSCs/differentiation cell markers in bovine mammary 
epithelium. We conclude that epithelial cells expressing NR5A2, NUP153, FNDC3B, 
HNF4A and MSI1 in the nucleus are potential MaSCs/progenitor cells. In contrast, 
ALDH1 is not a good marker for bovine MaSCs due to its expression by many epithelial 
cells and its lumenal localization. Interestingly, Notch3 may be associated with lumen 




5.2  Materials and Methods 
Tissue Samples 
 
In this study, we used tissues from prepubertal and from lactating Holstein cows.  
The tissues were archived samples of two previous studies.  Paraffin-embedded tissu s 
from prepubertal heifers were from a study (Capuco et al., 2009) designed to identify
putative MaSCs based upon the ability of these cells to retain BrdU.  Paraffin-embedded 
tissues from nonpregnant lactating cows were from a study designed to evaluate the 
kinetics of epithelial turnover (Capuco et al., 2001). Animal use and protocols for the 
original experiments were approved by the Beltsville Agricultural Research Center 
Animal Care and Use Committee.   
Immunohistochemistry 
Mammary tissues were sectioned at 5 µm thickness and placed on SuperfrostTM 
plus slides (Erie Scientific Co, Portsmouth, NH, USA) for immunohistochemical 
analysis, and all incubations were carried out at RT unless stated. Slides were de axed in 
xylene and rehydrated in ascending concentrations of ethanol to water. Tissue sections 
were quenched with a solution containing a specific inhibitor of endogenous peroxidase 
(Peroxo-block; Invitrogen Co. Frederick, MD) for 2 min. After washing sections in 
deionized water (3 x 2 min), antigen retrieval was performed by heating in 10 mM Tris-
HCl, 1 mM EDTA, pH 9. Slides were heated in a microwave oven at high power (650 W) 
in 400 mL of buffer in a covered glass staining dish for 5 min, left undisturbed for 5 min, 
then were microwaved for additional 5 min. Slides remained in buffer for a 25 min 
cooling period before washing with phosphate-buffered saline containing 0.05% Triton 




PBS at 60 ºC for 5 min (Choudhary et al., 2010a) followed by treatment with trypsin 
(Trypsin Histo-kit; Invitrogen Co., Camarillo, CA) for 30 min at 37 ºC produced similar 
results, the former method was used for convenience.  Antigen retrieval using microwave 
heating in 10 mM citrate buffer (pH 6.0) produced nonspecific staining with these 
markers.  
After antigen retrieval, slides were blocked with casein (CAS-BlockTM, 
Invitrogen, CA) for 10 min and then incubated with primary antibodies for 1-2 h at RT or 
overnight at 4oC.  Primary antibodies and dilutions were: BrdU mouse monoclonal 
(Roche Diagnostics; Mannheim, Germany, BMC9318; 1:50 dilution), NR5A2 rabbit 
polyclonal (Sigma-Aldrich, St. Louis, MO, USA, 1:100 dilution), NUP153 mouse 
monoclonal (Abcam Inc. Cambridge, MA, USA, 1:200 dilution), HNF4A mouse 
monoclonal (Abcam, 1:200 dilution), FNDC3B (Santa Cruz Biotech., Santa Cruz, CA, 
USA, 1:50 dilution), MSI1 (Sigma-Aldrich, rabbit polyclonal, 1:100 dilution), ALDH1 
mouse monoclonal (BD Transduction Lab, mouse monoclonal, 1:100 dilution), Notch 3 
mouse monoclonal (Santa Cruz, 1:100 dilution). 
After incubation with primary antibody, sections were washed with PBST (3 x 3 
min), and then incubated with Vector ImmPRESSTM anti-mouse/anti-rabbit Ig peroxidase 
conjugated secondary antibody (Vector Labs Inc. Burlingame, CA, USA) for 30 min, 
followed by washing with PBST (3 x 2 min) to remove unbound polymer. Markers were 
detected using Vector peroxidase substrate kits for brown (ImmPACTTM DAB), purple 
(ImmPACTTM VIP) or red (ImmPACTTM NovaREDTM) staining. Negative controls were 
performed by omitting primary antibody. Sections were counterstained with 0.5% 




0.05% acetic acid/acetone for 10 s and dehydrated in ascending concentrations of ethanol.
In the case of hematoxylin counterstaining, slides were washed in water and dipped into 
PBS (30 s) to develop blue color nuclei before dehydration in ethanol. Slides were 
mounted in DPX (Sigma-Aldrich Co. St. Louis, MO, USA). Photomicrographs were 
obtained using a light microscope (Olympus BX81; Olympus, Japan) equipped with a 
DP70 digital camera. 
For each marker (NR5A2, NUP153 and HNF4A) quantified, immunopositive 
cells were quantified from photomicrographs and expressed as as percentage of total 
epithelial cells counted (labeling index). For each stained slide (3-4 tissuesections per 
slide), 10-12 areas were photographed at a magnification of 320x.  The NR5A2, NUP153 
and HNF4A-labeled epithelial cells and total epithelial cells were enumerated from the 
digital images and labeling indices were calculated.  
5.3  Results and Discussion 
To evaluate the expression patterns of various markers for MaSCs, we performed 
immunohistochemistry on formalin-fixed paraffin-embedded tissue sections from 
prepubertal and lactating bovine mammary glands. Specificity, distribution and 
quantitation of the stained cells were performed.  All data are expressed as mean 
percentage and standard error (mean + SE). Negative controls for staining procedures 
were the omission of primary antibody and always showed no immunostaining of cells 
(Figure 15A). 
Expression of the novel MaSC/progenitor cell markers, NR5A2, NUP153, 




















Figure 15. Immunohistochemical localization of potential novel stem/progenitor cell 
markers in prepubertal and lactating mammary gland.  
Shown are the results of indirect immunostaining on paraffin sections using (A) no 
antibody (negative control), (B) BrdU antibody detecting label retaining epithelial cells. 
(C) Bar graph depicting percent of NR5A2 labeled mammary epithelium in prepubertal 
heifer calf and lactating mammary gland. NR5A2 staining in (D) calf and (E) lactating 
cow. (F) Bar graph depicting percent of NR5A2 labeled mammary epithelium at 90, 120 
and 240 d of lactation (dL). NUP153 staining in calf (G) and (H) lactating cow. (I) Bar 
graph depicting percent of NUP153 labeled mammary epithelium in prepubertal and peak 
lactating mammary gland. HNF4A staining in (J) calf and (K) lactating cow and 
FNDC3B staining in (L) calf and (M) lactating cow. Arrows indicate nuclear expression 
of markers in basal cells, arrowheads in embedded/lumenal cells and broken arrws point 
to cytoplasmsic expression of markers. Means without a common superscript differ (P < 









reported (Capuco, 2007; Capuco et al., 2009) staining for BrdU revealed LREC, which 
were located primarily in the basal layer or one or two cells above the basal layer in the 
mammary epithelium of prepubertal heifers (Figure 15B). LREC were seldom found to 
be in contact with the ductal lumen.  
We evaluated expression of NR5A2 in mammary tissue from prepubertal heifers 
and lactating cows. In prepubertal heifers, immunostaining of NR5A2 was observed in 
the nuclei of a small number of basal and embedded epithelial cells, with the basal cells 
visually appearing more intensely labeled (arrows) than embedded (arrowhead) (Figure 
15D). They were observed at a frequency of 2.6 + 0.51 % of total epithelial cells. 
However, the frequency of basally located NRA2-positive epithelial cells was 
approximately 1% of total epithelial cells. Our previous research (Capuco, 2007; Capuco 
et al., 2009) and recent transcriptome profiling of LREC (Choudhary et al., 2010a) 
suggested that the basally located LREC are MaSCs, which is consistent with the 
abundance of MaSCs in other species (Kordon and Smith, 1998; Shackleton et al., 2006). 
In lactating mammary gland, we evaluated NR5A2 expression at 90 (near peak), 240 
(late) and 300 d of lactation. Abundance of NR5A2-positive cells differed significantly 
between mammary tissues from prepubertal (Figure 15D) and lactating cows (Figure 
15E) and was influenced by stage of lactation (Figure 15F). There was a significant 
difference in abundance of NR5A2-positive cells from prepubertal vs. near peak lactation 
(P < 0.01; 2.6 + 0.51 vs. 14.9 + 2.6), near peak vs. 240 d lactation (P < 0.01; 14.9 ± 2.7 
vs. 1.5 + 0.3) (Figure 15C). As lactation advanced to 300 d there was a further numerical 
decrease in abundance of NR5A2-positive cells; however, this differences was not 




difference in the nuclear staining pattern of NR5A2 in prepubertal and lactating 
mammary epithelium. In prepubertal heifers, NR5A2 staining appeared to be intense and 
uniform throughout the nucleoplasm.  In lactating gland, some cells displayed intense and 
uniform nuclear staining; whereas others exhibited punctate nuclear staining (data not 
shown). The intense and uniform nuclear staining pattern was observed at all the stges 
of lactation. However, the punctate nuclear staining pattern was predominant at peak 
lactation. We hypothesize that intense, uniform nuclear staining is a characteristic of 
MaSCs, whereas punctuate nuclear staining is characteristic of more committed 
progenitor cells. Accordingly, the data suggest that there is a temporary increase in the 
progenitor cell population during early lactation and a decline as lactation advances. This 
is consistent with the role of the preparturient dry period in promoting the turnover of 
epithelial cells (Capuco, et al., 1997) and replacement of senescent cells, including 
senescent progenitors (Capuco and Akers, 1999).  
The frequency and distribution of NUP153 expression in mammary tissue of 
prepubertal and lactating Holsteins was similar to the expression of NR5A2. NUP153-
positive cells were distributed in the basal and embedded epithelial layers of the 
prepubertal gland. Immunostaining was detected in the nuclei, either in the nuclear 
envelope or in the nucleoplasm or both, of a limited number of epithelial cells. Nuclear 
staining in mammary tissue from prepubertal heifers was intense in basal (arrow) and 
moderate or weak in embedded cells (arrowhead) (Figure 15G). Abundance of NUP153-
positive cells was 2.5 +0.4 % of total epithelial cells. Basally located NUP153-positive 
cells accounted for 0.5% of total epithelial cells and these exhibited strong nuclear 




were characterized by staining around the nuclear envelope, with a small population of 
cells showing stronger staining of the nucleoplasm (Figure 15H). We also observed wak 
to moderate nucleoplasmic staining in epithelial cells within developing / regressing 
alveoli. The cells expressing weak to moderate nuclear envelope or nucleoplasmic 
staining might represent more committed progenitor cells. The frequency of NUP153-
positive cells differed between mammary tissues from prepubertal and lactating animals 
near peak lactation (P < 0.05; 2.5 + 0.45 vs. 36.7+ 3.3) (Figure 15I).  
Immunolocalization of HNF4A was exclusively nuclear during prepubertal and 
lactation phases of mammary development. In epithelium of prepubertal heifers, HNF4A-
positive cells were scattered in basal (arrow), embedded (arrowhead) and lumenal (not 
shown) layers (Figure I5J) and represented 6.1 + 0.7% of total epithelial cells.  HNF4A-
labeled cells located in the basal epithelium accounted for 1.5 + 0.21 % of total mammary 
epithelial cells in prepubertal heifers.  In lactating cows, mammary tissue obtained at 90 d 
of lactation contained 10.79 ± 0.97 % HNF4A-positive cells of total alveolar cells (Figure 
15K). The proportion of HNF4A-positive cells was significantly different in prepubertal 
vs. lactating mammary tissues (P < 0.05; 6.1 vs. 10.8).   
We next examined the expression of Fibronectin type III domain containing 3B 
(FNDC3B) in the mammary gland of prepubertal and lactating Holsteins.  FNDC3B was 
localized exclusively in the nucleus of epithelial cells in prepubertal heifers, but localized 
in the nucleus and cytoplasm of lactating cows.  In prepubertal heifers, the strongest 
nuclear staining was found in cells of basal epithelium (arrow), with moderate staining in 




the nucleus of a small number of alveolar cells (arrows), and the cytoplasm of 
myoepithelial cells (broken arrows) (Figure 15M). 
We also evaluated putative MaSCs and differentiation markers that other 
investigators have used in studies of mouse and human mammary gland.  We found 
intense nuclear staining of the putative MaSCs marker, MSI1, in basal (arrow) and 
moderate to weak staining (arrowhead) in embedded layers of the ductal epithe ium of 
the calf (Figure 16A). In lactating mammary gland, MSI1 was localized n the nuclei of a 
small proportion of alveolar cells (Figure 16B). 
We found abundant expression of ALDH1 in nuclei and cytoplasm of lumenal 
mammary epithelial cells of prepubertal calves (Figure 16C). In lactating cows (120 d) 
we found that many alveolar cells (48 + 2.25 %) were ALDH1-positive, expressing 
ALDH1 in the nucleus (Figure 16D).  Because mammary stem cells are present in low 
abundance and appear to be located within the basal layer of the prepubertal mammary 
gland, the distribution and abundance of ALDH1-positive cells is inconsistent with the 
utility of this enzyme as a marker for bovine MaSCs.  However, this does not preclude 
the possibility that another isoform of ALDH may serve as a potential MaSCs marker. 
Immunodetection of Notch 3 protein appeared to coincide with the formation of 
the lumenal space in mammary ducts of prepubertal heifers. In this study, we found 
strong cytoplasmic staining at the apical border of the lumenal epithelium as the ductal 
lumen was formed. Developing mammary ducts with no lumen did not express Notch 3 
protein (Figure 16E). Notch 3 expression was evident with the onset of lumen formation 




































Figure 16. Immunohistochemical localization of putative stem/progenitor cell markers in 
prepubertal and lactating mammary gland.  
MSI1 staining in (A) calf and (B) lactating cow; ALDH1 staining in (C) calf and (D) 
lactating cow. Arrows indicate nuclear expression of markers in basal cells, arrowheads 
in embedded cells and broken arrows indicate cytoplasmic expression. (E-H) Notch 3 
expression and lumen formation in prepubertal mammary duct. (E) Notch 3 was not 
expressed in a cluster of unorganized epithelial cells (an underdeveloped duct). (F) 
Initiation of Notch 3 expression was observed in concomitant with lumen formation. (G) 
Small developing duct with narrow lumen shows Notch 3 expression in apical side of 
lumenal cells. (H) Fully developed duct shows increased expression of Notch 3.  Cells are 







ducts (Figure 16H). The immunohistochemical expression pattern of other Notch proteins 
might suggest their definite involvement in lumen formation of mammary ducts. 
Discussion 
The limited information available for NR5A2 is consistent with its potential 
utility as a MaSCs marker. NR5A2 has been used as a component for transforming 
somatic cells into induced pluripotent stem cells (iPSC). Specifically NR5A2 can replace 
OCT4, a pluripotency transcription factor, previously thought to be essential for 
generation iPSC from somatic cells (Heng et al., 2010).  Similarly, up-regulation of 
NR5A2 has been suggested to regulate OCT4 transcription factor in embryonic stem cells 
via SOX2 (Rizzino, 2009).  In mammary gland, NR5A2 has also been shown to exert 
potential oncogenic effects through the estrogen receptor during breast cancer formation 
(Annicotte et al., 2005).  In conjunction with our finding that LREC express NR5A2 
(Choudhary et al., 2010a), our immunohistochemical results suggest that NR5A2 is a 
pluripotency transcription factor and potential MaSCs marker. 
Although nucleoporins (NUP) are structural elements of mammalian nuclear pore 
complexes (NPCs), other roles are emerging from recent studies. NUP153 has been 
shown to play a role in organization of the nuclear envelope and indirectly regulates 
cytoskeleton architecture and mechanical properties of the cells (Zhou and Pante, 2010). 
Association of NUP153 with large genomic regions (10-500 kb) reduced expression of 
X-linked genes in NUP153 knockout Drosophila and lack of efficient transcription of 
heat shock proteins in NUP98 knockdown cells provide evidence for a role of 
nucleoporins in regulation of transcription (Mendjan et al., 2006; Vaquerizas et al., 2010; 




proteins, but shuttle between the NPC and nucleoplasm. Another study demonstrated a 
role for NUP133 in cell differentiation and found that expression of NUP133 is cell type 
specific and developmental stage-restricted, with prominent expression in dividig 
progenitors (Lupu, et al., 2009). Our transciptome profiling data (Choudhary et al., 
2010a) indicate that NUP153 is differentially expressed by MaSC/progenitor cells. We 
now show that NUP153 is expressed in the nuclear envelope and/or nucleoplasm. This 
supports a novel role for NUP153 in the nucleoplasm, possibly in regulating proliferation 
and differentiation of cells. The transient increase in NUP153-positive cells at peak 
lactation may reflect an increase in the progenitor cell population.  The functional 
significance of the varied intensity of nucleoplasmic staining requires fu ther 
investigation. However, we suggest that the strongly positive cells in the basal epithelium 
of prepubertal heifers are MaSCs, as are strongly positive alveolar cells of lactating 
gland. 
The abundance and distribution pattern of HNF4A in the mammary epithelium 
suggest that HNF4A is a potential MaSCs/progenitor marker. It is noteworthy that 
HNF4A was at the hub of the most significant gene network to be highly expressed in 
putative MaSCs (basal LREC) (Choudhary et al., 2010a). Whether, HNF4A-positive cells 
co-expressing NR5A2 or NUP153 are more primitive MaSCs remains a topic for future
investigation. 
Cytoplasmic expression of FNDC3B in myoepithelial cells, which are juxtaposed 
to the extracellular matrix (ECM), is consistent with the affinity of FNDC3B for 
fibronectin (a component of ECM) and integrin. FNDC3B binds to extracellular and cell 




and differentiation (Geiger, et al., 2001) by activating integrin-mediated intracellular 
signals (Bowditch et al., 1994). FNDC3B null mice exhibit increased postnatal mortality 
and decreased proliferation, adhesion, spreading and migration of adipocytes and 
fibroblasts (Nishizuka et al., 2009). Altogether, these observations suggest the importance 
of interaction between FNDC3B and integrins in cell growth, migration and 
differentiation. This is the first suggested involvement of FNDC3B in the bovine 
mammary gland and its possible association with MaSCs. 
MSI1 has been hypothesized to be a marker of somatic stem/progenitor cells in a 
variety of tissues including intestine, endometrium, and mammary gland  (Gotteet al., 
2008; Gotte et al., 2011;  Potten et al., 2003). A role for MSI1 in progenitor cell 
expansion, acting through Wnt and Notch pathways, has been suggested (Okano et al., 
2005; Rezza et al., 2010; Wang et al., 2008). Our results are consistent with MSI1 
expression in ewe mammary epithelium (Colitti and Farinacci, 2009) and we conclude 
that MSI1 is a potential marker of MaSCs/progenitor cells in bovine mammary gland.   
In contrast to our findings in bovine mammary gland, ALDH1-positive cells in 
human breast possess characteristics of MaSCs (Ginestier et al., 2007).  Similarly, 
ALDH1 appears to serve as a stem cell marker in other tissues, including hematopoietic 
tissue (Hess et al., 2004; Armstrong et al., 2004). Typically, identification of ALDH1-
postive cells has been based primarily on enzymatic activity of living cells for the 
fluorogenic ALDH1 substrate, aldefluor.  However, a recent study using ALDH1A1 
knockout mice indicated that not only is ALDH1A1 not essential for hematopoietic stem 
cell function, but that ALDH1A1 deficiency did not affect aldefluor staining (Levi, t al., 




Furthermore, a recent study indicated that expression of ALDH1 protein alone does not 
predict outcome of breast cancer prognosis (Neumeister, et al., 2010)  In bovine 
mammary gland, we have found increased expression of ALDH3B1 in putative bovine 
mammary stem cells (Choudhary et al., 2010a).  However, due to the absence of specific 
antibodies for this ALDH isoform, we have been unable to evaluate the abundance and 
distribution of ALDH3B1-positive cells within the bovine mammary gland. 
The mechanism of lumen formation in bovine mammary gland is unknown, but is 
not mediated by apoptotic death of epithelial cells in the central region of the ductal cord 
(Capuco et al., 2002) as occurs during lumen formation of murine ducts (Humphreys, et 
al., 1997). Therefore, regulation of apoptosis is unlikely to be a function of increased 
Notch 3 expression during lumen formation in bovine mammary gland. We also observed 
a rare subset of basal cells and adjacent embedded cells showing Notch 3 expression (not 
shown). We speculate that MaSCs divides asymmetrically in the basal layer le ding to 
formation of daughter progenitor or transit amplifying cells in the above layer. Th  Notch 
pathway may be associated with this phenomenon, as it is associated with differentiation 
of human mammary stem cells to progenitor cells (Dontu et al., 2004). A role for Notch 3 
in development of the ductal lumen of the bovine mammary gland requires additional 
research. 
In summary, the abundance and localization of cells that express NR5A2, 
NUP153, HNF4A and FNDC3B is consistent with the utility of these proteins as novel 
markers for bovine mammary stem/progenitor cells.  Cells that express the mark rs most 
strongly are located in the basal layer of the mammary epithelium of prepubertal calves, 




The pattern of nuclear expression during lactation may provide a means to distinguish 
stem and progenitor cells and suggests that stem cells are present in the alveoli during 
lactation, not only in the mammary ducts.  Expression of other putative stem 
cell/differentiation markers were also evaluated and showed that ALDH1 is not an 
appropriate marker for bovine MaSC/progenitor cells, but MSI appears to be a 
MaSC/progenitor cell marker.  Expression of Notch 3 in the mammary epithelium of 
calves suggests that it may play a role in lumen formation and in regulation of 



























Chapter 6:  In vitro expansion of mammary stem/progenitor 




Mammary stem cells are critical for growth and maintenance of the mammary 
gland and therefore of considerable interest for improving productivity and efficiency of 
dairy animals.  Xanthosine treatment has been demonstrated to promote expansion of 
putative mammary stem cells in vivo and hepatic stem cells in vitro.  In the latter c se, 
xanthosine promoted the symmetrical division of hepatic stem cells.  The objective of this 
study was to determine if treating primary cultures of bovine mammary epithelial cells 
(MEC) with xanthosine increases the stem/progenitor cell population by promoting 
symmetrical division of mammary stem cells. In vitro treatment with xanthosine 
increased the population of MEC during the exponential phase of cell growth, reducing 
the doubling time from 86 h in control cultures to 60 h in xanthosine-treated cultures.  
The bromodeoxyuridine (BrdU) labeling index and the proportion of MEC in S-phase 
both were increased by xanthosine treatment, indicating that increased cell accr tion was 
due to increased cell proliferation.  Analysis of daughter-pairs indicated that xanthosine 
promoted a shift from asymmetric to symmetric cell division.  Moreover, the 30% 
increase in symmetric cell division was concomitant with an increase in the proportion of 
MEC that were positive for a putative stem cell marker (FNDC3B) and a trend toward 
increased telomerase activity.  These results suggest that xanthosine treatm nt in vitro 




stem/progenitor cell activity. Xanthosine treatment increased the proliferation rate of 
bovine MEC in vitro.  This was likely to be mediated by an increase in the proportion of 
stem/progenitor cells in the MEC population due to promotion of symmetrical stem cell 
division by xanthosine.   
 




6.1  Background 
Expansion of stem/progenitor cells is a prerequisite for their therapeutic or 
research uses. Mammary stem cells (MaSCs) are somatic stem cells that provide for the 
lineage of mammary epithelial cells. Consequently, they are of considerable interest to 
developmental biologists, agricultural scientists and cancer researchers. Bovine MaSCs 
have received little attention despite the inherent economic importance of the species and 
the potential for impacting animal production by MaSCs manipulation, and despite the 
similarity in cytoarchitecture of bovine mammary tissue to that of the human breast 
(Capuco et al., 2002). Bovine mammary epithelial cells and their stem cells are important 
in agricultural production and bioengineering applications. Additionally, information 
gained will potentially broaden our knowledge of human mammary epithelial cells and 
stem cells. 
Somatic stem cells can divide symmetrically or asymmetrically. Symmetric 
division of stem cells produces two identical stem cells and results in expansion of the 
stem cell population.  Asymmetric division produces a stem cell and a differentiated 
progenitor cell of more committed cell lineage, while maintaining the existing em cell 
population. A novel method of expanding the rat hepatic stem cell population has been 
identified and is based on suppression of asymmetric cell kinetics. Several in vitro 
experiments indicated that p53 promotes asymmetric proliferation of somatic stem cells 
through suppression of inosine-5’-monophosphate dehydrogenase (IMPDH) (Rambhatla, 
et al., 2005; Sherley, 1991; Sherley et al., 1995), a rate-limiting enzyme in guanine 
ribonucleotide biosynthesis. A decrease in guanine ribonucleotide concentration 




nucleoside) bypass IMPDH-mediated guanine synthesis and increase guanine 
concentration in the cell, thereby promoting symmetric division and expanding the stem 
cell population (Lee et al., 2003).  
Earlier, we reported that xanthosine promotes expansion of label-retaining 
epithelial cells (LREC), putative stem cells, in prepubertal mammary gl nd in vivo 
(Capuco et al., 2009).  In order to understand the role of xanthosine, in the current study 
we evaluated growth characteristics of primary mammary epithelial c ls from the 
lactating bovine mammary gland.  The objective of this study was to investigat the 
impact of xanthosine on cell proliferation and the kinetics of stem/progenitor cell 
expansion. We show that xanthosine enhances cell proliferation, promotes symmetrical 
cell division and increases the stem/progenitor cell population. Symmetric division was 
assessed by daughter pair analysis and stem cell number was assessed by xpression of a 
potential novel stem cell marker (FNDC3B) and by telomerase activity. 
6.2  Materials and Methods 
Cultivation of bovine primary mammary epithelial cells  
Frozen stocks of bovine mammary epithelial (MEC) cells from lactating cows 
were kindly provided by Dr. David Kerr, University of Vermont.  Isolation of these clls
was described previously (Wellnitz and Kerr, 2004). 
Cell culture conditions 
Frozen cells were revived in growth medium consisting of DMEM/F12 with 5% 
FBS, ITS supplement (5 µg/mL insulin, 5 µg/mL transferrin and 0.005 µg/mL sodium 
selenite), glutamine dipeptide (2 mM; GlutaMAXTM-I), penicillin G (100 µg/mL), and 




Corning, NY, USA).  These medium supplements were obtained from Gibco/Invitrogen 
(Carlsbad, CA, USA).  Initially, cells were allowed to attach to the bottom of the T75 
tissue culture flask for 5 h and then the medium was replaced with fresh medium.  Cells 
were grown at 37°C in a humidified atmosphere of 5% CO2 in air.  For cell passage, the 
medium was discarded and the monolayer washed with phosphate buffer saline (PBS).  
Cells were then incubated in 2 mL of 0.05% trypsin-EDTA (Invitrogen, Carlsbad, CA) 
for 10-15 min at 37°C, until most cells became detached. Trypsinization was stopped by 
adding 5 mL of growth medium.  After centrifugation (23°C, 6 min, 210 x g), the cell 
pellet was resuspended in 5 mL of growth medium. For routine passage, cells were 
subcultured at a 1:4 ratio.  Cells grew to 70-80% confluency in 5 to 7 d, at which time 
they were subcultured.  Medium was replaced every 2-3 d. 
Growth characteristics of bovine mammary epithelial cells 
To evaluate the impact of xanthosine on growth characteristicics of MEC, cells 
were seeded at a density of 3 × 104 cells/well of 24-well flat bottom tissue culture plates 
(Falcon, Oxnard, CA, USA) containing one mL of growth medium with or without 200 
µM xanthosine (Sigma, Saint Louis, MO), prepared from a 10 mM stock solution of 
xanthosine (prepared in alkaline distilled water and filtered through a sterile membrane, 
0.2 µ pore size). Cell number and viability of triplicate wells were determined daily for 8 
d. Cell number was assessed by haemocytometer counts of trypsinzed cell suspension  
and viability by dye exclusion, using 0.4% trypan blue (Gibco, Carlsbad, CA, USA). 
Morphology of cells in confluent monolayers was evaluated by microscopy on day 8 after
hematoxylin staining. Three independent experiments were conducted using two 




Bromodeoxyuridine labeling index and FNDC3B staining 
MEC were seeded in 5-cm2 Petri dishes (Corning) containing growth medium 
with or without 200 µM xanthosine and grown for five d (~80% confluent). BrdU 
(Sigma, St Louis, MO, USA) was added to culture medium at a concentration of 10 µM 
during the logarithmic phase of growth.  Cells in six replicate plates per treatment were 
incubated with BrdU for 5 h, after which the monolayers were washed with chilled PBS 
(2 x 1 min) and fixed in pre-chilled methanol for 15 min at -20°C.  Cells were then 
treated with 0.3% Triton X-100 (Sigma) for 30 min, and endogenous peroxidase was 
blocked with Peroxo-block (Invitrogen) for 1 min.  Cells were treated with 2N HCl for 30 
min at RT followed by acid neutralization with 0.1 M borate buffer (2 x 5 min) and 3 
washes (3 x 2 min) in PBST (PBS + 0.05% Triton X-100).  Cells were blocked with 
casein (CAS-BlockTM, Invitrogen) for 10 min, and then incubated with mouse 
monoclonal anti-BrdU (Roche Diagnostics, Mannheim, Germany) at 1:100 dilution in 
CAS-Block for 1-2 h at RT.  After washing with PBST (3 x 3 min), cell monolayers w e 
incubated with Vector ImmPRESSTM anti-mouse/anti-rabbit Ig peroxidase conjugated 
polymer detection reagent (Vector Labs Inc., Burlingame, CA, USA) for 30 min, 
followed by washing with PBST (3 x 2 min) to remove unbound polymer.  
Immunostained cells were visualized with DAB (Vector).  Negative control staining was 
performed by omitting primary antibody.  Sections were counter-stained with 
hematoxylin for 1 min, washed briefly in water and color developed in PBS (30 s).  Cells 
were dehydrated in ascending concentrations of ethanol. Photomicrographs were obtained 




with a DP70 digital camera.  The percentage of immuno-positive cells was enumerated 
from photomicrographs of 10-12 random fields per culture plate.   
FNDC3B staining was performed as for BrdU staining, except that neither HCl 
treatment nor other antigen retrieval step was used prior to incubation with primary 
antibody.  Primary antibody was a rabbit polyclonal (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) used at 1:100 dilution. The influence of xanthosine and culture passage 
on the FNDC3B labeling index was tested by two-way ANOVA with Bonferroni 
correction using GraphPad Prism (version 3; GraphPad Software Inc., San Diego,CA, 
USA).  
Flow cytometry analysis 
To support evaluations of population doubling time and BrdU labeling index, we 
analyzed the impact of xanthosine on cell cycle distribution, using a flow cytometric 
assay.  BrdU (10 µM) was added to cell culture medium for 45 min during the log phase 
of cell growth.  Cells were then harvested by trypsinization and fixed with 70% ethanol in 
PBS overnight at 4°C.  Cells were pelleted, permeabilized with 0.3% Triton-X100 in PBS 
for 30 min at RT, and then re-pelleted.  Nuclei were suspended and incubated in 2N HCl 
for 20 min at 37°C and then neutralized with 0.1 M sodium borate buffer.  Nuclei were 
pelleted and re-suspended in PBST before blocking with 200 µL of casein (CAS Block, 
Invitrogen) for 10 min and incubating with an Alexa 488-conjugated BrdU antibody (4 
µg/mL, Molecular Probes, Invitrogen) at RT for 40 min in the dark.  Samples were then 
rinsed twice in PBST and resuspended in 500 µL of propidium iodide/RNase staining 
buffer (BD Pharmingen, San Diego, CA) for 15 min before flow cytometry.  Samples 




cytometer (Beckman Coulter Inc., Palatine, IL) and collected data were analyzed using 
Cytomics RXP (Beckman). This experiment was repeated twice with 3-5 replicat s per 
group, using cells at two different passages.  
Label retention assay 
Cells were seeded at 3x104 cells/well of 6-well plates (Corning) with added BrdU 
(10 µM) and grown for one wk. At each weekly passage, two wells were fixed and 
processed for BrdU immunostaining, while cells in the remaining four wells were 
enzymatically dissociated and sub-cultured in six wells of another 6-well plate in control 
medium.  Cell monolayers during the 3rd (n=2), 4th (n =2), 5th (n = 2), and 6th (n = 6) wks 
after BrdU labeling were immunostained and the number of LREC were counted.  Wells 
used for negative control staining were not incubated with anti-BrdU antibody.  
Daughter pair analysis 
Cells were seeded at 1.5 x 105 per T25 flask and grown until approximately 80% 
confluent. Incorporation of BrdU into nuclear DNA was performed during the log phase 
of growth to label the maximum number of cycling cells. BrdU (10 µM) was added to the
medium for 1 h prior to cell harvest.  After trypsinization, cells were plated at a 
concentration of 200 cells per well (n = 4) of a 24-well plate.  This cell density allowed 
for discrimination of individual cells and subsequent daughter-pairs.  The influence of 
xanthosine on the proportion of cells undergoing symmetric vs. asymmetric division was 
evaluated by seeding cells in control medium or medium containing 200 µM xanthosine.  
Cells were cultured for an additional 48 h (doubling time 50-60 h).  The cell monolayer 
was then washed with chilled PBS (2 x 1 min), fixed in methanol at -20ºC and processed 




were counted to determine the percentage of asymmetrical (one labeled daughter cell) 
versus symmetrical (two labeled daughter cells) division. Three independent experiments 
were performed and provided analogous results.  
Telomerase assay 
To determine cellular telomerase activity, MEC were seeded in 12-well tissue 
culture plates (Corning) at 6 x 104 cells per well in 2 mL of media with or without 200 
µM xanthosine. At 80% confluency, 0.2 mL of trypsin-EDTA solution was added to each 
well and incubated for 15 min at 37°C. Cells were dislodged and a single cell suspension 
obtained by titurating in the micropipette tip. Then 0.8 mL of growth medium was added 
to inhibit trypsin activity and the cell suspension collected in a 1.5 mL microcentrifuge 
tube. A 50 µL aliquot of the cell suspension was removed from each tube to assess cell 
viability and cell number. The remaining cell suspension (950 µL) was used to determin  
telomerase activity using a quantitative real-time PCR-based telomerase assay (US 
Biomax, Rockville, MD, USA).  Briefly, the cell suspension was centrifuged at 220 x g 
for 6 min and the pelleted cells (~ 1.0 - 1.5x105 cells) were lysed by vortexing for 1 min 
in 200 µL of the provided lysis buffer and incubating on ice for 30 min. The cell lysate 
was then centrifuged for 30 min at 12,000 x g at 4°C.  The supernate was removed and 
collected in a 0.5 mL plastic microfuge tube.  A portion of each supernate was heat 
inactivated (85°C for 10 min) and served as the negative control for that sample.  One µL
of each of sample supernate and heat-inactivated supernate were assayed along with a 





6.3  Results and Discussion 
Growth kinetics and effect of xanthosine 
The initial experiment evaluated the impact of Xs on growth of primary bovine 
MEC.  MEC plated on plastic growth surfaces in both xanthosine and control culture 
conditions displayed a cobblestone-like morpohology typical of epithelia cells in 
monolayer (Figure 17A-B).  This cell morphology is consistent with characteristics of 
bovine mammary epithelial cells as reported by others (Zhao, et al., 2010).  The viability 
assessed by trypan blue staining of xanthosine-treated cells and control cells did not 
differ (mean >98%).  These observations suggest that neither cell morphology nor cell
death rate was influenced by xanthosine treatment. The population growth rate was 
equivalent for both groups until day 3 of culture but diverged on d 4 – 6 (P < 0.05).  On d 
4 and 5, xanthosine-treated cultures showed an 18% increase in cell number over control 
cultures.  Cell number plateaued by day 7 for both treatments, as the cultures reach d 
confluence (Figure 17C).  Doubling time was calculated during the last 3 d of the
exponential phase of growth using population doubling time software 
(http://www.doubling-time.com) (Roth, 2006). At passage 3, doubling times were 50 h 
vs. 66 h for xanthosine and control cultures, respectively. MEC from a different cow at 
passage 6 grew more slowly and doubling times were 71 h vs. 106 h for xanthosine and 
control cultures, respectively. Overall, the doubling time of xanthosine treated culures 






Figure 17. Evaluation of the effects of xanthosine on cell morphology and growth rate of 
bovine MEC. A-B- Micrographs of hematoxylin stained monolayers of early-passage 
bovine MEC, demonstrating typical cobblestone morphology of cells cultured in 
xanthosine (A) and control (B) medium.  C- Growth of primary MEC in the presence and 
absence of 200 µM xanthosine.  Data are from a representative experiment using MEC at 
passage 3 presented as the mean number of cells per well (± standard error) for triplicate 
cultures.  An increase (P < 0.05) in cell number of xanthosine-treated cultures was 










Cell cycle progression 
Consistent with the increased population growth rate of xanthosine-treated cells, 
cultures that were continuously exposed to xanthosine for five d showed an increase (P < 
0.05) in the proportion of cells in S-phase (16 + 0.8; n =6) compared with control cultures 
(10.8 + 1.2; n =5) (Figure 18A-D).  Additionally, cell cycle analysis (~ 5000-10000 cells) 
of xanthosine-treated and control cultures demonstrated that the percentage of cells in the 
S-phase plus G2/M-phases was greater in xanthosine-treated than control cultures (7.3 vs. 
2.2; Figure 18E-F).  Differences in the proliferation indices between these wo 
experiments are likely a function of the duration of BrdU labeling and the proliferation 
status of cells in the two experiments presented.  Together with the lack of effect of 
xanthosine on cell viability, these data indicate that xanthosine decreases the culture 
doubling time by promoting proliferation of MEC. 
Label retaining epithelial cells 
Monolayer cultures of MEC were continuously labeled with BrdU for 7 d and 
then the persistence of BrdU label retaining epithelial cells (LREC) was evaluated for the 
following 6 wk, with passage every week.  At the end of the first week, most of the cells 
were proliferating and were labeled with BrdU. On each subsequent weekly passage the 
number of LREC decreased gradually from 13.1% (3rd wk), 3.5% (4th wk), 0.46% (5th 
wk) to 0.4% (6th wk) (Figure 19 A-E). These LREC were cycling on every passage as 
evidenced by karyokinesis (arrows) and dilution of label (arrowheads) (Figure 19 A-D). 
This low frequency (0.4% by 6th wk) of LREC was consistent with the result of an in 
vivo study in which the frequency of LREC after 42 d (6 wk) were 0.4% of total 

























Figure 18. Effect of xanthosine on cell cycle progression.  
A-D- BrdU labeling of proliferating cultures. Micrograph depicting BrdU-labeled cells 
(brown nuclei) in xanthosine-treated (A) and control (B) cultures. Negative control for 
BrdU immunostaining (C). Quantification of the BrdU labeling index in xanthosine-
treated and control cultures (D), expressed as a percentage of total cells.  Tr atment with 
xanthosine led to an increase in the percentage (mean + SE, n = 6) of BrdU positive cells. 
Scale bar = 100 µm.  E - Flow cytometric evaluation (see Methods) of cell cycle 
distribution for MEC in xanthosine-treated (E) and control cultures (F).  Xanthosie 



































Figure 19. Primary cultures of bovine MEC contain label-retaining epithelial cells 
(LREC). Growing cultures of MEC were labeled with BrdU for one wk and the 
percentage of BrdU-positive cells tracked weekly thereafter, with cell passage every wk.  
There was a progressive decrease in the number of BrdU-positive cells from wk 3 (A; n 
=2), 4 (B; n =2) and 5 (C; n = 2) to wk 6 (D; n =6), depicted in panel E. By the 6th wk the 
percentage of LREC plateaued. The LREC were actively dividing, non-quiescent cells, as 
evidenced by karyokinesis (arrows) and dilution of BrdU label in some LREC 




Recent studies have suggested that LREC represent mammary stem/progenitor cells in 
bovine mammary gland in vivo (Capuco et al., 2009; Choudhary et al., 2010a) and in 
human mammosphere cultures (Dey et al., 2009). Our preliminary data (not shown) 
indicate the xanthosine increases symmetric division of LREC in bovine MEC cultures.  
However, further characterization of these LREC is necessary. 
Symmetrical cell division and stem/progenitor cells 
To evaluate the influence of xanthosine on symmetric/asymmetric division, an in 
situ immuno-cytochemical assay was used to visualize the distribution of BrdU label 
between the two daughter cells of a parental cell division.  MEC were incubated with 
BrdU, plated at cloning density, and the distribution of label was then tracked in daughter 
cells of a parental division.  When grown in the absence of xanthosine, 56% of daughter 
pairs contained two BrdU-positive cells, indicative of symmetrical cell division and the 
even distribution of BrdU-labeled DNA between the daughter cells (Figure 20A);
whereas 44% of daughter pairs contained a single BrdU-positive cell, indicatve 
asymmetrical parental cell division (Figure 20B).  In contrast, when cells w re incubated 
with xanthosine the proportion of cells undergoing symmetrical cell division increased 
from the 56% observed in control cultures to 72% in xanthosine-treated cultures (P < 
0.05; Figure 20C).  We assume that these dividing cells contain a substantial proportion 
of stem cells (or progenitor cells) and their population is expanded by the symmetrical 
division induced by xanthosine.  This is consistent with in vitro studies by Sherley and 
colleagues, who demonstrated that treatment of rat hepatocytes with xanthosine increased 




Figure 20.  Detection of symmetric and asymmetric cell division by daughter pair 
analysis. Representative micrographs illustrating symmetric division (A) and asymmetric 
division (B) of MEC (insets are higher magnification images of two daughter cells 
depicted in the panel). C- Treatment of MEC with xanthosine led to an increase in the 
proportion of cells undergoing symmetric cell division (P < 0.05) (representative data of 
three independent experiments). Photomicrographs of FNDC3B immunostaining in 
xanthosine-treated (D) and control (E) cultures.  F- Xanthosine led to an increase in the 
percentage (mean + SE, n = 3) of FNDC3B-positive cells across different passage (P). 





Additional support for the conclusion that xanthosine increased the population of 
stem/progenitor cells is provided by increased telomerase activity and FNDC3B 
expression by xanthosine-treated cells.  We observed that xanthosine-treated cultures 
tended to have more telomerase activity (pmol/106 cells) than control cultures (0.14 vs. 
0.075; P = 0.11).  This trend toward increased telomerase activity in xanthosine-treated 
cells was consistently observed in repeated experiments. Because telomerase activity is 
primarily found in stem cells and progenitor cells (Meeker and Coffey, 1997). These data 
are consistent with a xanthosine-induced increase in the population of these cells.  
Furthermore, we showed that xanthosine treatment increased the number of FNDC3B-
positive cells in culture (Figure 20D-F). FNDC3B is a potential marker of bovine 
mammary stem and progenitor cells that we recently identified by microarray nalysis of 
LREC, which were excised by laser microdissection from cryosections of mammary 
tissue (Choudhary et al., 2010a). We quantified the percentage of FNDC3B-positive cells 
and found an increased percentage of FNDC3B-positive cells in xanthosine-treated 
cultures (n =3) compared with control cultures (9.2 + 0.9 vs. 5.0 + 1.2; P < 0.05; passage 
6).  In a cell later passage, mean percentage of FNDC3B-positive cells decline  but the 
effect of xanthosine was highly significant (7.1 + .3 vs. 2.2 + 0.4; P <0.01; passage 9). 
The effect of xanthosine on two passages were significant (P = 0.015). Together these 
observations strengthen the hypothesis that xanthosine increases the population of bovine 
mammary stem/progenitor cells in vitro, which is consistent with an earlier in vivo study 
of prepubertal bovine mammary gland wherein intramammary infusion of xanthosine 
increased the putative mammary stem cell population (Capuco et al., 2009).  We 




cells, NR5A2 and NUP153 (Choudhary et al., 2010a).  However, unlike the situation in 
histological sections, where NR5A2 staining was exclusively nuclear, cells in culture 
showed varied NR5A2 staining that ranged from faint to intense nuclear staining and 
diffuse cytoplasmic staining. NUP153 stained the majority of epithelial cells with a 
gradient that ranged from intense to weak (data not shown), making quantitation difficult.  
Apart from having a role in maintaining nuclear envelope structure, NUP153 has been 
associated with spreading and migration of breast carcinoma cells (Zhou and Pante, 
2010) and may play a role in spreading and migration of epithelial cells in culture, 
rendering it a poor progenitor cell marker in vitro.   
In the present study, we evaluated the impact of xanthosine on proliferation of 
bovine MEC in culture.  We found that xanthosine enhanced proliferation of bovine 
MEC. Xanthosine increased the number of stem/progenitor cells in culture, as evidenc d 
by an increase in the expression of FNDC3B and telomerase activity and that this was 
accomplished by enhancing symmetrical division of mammary stem cells. This study 
provides support for the ability of xanthosine to expand the mammary stem cell 
population and support for the exciting prospect of regulating mammary stem cell 












Chapter 7: Conclusions 
The overall goal of this dissertation research was to expand our knowledge of 
bovine mammary stem cells.  Specific aims  were to: (1) characterize the global ene 
expression profiles of putative bovine MaSCs and progenitor cells in vivo (2) identify 
potential protein biomarkers of MaSCs and progenitor cells and (3) confirm the utility of 
xanthosine to increase expansion of MaSCs using an in vitro model system. 
Previous studies have evaluated MaSCs after removing them from their stem cell 
niche, i.e. the microenvironment of surrounding signaling molecules and other 
noncellular components that support stem cell function and survival.  In this thesis 
research, a novel approach was taken that retains histological information by 
characterizing gene expression in putative MaSCs directly after their in situ excision from 
intact tissue. Putative stem and progenitor cells (LREC) were identified and excised from 
cryosections using laser microdissection.  To enable this approach, a method for staining 
LREC within tissue cryosections while maintaining RNA quality was first developed.  
Using this method, LREC and neighboring epithelial control (non-LREC) cells wre
identified and excised from two different locations: basal and embedded layers of the 
mammary epithelium. The underlying hypotheses were that LREC in the basal epithelial 
layer are MaSCs, whereas those in embedded layers are more committed progenitor cells, 
and that by comparing the transcriptomes of these cells with neighboring c ntrol cells 
one can obtain molecular profiles and biomarkers for MaSCs and progenitor cells.   
Results support these hypotheses and provide novel candidate markers for 
MaSCs.  Transcriptome analysis uncovered several underlying networks consistent w th 




served as potential biomarkers of MaSCs and progenitor cells.  Among these, NR5A2, 
NUP153, HNF4A and FNDC3B genes were of particular note and have been evaluated 
by immunohistochemistry as novel potential markers of prepubertal and lactating gl nd. 
Frequencies and distributions of these markers were consistent with the expectation of 
their being stem/progenitor cell characteristics. Together, these results suggest that LREC 
in the basal layer are MaSCs and that the LREC in the suprabasal layers (e.g. embedded 
layer) are progenitor cells.   
Additionally, genes that were highly expressed in LREC and encode surface 
proteins were identified (Appendix Table 6). Some, if not all, of these genes might serve 
as potential surface markers, either alone or in combination. Whereas biomarkers 
expressed in nuclei facilitate histological identification of these target cells, biomarkers 
expressed on the cell surface facilitate the isolation of viable target cells for additional 
characterization.   
In another study, I attempted to manipulate stem cell number by treating primary 
cultures of bovine mammary epithelium with xanthosine.  Previous studies had suggested 
that xanthosine in increases stem cell number in hepatic tissue in vitro and bovine 
mammary stem cells (LREC) in vivo. In this study, I found that xanthosine treatment 
increases cell proliferation, promotes symmetric cell division and increases 
stem/progenitor cell activity. This study also suggests that primary cultures of mammary 
epithelium contain LREC and that these are actively dividing cells. 
Insights into the biology of stem cells will be gained by further confirmation of 
candidate MaSCs markers identified and evaluated in this research.  Appropriate 




their functions in mammary development, homeostasis and cancer.  Specific cell surface
markers will be useful for future isolation of MaSCs and investigations of their biology.  
In vitro studies showing that xanthosine promotes symmetric division and increased 
proliferation of primary bovine mammary epithelial cells confirm previous reports in 
other systems and suggest that this nucleoside may provide an effective means to 
promote the expansion of MaSCs. 
The research described in this dissertation provides a foundation for a number of 
important future studies.  (1) It is necessary to quantify the relationship between LREC 
and the candidate biomarkers identified by this thesis research.  This would involve an 
immunohistochemical evaluation of coexpression of the various markers to each other 
and the relationship to LREC.  (2) Because data profiling gene expression in LREC and 
control cells were derived from evaluation of cells in specific locations, it is pos ible to 
identify paracrine factors that regulate cell-cell interactions.  This has not yet been fully 
explored and remains an area for future data analysis and research.  (3) The data 
presented in this thesis support the hypothesis that LRECb are stem cells and that
embedded LREC are progenitor cells.  However, demonstration of the differentation 
potentcy of these cells necessitates their isolation and evaluation using and i  vitro 
system or an in vivo system, such as the cleared fat of an immunodeficient mouse 
(perhaps made more like the bovine fat pad by prior implantation of bovine fibroblasts). 
Utilization of the putative membrane MaSC/progenitor cell markers may makesuch cell 
isolations possible by single or multiparametric flow cytometry (4) Applicability of these 
potential biomarkers to other species should be investigated.  This would involve 




(e.g., mouse) that are known to have increased stem cell functionality. (5) The in vitro
study evaluating effects of xanthosine on primary cultures of bovine mammary epithelial 
cells supports the hypothesis that xanthosine can induce expansion of the stem cell 
population.  Thus, further studies are warrented to evaluate the impact of intramammary 









Appendix Figure 1. Flow chart for identification, isolation and characterization of 









































Appendix Table 1: Transcripts that were differentially expressed in LRECb vs. ECb 




Bovine RefSeq_Description P value Fold 
change* 
XM_584232.4  PREDICTED: Bos taurus hypothetical 





XM_001788604.1  PREDICTED: Bos taurus similar to 
guanylate binding protein 4 (LOC507055), 
mRNA 
0.0000774 2.38 
XM_001790319.1  PREDICTED: Bos taurus sirtuin (silent 
mating type information regulation 2 
homolog) 2 (S. cerevisiae) (SIRT2), mRNA 
0.0001415 2.04 
XM_614275.4  PREDICTED: Bos taurus similar to one 
twenty two protein, transcript variant 1 
(RBM15), mRNA 
0.0003939 2.70 
NM_001102150.1  Bos taurus phosphoserine aminotransferase 
1 (PSAT1), mRNA 
0.0006365 2.08 
XM_001251199.1  PREDICTED: Bos taurus similar to 
SWI/SNF-related, matrix-associated actin-
dependent regulator of chromatin, subfamily 
a, containing DEAD/H box 1, transcript 
variant 1 (SMARCAD1), mRNA 
0.0007888 2.27 
NM_001037629.1  Bos taurus translocase of inner 
mitochondrial membrane 8 homolog B 
(yeast) (TIMM8B), nuclear gene encoding 
mitochondrial protein, mRNA 
0.0010158 3.44 
XR_028625.1  PREDICTED: Bos taurus misc_RNA 
(LOC521100), miscRNA 
0.0010857 2.43 
NM_001046166.1  Bos taurus PWP1 homolog (S. cerevisiae) 
(PWP1), mRNA 
0.0010980 3.22 
NM_001035424.1  Bos taurus myoneurin (Mynn), mRNA 0.0012259 2.22 
NM_001077928.1  Bos taurus plexin domain containing 2 
(PLXDC2), mRNA 
0.0012746 3.22 
XM_001249400.2  PREDICTED: Bos taurus similar to 
fibronectin type III domain containing 3B, 
transcript variant 1 (FNDC3B), mRNA 
0.0013167 2.85 
NM_001100293.1  Bos taurus chemokine (C-C motif) receptor 
4 (CCR4), mRNA 
0.0014255 2.77 
XM_610845.4  PREDICTED: Bos taurus serum deprivation 
response (phosphatidylserine binding 
protein) (SDPR), partial mRNA 
0.0014426 3.57 




regulator 1 (CCAR1), mRNA 
NM_001035405.1  Bos taurus SLAIN motif family, member 2 
(SLAIN2), mRNA 
0.0017160 2.32 
NM_001075966.1  Bos taurus reticulon 1 (RTN1), mRNA 0.0017330 2.22 
XM_615384.4  PREDICTED: Bos taurus hypothetical 
LOC535329, transcript variant 1 
(LOC535329), mRNA 
0.0017493 2.94 
XM_611687.3  PREDICTED: Bos taurus similar to WW 
and C2 domain containing 2 (WWC2), 
mRNA 
0.0018918 2.17 
XM_602501.4  PREDICTED: Bos taurus similar to 
CG10038 CG10038-PB (LOC524181), 
mRNA 
0.0019341 2.94 
NM_001001153.2  Bos taurus monoacylglycerol O-
acyltransferase 1 (MOGAT1), mRNA 
0.0019923 2.38 
XM_588427.3  PREDICTED: Bos taurus similar to cell 
division cycle 2-like 5, transcript variant 3 
(CDC2L5), mRNA 
0.0019942 2.32 
NM_001035489.1  Bos taurus mitochondrial ribosomal protein 
L38 (MRPL38), nuclear gene encoding 
mitochondrial protein, mRNA 
0.0020430 2.56 
XM_864360.3  PREDICTED: Bos taurus DEAH (Asp-Glu-
Ala-His) box polypeptide 29, transcript 
variant 3 (DHX29), mRNA 
0.0020763 2.00 
XM_591626.4  PREDICTED: Bos taurus similar to 
NKG2A (LOC513869), mRNA 
0.0022039 2.08 
NM_001076853.1  Bos taurus zinc finger, CW type with 
PWWP domain 1 (ZCWPW1), mRNA 
0.0024420 6.25 
XM_582828.3  PREDICTED: Bos taurus similar to 
exonuclease 1 (EXO1), mRNA 
0.0025101 3.33 
NM_001046051.1  Bos taurus PRP3 pre-mRNA processing 
factor 3 homolog (S. cerevisiae) (PRPF3), 
mRNA 
0.0025905 4.76 
XM_001787646.1  PREDICTED: Bos taurus similar to 
phospholipase C-like 1 (LOC537873), 
partial mRNA 
0.0026253 2.94 
NM_001101278.1  Bos taurus family with sequence similarity 
108, member B1 (FAM108B1), mRNA 
0.0026324 2.22 
XM_867682.3  PREDICTED: Bos taurus hypothetical 
LOC615784 (LOC615784), mRNA 
0.0027999 3.44 
NM_001038167.1  Bos taurus ubiquitin-conjugating enzyme 
E2D 1 (UBC4/5 homolog, yeast) (UBE2D1), 
mRNA 
0.0029172 2.56 
NM_001077009.1  Bos taurus purinergic receptor P2Y, G-





NM_001080272.1  Bos taurus oncostatin M receptor (OSMR), 
mRNA 
0.0029895 2.12 
NM_001077885.1  Bos taurus transcription factor 12 (TCF12), 
mRNA 
0.0030053 2.17 
NM_001080232.1  Bos taurus regulator of G-protein signaling 
13 (RGS13), mRNA 
0.0030566 2.04 
NM_001045944.1  Bos taurus cysteinyl-tRNA synthetase 2, 
mitochondrial (putative) (CARS2), nuclear 
gene encoding mitochondrial protein, 
mRNA 
0.0031095 2.00 
NM_001102336.1  Bos taurus hypothetical protein LOC785165 
(MGC157332), mRNA 
0.0032146 2.22 
NM_001076549.1  Bos taurus zinc finger protein 181 
(ZNF181), mRNA 
0.0035618 2.32 
NM_001102038.1  Bos taurus hippocampus abundant transcript 
1 (HIAT1), mRNA 
0.0037120 2.04 
XM_584315.4  PREDICTED: Bos taurus similar to 
chromosome 14 open reading frame 106 
(LOC507661), mRNA 
0.0038451 3.84 
NM_001099378.1  Bos taurus solute carrier family 15 
(oligopeptide transporter), member 1 
(SLC15A1), mRNA 
0.0039187 2.17 
XM_001251108.2  PREDICTED: Bos taurus similar to 
mitogen-activated protein kinase kinase 
kinase kinase 3, transcript variant 1 
(MAP4K3), mRNA 
0.0039209 2.50 
XM_612879.3  PREDICTED: Bos taurus zinc finger 
CCCH-type containing 13, transcript variant 
1 (ZC3H13), mRNA 
0.0040668 2.50 
XM_001250449.2  PREDICTED: Bos taurus mitogen-activated 
protein kinase 8 (MAPK8), mRNA 
0.0040971 2.12 
XM_592304.4  PREDICTED: Bos taurus similar to Protein 
flightless-1 homolog, transcript variant 1 
(FLII), mRNA 
0.0041069 2.12 
NM_001014923.1  Bos taurus nuclear factor (erythroid-derived 
2), 45kDa (NFE2), mRNA 
0.0041825 2.38 
NM_203323.2  Bos taurus spermidine/spermine N1-
acetyltransferase family member 2 (SAT2), 
mRNA 
0.0041956 4.34 
XM_864360.3  PREDICTED: Bos taurus DEAH (Asp-Glu-
Ala-His) box polypeptide 29, transcript 
variant 3 (DHX29), mRNA 
0.0043129 2.08 
NM_001046430.1  Bos taurus ubiquitin specific peptidase 15 
(USP15), mRNA 
0.0043334 10.00 
XM_868974.2  PREDICTED: Bos taurus THAP domain 





NM_001102190.1  Bos taurus regulating synaptic membrane 
exocytosis 2 (RIMS2), mRNA 
0.0044392 2.12 
XM_001789737.1  PREDICTED: Bos taurus hypothetical 
protein LOC616962 (LOC616962), mRNA 
0.0044770 2.50 
NM_001098066.1  Bos taurus poly(A) polymerase gamma 
(PAPOLG), mRNA 
0.0045062 3.44 
NM_001034419.1  Bos taurus hydroxyprostaglandin 
dehydrogenase 15-(NAD) (HPGD), mRNA 
0.0046655 2.70 
NM_001037463.1  Bos taurus WW domain containing E3 
ubiquitin protein ligase 1 (WWP1), mRNA 
0.0046752 3.03 
XM_599499.4  PREDICTED: Bos taurus similar to iroquois 
homeobox protein-like 1 (MKX), mRNA 
0.0048161 2.27 
XM_593139.4  PREDICTED: Bos taurus similar to 
5033413D22Rik protein (LOC515167), 
mRNA 
0.0048473 2.43 
NM_001083500.1  Bos taurus hypothetical LOC541171 
(MGC143035), mRNA 
0.0050889 2.56 
XM_001788244.1  PREDICTED: Bos taurus similar to 
ceramide kinase-like (LOC617767), mRNA 
0.0052627 2.27 
NM_001046143.1  Bos taurus CDKN2A interacting protein 
(CDKN2AIP), mRNA 
0.0053890 4.54 
NM_001035412.1  Bos taurus mitochondrial fission regulator 1 
(MTFR1), nuclear gene encoding 
mitochondrial protein, mRNA 
0.0053943 2.32 
XM_596359.4  PREDICTED: Bos taurus crumbs homolog 
1 (Drosophila) (CRB1), mRNA 
0.0054225 3.22 
XM_606001.4  PREDICTED: Bos taurus similar to 
Elongation factor Tu GTP-binding domain-
containing protein 1 (EFTUD1), partial 
mRNA 
0.0054279 2.08 
XM_864645.3  PREDICTED: Bos taurus similar to 
alkylglycerone phosphate synthase, 
transcript variant 2 (AGPS), mRNA 
0.0054312 3.22 
XM_584095.4  PREDICTED: Bos taurus similar to ankyrin 
repeat and SOCS box-containing protein 7 
(ASB7), mRNA 
0.0055161 2.32 
NM_001098106.1  Bos taurus basic transcription factor 3-like 4 
(BTF3L4), mRNA 
0.0055990 2.00 
XM_001249810.2  PREDICTED: Bos taurus similar to LON 
peptidase N-terminal domain and RING 
finger protein 3, transcript variant 1 
(LONRF3), mRNA 
0.0057335 2.38 
XM_617670.4  PREDICTED: Bos taurus similar to ankyrin 
repeat domain 41 (ANKRD41), mRNA 
0.0058692 2.63 
XM_869350.3  PREDICTED: Bos taurus similar to histone 






XM_581038.3  PREDICTED: Bos taurus similar to 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, Drosophila); 
translocated to, 4 (MLLT4), mRNA 
0.0059144 2.00 
NM_174554.2  Bos taurus insulin-like growth factor 
binding protein 1 (IGFBP1), mRNA 
0.0059435 2.56 
XM_581757.3  PREDICTED: Bos taurus similar to 
cytochrome P450 2C92 (LOC505468), 
mRNA 
0.0059466 2.38 
XM_605785.4  PREDICTED: Bos taurus similar to 
Pygopus homolog 1 (PYGO1), mRNA 
0.0059950 2.94 
XM_603252.4  PREDICTED: Bos taurus similar to 
progesterone-induced blocking factor 1 
(PIBF1), mRNA 
0.0059989 2.17 
NM_001076926.1  Bos taurus neuronal guanine nucleotide 
exchange factor (NGEF), mRNA 
0.0060157 2.27 
XM_616050.3  PREDICTED: Bos taurus similar to LATS 
homolog 1, transcript variant 1 (LATS1), 
mRNA 
0.0061121 2.27 
XM_001790585.1  PREDICTED: Bos taurus similar to 
cytoplasmic FMR1 interacting protein 1 
(LOC100141021), mRNA 
0.0063718 2.27 
XM_589504.3  PREDICTED: Bos taurus similar to DIP2 
disco-interacting protein 2 homolog B 
(DIP2B), mRNA 
0.0066679 2.63 
NM_174056.3  Bos taurus fibroblast growth factor 2 (basic) 
(FGF2), mRNA 
0.0066798 3.03 
NM_001038201.1  Bos taurus signal recognition particle 54kDa 
(SRP54), mRNA 
0.0068338 2.08 
XM_589621.4  PREDICTED: Bos taurus similar to NFX1-
type zinc finger-containing protein 1 
(ZNFX1), mRNA 
0.0071001 2.63 
XM_615492.4  PREDICTED: Bos taurus similar to 
membrane bound O-acyltransferase domain 
containing 1 (MBOAT1), mRNA 
0.0071345 2.04 
XM_615597.4  PREDICTED: Bos taurus similar to nuclear 
receptor subfamily 5, group A, member 2, 
transcript variant 1 (NR5A2), mRNA 
0.0072373 2.50 
NM_001040510.2  Bos taurus Down syndrome critical region 
protein 3 (DSCR3), mRNA 
0.0072837 2.00 
XM_614439.4  PREDICTED: Bos taurus similar to early 
endosome antigen 1, transcript variant 4 
(LOC534614), mRNA 
0.0072842 2.22 




subunit (RPP30), mRNA 
NM_001099209.1  Bos taurus hypothetical protein LOC788754 
(MGC152484), mRNA 
0.0074665 3.12 
XR_042701.1  PREDICTED: Bos taurus misc_RNA 
(LOC786759), miscRNA 
0.0075318 3.44 
NM_001075518.1  Bos taurus aldehyde dehydrogenase 3 
family, member B1 (ALDH3B1), mRNA 
0.0075521 2.00 
NM_001075547.1  Bos taurus secernin 3 (SCRN3), mRNA 0.0077030 .12 
XM_596263.4  PREDICTED: Bos taurus similar to ATP-
binding cassette transporter 13 
(LOC518080), mRNA 
0.0078359 2.77 
NM_173879.2  Bos taurus coagulation factor V 
(proaccelerin, labile factor) (F5), mRNA 
0.0078616 2.56 
XM_875092.3  PREDICTED: Bos taurus similar to 
Cytoplasmic polyadenylation element-
binding protein 3 (CPE-binding protein 3) 
(CPE-BP3) (hCPEB-3), transcript variant 3 
(CPEB3), mRNA 
0.0079752 2.12 
NM_001080289.1  Bos taurus hypothetical LOC526913 
(MGC148942), mRNA 
0.0079944 3.70 
XM_864068.3  PREDICTED: Bos taurus similar to v-raf 
murine sarcoma viral oncogene homolog B1, 
transcript variant 2 (BRAF), partial mRNA 
0.0080007 2.08 
NM_001076865.1  Bos taurus telomeric repeat binding factor 
(NIMA-interacting) 1 (TERF1), mRNA 
0.0080705 3.70 
NM_001081616.1  Bos taurus VMA21 vacuolar H+-ATPase 
homolog (S. cerevisiae) (VMA21), mRNA 
0.0082859 4.54 
NM_001109789.1  Bos taurus PRP39 pre-mRNA processing 
factor 39 homolog (S. cerevisiae) (PRPF39), 
mRNA 
0.0084216 2.77 
NM_001110181.1  Bos taurus excision repair cross-
complementing rodent repair deficiency, 
complementation group 8 (ERCC8), mRNA 
0.0084751 2.38 
XM_001790639.1  PREDICTED: Bos taurus NOL1/NOP2/Sun 
domain family, member 4 (NSUN4), mRNA 
0.0087732 2.70 
XM_001789358.1  PREDICTED: Bos taurus similar to 
membrane associated guanylate kinase, WW 
and PDZ domain containing 1, transcript 
variant 1 (LOC783484), mRNA 
0.0088459 2.43 
NM_001046029.1  Bos taurus chromosome X open reading 
frame 41 ortholog (CXHXORF41), mRNA 
0.0088953 2.00 
XM_603300.3  PREDICTED: Bos taurus similar to nuclear 
receptor interacting protein 1 (NRIP1), 
mRNA 
0.0089694 5.55 
XM_001789545.1  PREDICTED: Bos taurus similar to Obg-






XM_586772.4  PREDICTED: Bos taurus alcohol 
dehydrogenase 1C (class I), gamma 
polypeptide, transcript variant 1 (ADH1C), 
mRNA 
0.0091125 2.08 
NM_001113232.1  Bos taurus dermatan sulfate epimerase 
(DSE), mRNA 
0.0093964 2.70 
XM_592213.4  PREDICTED: Bos taurus coiled-coil 
domain containing 11 (CCDC11), mRNA 
0.0095257 4.16 
NM_001076354.1  Bos taurus MAP6 domain containing 1 
(MAP6D1), mRNA 
0.0096048 2.08 
NM_001102215.1  Bos taurus zinc finger, ZZ-type containing 3 
(ZZZ3), mRNA 
0.0096630 2.63 
NM_001046113.1  Bos taurus myocyte enhancer factor 2C 
(MEF2C), mRNA 
0.0096783 2.04 
NM_001075823.1  Bos taurus sulfotransferase family, 
cytosolic, 1B, member 1 (SULT1B1), 
mRNA 
0.0097722 2.77 
NM_001075118.1  Bos taurus pyrophosphatase (inorganic) 1 
(PPA1), mRNA 
0.0097963 2.38 
NM_001046309.1  Bos taurus BMP and activin membrane-
bound inhibitor homolog (Xenopus laevis) 
(BAMBI), mRNA 
0.0098548 2.00 
NM_001075749.1  Bos taurus radixin (RDX), mRNA 0.0099143 2.50 
NM_001113282.1  Bos taurus processing of precursor 4, 
ribonuclease P/MRP subunit (S. cerevisiae) 
(POP4), transcript variant 1, mRNA 
0.0100811 2.94 
XM_585315.3  PREDICTED: Bos taurus hypothetical 
LOC508527 (LOC508527), mRNA 
0.0101561 2.32 
NM_001046060.1  Bos taurus GTPase, IMAP family member 4 
(GIMAP4), mRNA 
0.0102828 2.77 
NM_174011.3  Bos taurus CD3e molecule, epsilon (CD3-
TCR complex) (CD3E), mRNA 
0.0103942 2.08 
NM_001083734.1  Bos taurus ring finger and SPRY domain 
containing 1 (RSPRY1), mRNA 
0.0104790 2.43 
NM_001081736.1  Bos taurus IKK interacting protein (IKIP), 
mRNA 
0.0105793 2.32 
XM_001253151.2  PREDICTED: Bos taurus similar to von 
Willebrand factor C and EGF domains 
(VWCE), mRNA 
0.0106237 2.22 
NM_001076112.1  Bos taurus GLI pathogenesis-related 2 
(GLIPR2), mRNA 
0.0107706 2.50 
XM_864958.3  PREDICTED: Bos taurus similar to G 






NM_001015557.1  Bos taurus hepatocyte nuclear factor 4, 
alpha (HNF4A), mRNA 
0.0109094 2.00 
XM_615064.4  PREDICTED: Bos taurus similar to Dixin 
(DIX domain-containing protein 1) (Coiled-
coil protein DIX1) (Coiled-coil-DIX1) 
(DIXDC1), mRNA 
0.0109587 2.22 
XM_590563.4  PREDICTED: Bos taurus similar to Protein 
SPT2 homolog (SPT2 domain-containing 
protein 1) (Protein KU002155) (SPTY2D1), 
mRNA 
0.0110319 2.50 
NM_174071.2  Bos taurus glycine receptor, beta (GLRB), 
mRNA 
0.0110402 2.56 
NM_001076164.1  Bos taurus protein phosphatase 1, regulatory 
(inhibitor) subunit 3C (PPP1R3C), mRNA 
0.0111674 2.04 
NM_001076835.1  Bos taurus kelch-like 20 (Drosophila) 
(KLHL20), mRNA 
0.0113016 2.22 
XM_592504.4  PREDICTED: Bos taurus similar to START 
domain containing 10 (STARD10), mRNA 
0.0114595 4.54 
XM_878406.3  PREDICTED: Bos taurus similar to protein 
kinase N2, transcript variant 3 (PKN2), 
mRNA 
0.0115115 2.94 
NM_174385.2  Bos taurus latent transforming growth factor 
beta binding protein 2 (LTBP2), mRNA 
0.0116489 2.27 
NM_001076065.1  Bos taurus esterase D/formylglutathione 
hydrolase (ESD), mRNA 
0.0118133 2.27 
NM_001081529.1  Bos taurus family with sequence similarity 
55, member C (FAM55C), mRNA 
0.0118487 2.63 
NM_001012399.1  Bos taurus hemochromatosis (hfe), mRNA 0.0119556 2.00 
XM_001253405.2  PREDICTED: Bos taurus similar to dual 
specificity phosphatase 11 (LOC786531), 
mRNA 
0.0119634 2.56 
NM_001083791.1  Bos taurus SH3 domain binding glutamic 
acid-rich protein like 2 (SH3BGRL2), 
mRNA 
0.0121882 2.00 
NM_001076973.1  Bos taurus hypothetical protein FLJ13868 
(FLJ13868), mRNA 
0.0122437 2.32 
XM_587287.4  PREDICTED: Bos taurus proline-rich 
cyclin A1-interacting protein (PROCA1), 
mRNA 
0.0122585 2.08 
NM_001046523.1  Bos taurus hepatitis A virus cellular 
receptor 1 N-terminal domain containing 
protein (MGC137099), mRNA 
0.0123479 3.12 
NM_001076299.3  Bos taurus solute carrier family 25, member 
40 (SLC25A40), nuclear gene encoding 





XM_581753.4  PREDICTED: Bos taurus similar to 
pseudouridylate synthase 7 homolog (S. 
cerevisiae)-like (PUS7L), mRNA 
0.0125166 3.84 
NM_174456.2  Bos taurus N-myristoyltransferase 2 
(NMT2), mRNA 
0.0126052 2.38 
NM_001034599.1  Bos taurus chromosome 10 open reading 
frame 58 ortholog (C28H10orf58), mRNA 
0.0127909 2.27 
NM_001075479.1  Bos taurus paraoxonase 3 (PON3), mRNA 0.0127931 2. 2 
NM_001113277.1  Bos taurus kininogen 1 (KNG1), transcript 
variant II, mRNA 
0.0127964 2.22 
XM_592026.4  PREDICTED: Bos taurus caspase 1, 
apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase), transcript 
variant 1 (CASP1), mRNA 
0.0128057 2.32 
XM_588044.3  PREDICTED: Bos taurus similar to 
Uncharacterized protein KIAA0247 
(LOC510837), mRNA 
0.0128084 2.27 
NM_001015642.2  Bos taurus carboxypeptidase X (M14 
family), member 1 (CPXM1), mRNA 
0.0129254 2.77 
NM_001101167.1  Bos taurus RCD1 required for cell 
differentiation1 homolog (S. pombe) 
(RQCD1), mRNA 
0.0130297 2.22 
NM_001099066.1  Bos taurus solute carrier family 25 
(mitochondrial carrier; phosphate carrier), 
member 24 (SLC25A24), nuclear gene 
encoding mitochondrial protein, mRNA 
0.0131019 2.43 
NM_001130931.1  Bos taurus nucleoporin 205kDa (NUP205), 
mRNA 
0.0132027 2.12 
NM_001038195.1  Bos taurus IQ motif containing G (IQCG), 
mRNA 
0.0133012 2.70 
NM_001014933.2  Bos taurus CSE1 chromosome segregation 
1-like (yeast) (CSE1L), mRNA 
0.0139152 2.43 
XM_864293.3  PREDICTED: Bos taurus similar to 
Transcription cofactor vestigial-like protein 
1 (Vgl-1) (Protein TONDU), transcript 
variant 4 (VGLL1), mRNA 
0.0139606 2.94 
XR_043028.1  PREDICTED: Bos taurus misc_RNA 
(LOC100138100), miscRNA 
0.0140994 2.17 
XM_606667.4  PREDICTED: Bos taurus similar to 
jumonji, AT rich interactive domain 2 
protein, transcript variant 6 (JARID2), 
mRNA 
0.0141447 2.50 
NM_174684.2  Bos taurus ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha subunit 1, 
cardiac muscle (ATP5A1), nuclear gene 





NM_001015639.1  Bos taurus proteasome (prosome, 
macropain) 26S subunit, ATPase, 2 
(PSMC2), mRNA 
0.0144093 3.33 
XM_001252669.1  PREDICTED: Bos taurus similar to 
Endopin 1b, transcript variant 1 
(LOC784964), mRNA 
0.0145056 2.08 
NM_001105457.1  Bos taurus cytotoxic and regulatory T cell 
molecule (CRTAM), mRNA 
0.0145094 2.00 
NM_001083437.1  Bos taurus chromosome 8 open reading 
frame 70 ortholog (C14H8ORF70), mRNA 
0.0146269 2.12 
NM_001083416.1  Bos taurus EF-hand domain family, member 
A1 (EFHA1), mRNA 
0.0147691 2.04 
NM_174714.2  Bos taurus elastase 2A (ELA2A), mRNA 0.0149778 3.22 
XM_614458.4  PREDICTED: Bos taurus CAP-GLY 
domain containing linker protein 1, 
transcript variant 1 (CLIP1), mRNA 
0.0150572 4.76 
XM_001251704.2  PREDICTED: Bos taurus GTP 
cyclohydrolase 1 (dopa-responsive dystonia) 
(GCH1), mRNA 
0.0151185 2.04 
XM_865801.2  PREDICTED: Bos taurus similar to DNA 
polymerase zeta catalytic subunit (hREV3), 
transcript variant 2 (REV3L), mRNA 
0.0151627 2.32 
NM_001098157.1  Bos taurus hypothetical protein LOC784871 
(MGC155143), mRNA 
0.0152206 2.38 
XM_871203.3  PREDICTED: Bos taurus similar to cDNA 
sequence BC004004 (LOC618886), mRNA 
0.0152369 2.38 
XM_868213.3  PREDICTED: Bos taurus similar to 
Transcobalamin-1 precursor 
(Transcobalamin I) (TCI) (TC I) (TCN1), 
mRNA 
0.0153443 3.12 
XR_042741.1  PREDICTED: Bos taurus misc_RNA 
(LOC785805), miscRNA 
0.0156604 2.56 
XM_594174.3  PREDICTED: Bos taurus NOL1/NOP2/Sun 
domain family, member 2 (NSUN2), mRNA 
0.0157375 4.54 
NM_174199.2  Bos taurus transition protein 1 (during 
histone to protamine replacement) (TNP1), 
mRNA 
0.0157765 2.08 
XM_868284.3  PREDICTED: Bos taurus similar to MRG-
binding protein (LOC616297), mRNA 
0.0160638 2.63 
NM_001101217.1  Bos taurus far upstream element (FUSE) 
binding protein 3 (FUBP3), mRNA 
0.0163915 2.00 
NM_001083757.1  Bos taurus adenylate kinase 5 (AK5), 
mRNA 
0.0165100 2.50 
NM_001098085.1  Bos taurus copine VIII (CPNE8), mRNA 0.0166754 2.38 






NM_001105436.1  Bos taurus AU RNA binding protein/enoyl-
Coenzyme A hydratase (AUH), nuclear gene 
encoding mitochondrial protein, mRNA 
0.0168548 2.70 
NM_001015672.2  Bos taurus family with sequence similarity 
134, member B (FAM134B), mRNA 
0.0169066 2.04 
XM_001250879.2  PREDICTED: Bos taurus similar to Rho 
guanine nucleotide exchange factor 3 
(Exchange factor found in platelets and 
leukemic and neuronal tissues) (XPLN) 
(ARHGEF3), mRNA 
0.0169439 2.00 
NM_001079773.1  Bos taurus sperm equatorial segment protein 
1 (SPESP1), mRNA 
0.0169528 2.56 
NM_001109789.1  Bos taurus PRP39 pre-mRNA processing 
factor 39 homolog (S. cerevisiae) (PRPF39), 
mRNA 
0.0171074 2.50 
XM_614941.4  PREDICTED: Bos taurus similar to 
ATPase, class I, type 8B, member 1, 
transcript variant 1 (ATP8B1), mRNA 
0.0173030 2.56 
NM_001075782.1  Bos taurus ADP-ribosylation factor-like 6 
(ARL6), mRNA 
0.0173410 2.32 
NM_001075430.1  Bos taurus retinoic acid receptor responder 
(tazarotene induced) 1 (RARRES1), mRNA 
0.0173763 2.94 
NM_001082601.1  Bos taurus ubiquitin protein ligase E3 
component n-recognin 7 (putative) (UBR7), 
mRNA 
0.0175333 2.77 
NM_001034447.1  Bos taurus fructose-1,6-bisphosphatase 1 
(FBP1), mRNA 
0.0176705 2.56 
NM_001105258.1  Bos taurus kinesin family member 20B 
(KIF20B), mRNA 
0.0176928 2.32 
NM_174301.3  Bos taurus chemokine (C-X-C motif) 
receptor 4 (CXCR4), mRNA 
0.0177191 4.00 
NM_194465.2  Bos taurus murine retrovirus integration site 
1 homolog (MRVI1), transcript variant 2, 
mRNA 
0.0178000 2.85 
XM_594801.4  PREDICTED: Bos taurus non-SMC 
condensin II complex, subunit G2 
(NCAPG2), mRNA 
0.0178074 2.56 
XR_027254.2  PREDICTED: Bos taurus misc_RNA 
(LOC530341), miscRNA 
0.0178521 2.17 
XM_592997.4  PREDICTED: Bos taurus similar to deltex 
3-like (Drosophila) (DTX3L), mRNA 
0.0178923 2.17 
NM_001102264.1  Bos taurus cystinosis, nephropathic 
(CTNS), mRNA 
0.0180025 2.00 
NM_001083665.1  Bos taurus chromosome X open reading 





XM_587403.4  PREDICTED: Bos taurus similar to Zinc 
finger protein 800, transcript variant 1 
(ZNF800), mRNA 
0.0182360 2.63 
NM_001075523.1  Bos taurus keratin 25 (KRT25), mRNA 0.0183781 2.00 
NM_001075704.1  Bos taurus chromosome 12 open reading 
frame 4 ortholog (C5H12ORF4), mRNA 
0.0184511 2.12 
XR_028361.2  PREDICTED: Bos taurus misc_RNA 
(LOC535064), miscRNA 
0.0188705 2.22 
NM_001100314.1  Bos taurus phosphoinositide-3-kinase, 
regulatory subunit 4 (PIK3R4), mRNA 
0.0189040 2.17 
XM_588277.3  PREDICTED: Bos taurus similar to zinc 
finger, CCHC domain containing 8, 
transcript variant 1 (ZCCHC8), mRNA 
0.0190035 2.85 
NM_001029846.1  Bos taurus 2',5'-oligoadenylate synthetase 1, 
40/46kDa (OAS1), mRNA 
0.0190270 2.27 
NM_001100384.1  Bos taurus PPPDE peptidase domain 
containing 1 (PPPDE1), mRNA 
0.0190358 2.12 
XM_001788655.1  PREDICTED: Bos taurus similar to ATP-
dependent Clp protease ATP-binding subunit 
clpX-like, mitochondrial (LOC100138870), 
mRNA 
0.0192995 2.04 
XM_001253451.1  PREDICTED: Bos taurus CD320 molecule 
(CD320), mRNA 
0.0194922 2.22 
XM_614763.4  PREDICTED: Bos taurus asp (abnormal 
spindle) homolog, microcephaly associated 
(Drosophila) (ASPM), mRNA 
0.0196826 2.70 
XM_001252887.2  PREDICTED: Bos taurus regulator of G-
protein signaling 1, transcript variant 1 
(RGS1), mRNA 
0.0199903 3.33 
XM_001790155.1  PREDICTED: Bos taurus hydroxysteroid 
(17-beta) dehydrogenase 6 homolog (mouse) 
(HSD17B6), mRNA 
0.0200277 2.22 
XM_612914.4  PREDICTED: Bos taurus killer cell lectin-
like receptor subfamily B, member 1 
(KLRB1), mRNA 
0.0204399 2.12 
XM_001253131.2  PREDICTED: Bos taurus similar to solute 
carrier family 10 (sodium/bile acid 
cotransporter family), member 5 
(SLC10A5), mRNA 
0.0204546 10.00 
NM_174002.2  Bos taurus calcium-sensing receptor 
(CASR), mRNA 
0.0205922 3.12 
XM_582594.4  PREDICTED: Bos taurus similar to zinc 
finger protein 77 (pT1) (LOC506181), 
partial mRNA 
0.0206840 2.56 






NM_001034497.1  Bos taurus solute carrier family 25, member 
34 (SLC25A34), mRNA 
0.0208241 2.70 
XM_581232.3  PREDICTED: Bos taurus similar to Rho 
GTPase activating protein 21 (ARHGAP21), 
mRNA 
0.0208455 6.25 
NM_001081519.1  Bos taurus DNA-damage-inducible 
transcript 4-like (DDIT4L), mRNA 
0.0209815 2.27 
NM_174327.1  Bos taurus guanine nucleotide binding 
protein (G protein), gamma transducing 
activity polypeptide 1 (GNGT1), mRNA 
0.0214050 2.94 
NM_001101962.1  Bos taurus tubulin, epsilon 1 (TUBE1), 
mRNA 
0.0214546 2.04 
XM_597427.4  PREDICTED: Bos taurus similar to 
phosphatidylinositol glycan class V (PIGV), 
mRNA 
0.0217290 3.84 
NM_001098879.1  Bos taurus UTP18, small subunit (SSU) 
processome component, homolog (yeast) 
(UTP18), mRNA 
0.0219434 2.56 
XM_580785.4  PREDICTED: Bos taurus similar to MORC 
family CW-type zinc finger protein 2 (Zinc 
finger CW-type coiled-coil domain protein 
1), transcript variant 1 (MORC2), mRNA 
0.0221592 2.00 
NM_001015619.1  Bos taurus coiled-coil domain containing 51 
(CCDC51), mRNA 
0.0222191 2.04 
XM_591264.3  PREDICTED: Bos taurus similar to 
phospholipase C-like 3 (PLCH1), mRNA 
0.0222957 2.32 
NM_001076201.2  Bos taurus C1q and tumor necrosis factor 
related protein 7 (C1QTNF7), mRNA 
0.0223325 2.00 
NM_001034687.1  Bos taurus S100P binding protein 
(S100PBP), mRNA 
0.0223941 3.44 
XR_028739.2  PREDICTED: Bos taurus misc_RNA 
(LOC789229), miscRNA 
0.0227563 2.43 
NM_001046265.1  Bos taurus sclerostin domain containing 1 
(SOSTDC1), mRNA 
0.0227934 2.00 
XM_001788685.1  PREDICTED: Bos taurus similar to 
Kynureninase (L-kynurenine hydrolase) 
(KYNU), mRNA 
0.0228712 2.00 
NM_174083.3  Bos taurus histamine receptor H1 (HRH1), 
mRNA 
0.0229477 2.08 
NM_001105407.1  Bos taurus SUB1 homolog (S. cerevisiae) 
(SUB1), mRNA 
0.0230015 2.56 
XM_598653.4  PREDICTED: Bos taurus similar to Protein 
FAM23A (Brush border protein AdRab-C) 
(LOC520412), mRNA 
0.0230439 2.27 






NM_181029.2  Bos taurus casein alpha s1 (CSN1S1), 
mRNA 
0.0232999 2.12 
XM_614126.4  PREDICTED: Bos taurus similar to CSRP2 
binding protein, transcript variant 2 
(CSRP2BP), mRNA 
0.0234880 2.08 
XM_001252642.2  PREDICTED: Bos taurus similar to 
serine/threonine kinase (TAOK3), mRNA 
0.0236494 2.27 
NM_001083777.1  Bos taurus receptor (G protein-coupled) 
activity modifying protein 1 (RAMP1), 
mRNA 
0.0236663 2.38 
NM_001105390.1  Bos taurus importin 13 (IPO13), mRNA 0.0239759 2.43 
XM_001253780.2  PREDICTED: Bos taurus similar to 
adiponutrin (PNPLA3), mRNA 
0.0239887 2.32 
NM_001002883.2  Bos taurus ST3 beta-galactoside alpha-2,3-
sialyltransferase 6 (ST3GAL6), mRNA 
0.0240124 2.43 
XM_608505.4  PREDICTED: Bos taurus neuroligin 1 
(NLGN1), mRNA 
0.0244244 2.38 
NM_001081579.1  Bos taurus ankyrin repeat domain 22 
(ANKRD22), mRNA 
0.0244657 2.32 
NM_001038067.1  Bos taurus calcium binding tyrosine-(Y)-
phosphorylation regulated (CABYR), 
mRNA 
0.0244798 5.55 
NM_174106.2  Bos taurus microtubule-associated protein 
tau (MAPT), mRNA 
0.0245334 2.17 
NM_001079646.1  Bos taurus FXYD domain containing ion 
transport regulator 3 (FXYD3), mRNA 
0.0247732 2.70 
XM_001787389.1  PREDICTED: Bos taurus similar to methyl-
CpG binding domain protein 5 
(LOC541084), mRNA 
0.0247842 2.63 
XM_001790251.1  PREDICTED: Bos taurus similar to vesicle 
transport-related protein (LOC100140328), 
mRNA 
0.0249290 3.70 
NM_001101090.1  Bos taurus L-2-hydroxyglutarate 
dehydrogenase (L2HGDH), nuclear gene 
encoding mitochondrial protein, mRNA 
0.0249644 2.12 
XM_618164.4  PREDICTED: Bos taurus collagen, type IV, 
alpha 3 (Goodpasture antigen) (COL4A3), 
mRNA 
0.0249944 2.77 
XM_872571.3  PREDICTED: Bos taurus isocitrate 
dehydrogenase 3 (NAD+) beta, transcript 
variant 6 (IDH3B), mRNA 
0.0250154 2.63 
XM_001251796.1  PREDICTED: Bos taurus similar to Zinc 
finger X-linked protein ZXDB 
(LOC783265), mRNA 
0.0251185 2.17 






NM_001101908.1  Bos taurus transmembrane protein 120B 
(TMEM120B), mRNA 
0.0254946 2.17 
NM_001110082.1  Bos taurus RNA binding motif protein 34 
(RBM34), mRNA 
0.0255110 2.22 
NM_001034218.1  Bos taurus fetuin B (FETUB), mRNA 0.0256586 3.33 
NM_001098066.1  Bos taurus poly(A) polymerase gamma 
(PAPOLG), mRNA 
0.0257392 2.56 
XM_001254432.2  PREDICTED: Bos taurus similar to zinc 
finger protein 568 (ZNF793), mRNA 
0.0258698 2.17 
NM_001013601.3  Bos taurus histocompatibility complex, 
class II, DQ alpha, type 1 (BOLA-DQA1), 
mRNA 
0.0261112 2.38 
XM_864818.2  PREDICTED: Bos taurus similar to sirtuin 
1, transcript variant 2 (SIRT1), mRNA 
0.0262694 2.04 
XM_590508.4  PREDICTED: Bos taurus similar to 
carboxypeptidase A3 (LOC512903), mRNA 
0.0271513 2.17 
XM_870453.2  PREDICTED: Bos taurus similar to 
desmuslin (DMN), mRNA 
0.0275501 2.38 
XM_001252642.2  PREDICTED: Bos taurus similar to 
serine/threonine kinase (TAOK3), mRNA 
0.0275658 2.08 
XM_588670.3  PREDICTED: Bos taurus similar to coiled-
coil and C2 domain containing 1B 
(CC2D1B), mRNA 
0.0275952 2.27 
NM_001035491.1  Bos taurus hypothetical protein LOC617088 
(LOC617088), mRNA 
0.0279244 2.12 
XM_001787333.1  PREDICTED: Bos taurus similar to zinc 
finger protein 665 (LOC785630), mRNA 
0.0280773 2.08 
XM_614908.4  PREDICTED: Bos taurus similar to TBC1 
domain family, member 8B (with GRAM 
domain) (TBC1D8B), mRNA 
0.0281442 2.17 
NM_181812.1  Bos taurus tRNA aspartic acid 
methyltransferase 1 (TRDMT1), mRNA 
0.0282625 2.08 
XM_865774.3  PREDICTED: Bos taurus similar to Heat 
shock 70 kDa protein 4L (Osmotic stress 
protein 94) (Heat shock 70-related protein 
APG-1), transcript variant 3 (HSPA4L), 
mRNA 
0.0283125 2.63 
NM_001101213.1  Bos taurus isochorismatase domain 
containing 1 (ISOC1), mRNA 
0.0283238 2.43 
NM_001102238.1  Bos taurus methyltransferase like 3 
(METTL3), mRNA 
0.0283867 2.27 
NM_001105034.1  Bos taurus GTPase, IMAP family member 
(LOC100125415), mRNA 
0.0284496 2.70 
XM_591968.4  PREDICTED: Bos taurus similar to aurora 






NM_174015.1  Bos taurus CD8a molecule (CD8A), mRNA 0.0286867 2.50 
NM_001075447.1  Bos taurus SP140 nuclear body protein-like 
(SP140L), mRNA 
0.0287418 2.12 
XM_603502.3  PREDICTED: Bos taurus similar to acyl-
CoA thioesterase 12 (ACOT12), mRNA 
0.0289836 2.22 
NM_174339.3  Bos taurus hypoxia inducible factor 1, alpha 
subunit (basic helix-loop-helix transcription 
factor) (HIF1A), mRNA 
0.0291543 2.08 
XM_618363.4  PREDICTED: Bos taurus similar to Cyclin-
Y-like protein 1 (CCNYL1), mRNA 
0.0291846 2.50 
XM_589151.4  PREDICTED: Bos taurus similar to Cell 
division protein kinase 6 (Serine/threonine-
protein kinase PLSTIRE) (CDK6), mRNA 
0.0293028 2.77 
NM_174007.1  Bos taurus chemokine (C-C motif) ligand 8 
(CCL8), mRNA 
0.0293548 2.00 
NM_001101872.1  Bos taurus C1q and tumor necrosis factor 
related protein 6 (C1QTNF6), mRNA 
0.0294489 2.00 
XM_001251030.1  PREDICTED: Bos taurus cutC copper 
transporter homolog (E. coli), transcript 
variant 1 (CUTC), partial mRNA 
0.0296485 2.94 
XM_599803.3  PREDICTED: Bos taurus similar to Alpha-
mannosidase 2 (Alpha-mannosidase II) 
(Mannosyl-oligosaccharide 1,3-1,6-alpha-
mannosidase) (MAN II) (Golgi alpha-
mannosidase II) (Mannosidase alpha class 
2A member 1) (MAN2A1), mRNA 
0.0297501 2.77 
XR_027328.1  PREDICTED: Bos taurus misc_RNA 
(LOC781692), miscRNA 
0.0297995 3.22 
NM_001102346.1  Bos taurus protein phosphatase 2 (formerly 
2A), regulatory subunit B'', alpha 
(PPP2R3A), mRNA 
0.0298039 2.38 
NM_001046494.1  Bos taurus dynamin 1-like (DNM1L), 
mRNA 
0.0298650 2.04 
XM_001790322.1  PREDICTED: Bos taurus coiled-coil 
domain containing 84 (CCDC84), mRNA 
0.0299294 2.12 
XR_042678.1  PREDICTED: Bos taurus misc_RNA 
(LOC510404), miscRNA 
0.0301380 2.00 
XM_611908.4  PREDICTED: Bos taurus similar to mutS 
homolog 6, transcript variant 1 (MSH6), 
mRNA 
0.0301904 4.34 
NM_001046600.1  Bos taurus regulator of G-protein signaling 
4 (RGS4), mRNA 
0.0302189 2.56 
XM_594786.4  PREDICTED: Bos taurus similar to RIKEN 
cDNA 1110067D22 (LOC516629), mRNA 
0.0302917 2.32 
NM_174651.2  Bos taurus S100 calcium binding protein 





XM_614758.4  PREDICTED: Bos taurus similar to 
Thrombospondin type-1 domain-containing 
protein 4 (LOC534844), mRNA 
0.0304536 2.17 
XM_882711.3  PREDICTED: Bos taurus similar to myosin, 
heavy chain 14, transcript variant 4 
(MYH14), mRNA 
0.0306605 2.85 
XM_581000.4  PREDICTED: Bos taurus similar to Nuclear 
pore complex protein Nup107 (Nucleoporin 
Nup107) (107 kDa nucleoporin) (NUP107), 
mRNA 
0.0316379 2.63 
NM_001037597.1  Bos taurus 5'-nucleotidase, cytosolic III 
(NT5C3), mRNA 
0.0319203 2.12 
XM_867943.3  PREDICTED: Bos taurus similar to round 
spermatid basic protein 1, transcript variant 2 
(RSBN1), mRNA 
0.0320925 2.04 
NM_174043.2  Bos taurus dopamine receptor D2 (DRD2), 
mRNA 
0.0321101 3.12 
XM_586416.3  PREDICTED: Bos taurus similar to COBW 
domain-containing protein 2, transcript 
variant 1 (CBWD2), mRNA 
0.0321480 2.04 
XM_001250216.2  PREDICTED: Bos taurus similar to mutant 
UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase (GNE), mRNA 
0.0323392 2.38 
NM_001102115.1  Bos taurus bol, boule-like (Drosophila) 
(BOLL), mRNA 
0.0323714 2.38 
NM_174274.1  Bos taurus DnaJ (Hsp40) homolog, 
subfamily C, member 14 (DNAJC14), 
mRNA 
0.0324111 2.04 
NM_173948.2  Bos taurus peptidylglycine alpha-amidating 
monooxygenase (PAM), mRNA 
0.0327065 2.17 
NM_001075701.2  Bos taurus DnaJ (Hsp40) homolog, 
subfamily C, member 22 (DNAJC22), 
mRNA 
0.0327685 2.00 
XM_001252924.2  PREDICTED: Bos taurus similar to 
FLJ20489 protein (LOC784685), mRNA 
0.0327946 2.22 
NM_174225.1  Bos taurus actin, alpha 1, skeletal muscle 
(ACTA1), mRNA 
0.0333505 2.00 
NM_174041.2  Bos taurus dihydropyrimidine 
dehydrogenase (DPYD), mRNA 
0.0333591 2.12 
NM_173951.2  Bos taurus plasminogen (PLG), mRNA 0.0333752 2.17 
NM_174564.2  Bos taurus NADH dehydrogenase 
(ubiquinone) 1, subcomplex unknown, 1, 
6kDa (NDUFC1), mRNA 
0.0333782 2.94 
NM_001034361.1  Bos taurus amiloride binding protein 1 






NM_174450.3  Bos taurus regulator of G-protein signaling 
16 (RGS16), mRNA 
0.0335175 2.77 
NM_001080247.1  Bos taurus JNK1-associated membrane 
protein (JAMP), mRNA 
0.0335346 2.77 
NM_001081530.1  Bos taurus thyroid hormone receptor 
interactor 10 (TRIP10), mRNA 
0.0336298 2.00 
NM_001083468.1  Bos taurus protein phosphatase 2, regulatory 
subunit B', epsilon isoform (PPP2R5E), 
mRNA 
0.0338695 2.50 
XM_001251924.2  PREDICTED: Bos taurus similar to 
enhancer of rudimentary homolog 
(LOC783761), mRNA 
0.0340298 3.57 
XM_001787807.1  PREDICTED: Bos taurus similar to 
Leucine-rich PPR motif-containing protein, 
mitochondrial precursor (130 kDa leucine-
rich protein) (LRP 130) (GP130) 
(LOC509995), mRNA 
0.0341662 2.94 
NM_001046088.1  Bos taurus glutathione peroxidase 8 
(putative) (GPX8), mRNA 
0.0343155 3.03 
XR_028567.2  PREDICTED: Bos taurus misc_RNA 
(LOC615842), miscRNA 
0.0343346 2.32 
NM_180999.1  Bos taurus lysozyme C-2 (LYZ2), mRNA 0.0345633 2.56 
XR_027344.2  PREDICTED: Bos taurus misc_RNA 
(LOC781850), miscRNA 
0.0347901 2.08 
XM_588297.4  PREDICTED: Bos taurus similar to laminin 
5 gamma 2 subunit (LAMC2), mRNA 
0.0349305 2.08 
NM_001014382.2  Bos taurus myeloid differentiation primary 
response gene (88) (MYD88), mRNA 
0.0349376 2.08 
NM_001102191.1  Bos taurus oculocerebrorenal syndrome of 
Lowe (OCRL), mRNA 
0.0355277 2.70 
XM_001787544.1  PREDICTED: Bos taurus similar to 
cytosolic beta-glucosidase (LOC539625), 
mRNA 
0.0356552 4.76 
XM_001787931.1  PREDICTED: Bos taurus similar to 
shugoshin-like 2 (LOC532412), mRNA 
0.0357925 2.43 
NM_001007805.1  Bos taurus intestinal lysozyme (LYSB), 
mRNA 
0.0360261 2.43 
XM_583697.4  PREDICTED: Bos taurus similar to 
grancalcin (GCA), mRNA 
0.0363803 2.08 
NM_001011681.3  Bos taurus growth factor receptor-bound 
protein 14 (GRB14), mRNA 
0.0364831 2.63 
XM_001789124.1  PREDICTED: Bos taurus hypothetical 
protein LOC100137763 (LOC100137763), 
mRNA 
0.0373086 3.84 






XR_027276.2  PREDICTED: Bos taurus misc_RNA 
(LOC530104), miscRNA 
0.0378476 3.22 
NM_001046118.1  Bos taurus lysosomal multispanning 
membrane protein 5 (LAPTM5), mRNA 
0.0380083 2.38 
NM_001098032.1  Bos taurus cytoskeleton associated protein 2 
(CKAP2), mRNA 
0.0380359 3.12 
NM_001035065.1  Bos taurus small nuclear ribonucleoprotein 
D1 polypeptide 16kDa (SNRPD1), mRNA 
0.0382284 3.44 
NM_001101072.1  Bos taurus hypothetical LOC510651 
(LOC510651), mRNA 
0.0384583 2.27 
XR_028354.2  PREDICTED: Bos taurus misc_RNA 
(LOC614048), miscRNA 
0.0385518 2.43 
XM_882441.2  PREDICTED: Bos taurus hypothetical 
LOC617028 (LOC617028), mRNA 
0.0387272 2.22 
XM_608629.4  PREDICTED: Bos taurus similar to 
membrane glycoprotein SP55 (SLC17A5), 
mRNA 
0.0387823 2.08 
XR_028786.2  PREDICTED: Bos taurus misc_RNA 
(LOC789688), miscRNA 
0.0388752 2.43 
NM_001083406.1  Bos taurus chromosome 2 open reading 
frame 47 ortholog (C2H2orf47), mRNA 
0.0390070 2.38 
NM_174055.2  Bos taurus fibroblast growth factor 1 
(acidic) (FGF1), mRNA 
0.0395901 2.04 
XM_869563.3  PREDICTED: Bos taurus similar to 
karyopherin beta 1, transcript variant 2 
(KPNB1), mRNA 
0.0396176 2.32 
NM_001075503.1  Bos taurus TATA box binding protein 
(TBP)-associated factor, RNA polymerase I, 
B, 63kDa (TAF1B), mRNA 
0.0397413 2.04 
NM_001102529.1  Bos taurus SCY1-like 2 (S. cerevisiae) 
(SCYL2), mRNA 
0.0398505 2.22 
XM_590933.4  PREDICTED: Bos taurus similar to 
nucleoporin 153kDa (NUP153), mRNA 
0.0401906 7.14 
NM_001024568.1  Bos taurus ribosomal protein S11 (RPS11), 
mRNA 
0.0402654 2.50 
XM_592611.4  PREDICTED: Bos taurus fibroblast growth 
factor 10, transcript variant 2 (FGF10), 
mRNA 
0.0404237 2.63 
NM_001075737.1  Bos taurus CUE domain containing 2 
(CUEDC2), mRNA 
0.0407237 2.50 
NM_001035092.1  Bos taurus LMBR1 domain containing 1 
(LMBRD1), mRNA 
0.0410314 3.12 
XM_580765.4  PREDICTED: Bos taurus similar to 
Serine/threonine-protein phosphatase with 
EF-hands 1 (PPEF-1) (Protein phosphatase 





(Serine/threonine-protein phosphatase 7) 
(PP7) (PPEF1), mRNA 
XM_584216.4  PREDICTED: Bos taurus similar to ELL 
associated factor 1, transcript variant 1 
(EAF1), mRNA 
0.0416540 3.12 
NM_001099023.1  Bos taurus zinc finger protein 639 
(ZNF639), mRNA 
0.0418450 2.32 
XM_609023.4  PREDICTED: Bos taurus EF-hand domain 
family, member B (EFHB), mRNA 
0.0419448 2.27 
NM_001077991.1  Bos taurus RecQ protein-like (DNA 
helicase Q1-like) (RECQL), mRNA 
0.0422332 3.03 
XM_001789789.1  PREDICTED: Bos taurus similar to 
Myeloid cell surface antigen CD33 precursor 
(Sialic acid-binding Ig-like lectin 3) (Siglec-
3) (gp67) (LOC100138951), mRNA 
0.0424703 2.27 
NM_001035349.1  Bos taurus AT rich interactive domain 5A 
(MRF1-like) (ARID5A), mRNA 
0.0426112 2.38 
XM_001790636.1  PREDICTED: Bos taurus SWI/SNF related, 
matrix associated, actin dependent regulator 
of chromatin, subfamily c, member 2 
(SMARCC2), mRNA 
0.0429422 2.12 
NM_001099033.1  Bos taurus guanine nucleotide binding 
protein (G protein), beta polypeptide 4 
(GNB4), mRNA 
0.0437781 2.27 
XR_042741.1  PREDICTED: Bos taurus misc_RNA 
(LOC785805), miscRNA 
0.0437873 2.22 
NM_001034311.1  Bos taurus interleukin 22 receptor, alpha 1 
(IL22RA1), mRNA 
0.0438179 4.34 
XM_867922.3  PREDICTED: Bos taurus similar to zinc 
finger protein 1 homolog (mouse), transcript 
variant 2 (ZFP1), mRNA 
0.0438789 2.94 
XM_866635.2  PREDICTED: Bos taurus similar to 
Echinoderm microtubule-associated protein-
like 4 (EMAP-4) (Restrictedly 
overexpressed proliferation-associated 
protein) (Ropp 120), transcript variant 3 
(EML4), mRNA 
0.0439162 3.70 
NM_001082606.1  Bos taurus chromosome 9 open reading 
frame 102 ortholog (LOC508357), mRNA 
0.0439431 2.08 
NM_001101205.1  Bos taurus WEE1 homolog (S. pombe) 
(WEE1), mRNA 
0.0440466 2.32 
NM_175801.2  Bos taurus follistatin (FST), mRNA 0.0440795 4.00 
XM_585347.4  PREDICTED: Bos taurus similar to 
mesoderm induction early response 1, family 





XM_582977.4  PREDICTED: Bos taurus WNK lysine 
deficient protein kinase 2 (WNK2), mRNA 
0.0442389 3.44 
NM_174587.1  Bos taurus protein kinase C, beta (PRKCB), 
mRNA 
0.0443706 2.32 
XM_864033.3  PREDICTED: Bos taurus similar to Host 
cell factor 2 (HCF-2) (C2 factor), transcript 
variant 3 (HCFC2), mRNA 
0.0446866 2.43 
XM_870414.2  PREDICTED: Bos taurus similar to 
transmembrane protein 7 (RTP3), mRNA 
0.0448472 3.44 
XM_581568.3  PREDICTED: Bos taurus dual specificity 
phosphatase 12 (DUSP12), mRNA 
0.0452239 2.77 
XM_001787706.1  PREDICTED: Bos taurus similar to zinc 
finger protein 605 (LOC782885), mRNA 
0.0452889 2.63 
NM_001100386.1  Bos taurus yippee-like 1 (Drosophila) 
(YPEL1), mRNA 
0.0456279 2.12 
NM_174146.3  Bos taurus plasminogen activator, tissue 
(PLAT), mRNA 
0.0457835 2.17 
NM_001101143.1  Bos taurus S-adenosylhomocysteine 
hydrolase-like 2 (AHCYL2), mRNA 
0.0462430 2.56 
NM_001077994.1  Bos taurus Protein FAM149B1 
(FAM149B1), mRNA 
0.0463730 2.32 
NM_001001441.1  Bos taurus troponin T type 3 (skeletal, fast) 
(TNNT3), mRNA 
0.0465125 2.77 
NM_001076320.1  Bos taurus ADP-ribosylation factor-like 10 
(ARL10), mRNA 
0.0468835 3.33 
NM_001083469.1  Bos taurus transmembrane protein 156 
(TMEM156), mRNA 
0.0474462 2.94 
XM_585792.4  PREDICTED: Bos taurus similar to 
Oxysterol-binding protein-related protein 7 
(OSBP-related protein 7) (ORP-7), transcript 
variant 1 (OSBPL7), mRNA 
0.0474739 2.38 
NM_177510.2  Bos taurus glucosaminyl (N-acetyl) 




XM_582282.4  PREDICTED: Bos taurus similar to zinc 
finger protein 709 (ZNF627), mRNA 
0.0476163 2.85 
NM_001105477.1  Bos taurus glutamate receptor, ionotropic, 
N-methyl D-aspartate-like 1A (GRINL1A), 
mRNA 
0.0480948 2.04 
XM_867982.2  PREDICTED: Bos taurus 
microseminoprotein, beta- (MSMB), mRNA 
0.0483755 2.22 
XM_867753.3  PREDICTED: Bos taurus similar to 






XM_001787912.1  PREDICTED: Bos taurus pleckstrin 
homology domain containing, family A 
(phosphoinositide binding specific) member 
2 (PLEKHA2), mRNA 
0.0488026 2.94 
NM_001101091.1  Bos taurus DnaJ (Hsp40) homolog, 
subfamily C, member 16 (DNAJC16), 
mRNA 
0.0491185 2.04 
XM_582124.3  PREDICTED: Bos taurus similar to GC-rich 
promoter binding protein 1-like 1, transcript 
variant 1 (GPBP1L1), mRNA 
0.0492615 3.22 
NM_001114192.1  Bos taurus heat shock 70kDa protein 4 
(HSPA4), mRNA 
0.0235230 -8.10 
NM_001035052.1  Bos taurus chromosome 10 open reading 
frame 84 ortholog (C26H10orf84), mRNA 
0.0075412 -4.86 
XM_001787175.1  PREDICTED: Bos taurus hypothetical 
LOC784541 (LOC784541), mRNA 
0.0181949 -4.39 
NM_181008.2  Bos taurus casein beta (CSN2), mRNA 0.0380616 -7.51 
XR_028130.2  PREDICTED: Bos taurus misc_RNA 
(LOC617326), miscRNA 
0.0217198 -6.85 
NR_001464.2  Bos taurus X (inactive)-specific transcript 
(XIST), non-coding RNA 
0.0102795 -17.12 
XM_876383.3  PREDICTED: Bos taurus tubulin, alpha 1a, 
transcript variant 4 (TUBA1A), mRNA 
0.0227675 -5.10 
NM_001035497.1  Bos taurus ubiquitin-conjugating enzyme 
E2 variant 1 (UBE2V1), mRNA 
0.0253026 -6.16 
NM_001101875.1  Bos taurus thioredoxin interacting protein 
(TXNIP), mRNA 
0.0344490 -5.71 
NM_001034548.1  Bos taurus splicing factor 3a, subunit 3, 
60kDa (SF3A3), mRNA 
0.0125753 -2.11 
XM_001789101.1  PREDICTED: Bos taurus similar to 
endonuclease reverse transcriptase 
(LOC100140868), mRNA 
0.0264338 -10.06 
NM_174345.3  Bos taurus heat shock 70kDa protein 8 
(HSPA8), mRNA 
0.0171717 -11.20 
XM_867454.3  PREDICTED: Bos taurus similar to 
transmembrane anterior posterior 
transformation 1 (TAPT1), mRNA 
0.0273066 -6.14 
NM_001037468.1  Bos taurus cell division cycle 7 homolog (S. 
cerevisiae) (CDC7), mRNA 
0.0497627 -2.99 
NM_001078121.1  Bos taurus hypothetical protein LOC768255 
(LOC768255), mRNA 
0.0189405 -2.01 
NM_174286.2  Bos taurus cAMP responsive element 
binding protein 3 (CREB3), mRNA 
0.0354769 -7.24 
XM_614891.3  PREDICTED: Bos taurus similar to 






NM_176639.2  Bos taurus ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit e 
(ATP5I), nuclear gene encoding 
mitochondrial protein, mRNA 
0.0149600 -8.66 
XM_605970.4  PREDICTED: Bos taurus similar to 
tripartite motif protein TRIM4, transcript 
variant 1 (TRIM4), partial mRNA 
0.0365157 -2.41 
NM_001097570.1  Bos taurus STT3, subunit of the 
oligosaccharyltransferase complex, homolog 
B (S. cerevisiae) (STT3B), mRNA 
0.0105277 -2.21 
XM_614825.3  PREDICTED: Bos taurus similar to 
centrosome-associated protein 350, 
transcript variant 1 (CEP350), mRNA 
0.0381474 -3.35 
NM_001098070.1  Bos taurus O-linked N-acetylglucosamine 
(GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) (OGT), 
mRNA 
0.0100134 -4.20 
NM_175780.1  Bos taurus myosin, light chain 6, alkali, 
smooth muscle and non-muscle (MYL6), 
mRNA 
0.0390013 -9.53 
NM_001102041.1  Bos taurus Uncharacterized protein 
C13orf18 homolog (MGC165939), mRNA 
0.0038571 -5.09 
XM_864671.2  PREDICTED: Bos taurus WD repeat 
domain 40A, transcript variant 2 
(WDR40A), mRNA 
0.0206149 -12.45 
NM_001105617.1  Bos taurus homeobox A9 (HOXA9), 
mRNA 
0.0099490 -23.15 
NM_001075509.1  Bos taurus transcription factor AP-2 gamma 
(activating enhancer binding protein 2 
gamma) (TFAP2C), mRNA 
0.0188863 -14.68 
XM_876203.3  PREDICTED: Bos taurus similar to 
UPF0474 protein C5orf41, transcript variant 
2 (LOC513587), mRNA 
0.0378321 -10.19 
NM_001001443.1  Bos taurus estrogen receptor 1 (ESR1), 
mRNA 
0.0218312 -3.56 
NM_001046351.1  Bos taurus thyroid hormone receptor 
interactor 4 (TRIP4), mRNA 
0.0484421 -4.17 
NM_001076532.1  Bos taurus cell division cycle and apoptosis 
regulator 1 (CCAR1), mRNA 
0.0451928 -4.76 
XM_582135.4  PREDICTED: Bos taurus neurofilament, 
medium polypeptide (NEF3), mRNA 
0.0181622 -38.09 
XM_593741.4  PREDICTED: Bos taurus similar to 
CG33196-PB (LOC515676), mRNA 
0.0126734 -5.78 
NM_001077114.1  Bos taurus HIG1 domain family, member 





NM_001046357.1  Bos taurus transmembrane protein 173 
(TMEM173), mRNA 
0.0363261 -2.60 
NR_001464.2  Bos taurus X (inactive)-specific transcript 
(XIST), non-coding RNA 
0.0144777 -5.54 
NM_001038647.1  Bos taurus transmembrane protein 57 
(TMEM57), mRNA 
0.0036628 -2.24 
XR_028861.2  PREDICTED: Bos taurus misc_RNA 
(LOC790266), miscRNA 
0.0262241 -3.20 
XM_600663.4  PREDICTED: Bos taurus nestin (NES), 
mRNA 
0.0064388 -3.57 
NM_001083708.1  Bos taurus arsenate resistance protein 2 
(ARS2), mRNA 
0.0412354 -2.53 
XM_001788694.1  PREDICTED: Bos taurus diazepam binding 
inhibitor (GABA receptor modulator, acyl-
Coenzyme A binding protein) (DBI), mRNA 
0.0231186 -2.06 
NM_001100294.1  Bos taurus calmodulin binding transcription 
activator 1 (CAMTA1), mRNA 
0.0213992 -3.38 
NM_001008663.1  Bos taurus keratin 5 (KRT5), mRNA 0.0060916 -4.74 
NM_001099133.1  Bos taurus lactamase, beta (LACTB), 
nuclear gene encoding mitochondrial 
protein, mRNA 
0.0219931 -2.41 
NM_174568.2  Bos taurus poly(A) binding protein, 
cytoplasmic 1 (PABPC1), mRNA 
0.0016273 -22.78 
XR_042588.1  PREDICTED: Bos taurus misc_RNA 
(LOC100139984), partial miscRNA 
0.0279057 -3.04 
XM_590469.4  PREDICTED: Bos taurus similar to RAS 
protein activator like 1 (GAP1 like) 
(RASAL1), mRNA 
0.0090279 -2.45 
XM_609842.3  PREDICTED: Bos taurus similar to BTB 
and CNC homology 1 (BACH1), mRNA 
0.0022440 -4.33 
NM_001076814.1  Bos taurus malic enzyme 2, NAD(+)-
dependent, mitochondrial (ME2), nuclear 
gene encoding mitochondrial protein, 
mRNA 
0.0279784 -4.15 
XM_864452.2  PREDICTED: Bos taurus similar to 
LOC616164 protein (LOC613544), mRNA 
0.0426139 -3.43 
XM_595505.4  PREDICTED: Bos taurus similar to 
mediator complex subunit 13-like 
(MED13L), mRNA 
0.0329109 -2.43 
NM_001113745.1  Bos taurus DnaJ (Hsp40) homolog, 
subfamily C, member 13 (DNAJC13), 
mRNA 
0.0274418 -2.73 
NM_001083792.1  Bos taurus tetratricopeptide repeat domain 
9C (TTC9C), mRNA 
0.0071432 -3.00 
XM_581038.3  PREDICTED: Bos taurus similar to 





leukemia (trithorax homolog, Drosophila); 
translocated to, 4 (MLLT4), mRNA 
NM_001012682.1  Bos taurus ribosomal protein, large, P0 
(RPLP0), mRNA 
0.0269574 -7.07 
NM_001098929.1  Bos taurus splicing factor, arginine/serine-
rich 5 (SFRS5), mRNA 
0.0046074 -5.62 
NM_001040498.1  Bos taurus MHC Class I JSP.1 (JSP.1), 
mRNA 
0.0003902 -5.76 
NM_001040487.1  Bos taurus eukaryotic translation elongation 
factor 1 gamma (EEF1G), mRNA 
0.0196198 -8.68 
XM_593043.4  PREDICTED: Bos taurus similar to Zinc 
finger protein 91 (Zinc finger protein 
HTF10) (HPF7) (ZNF665), mRNA 
0.0025301 -3.92 
XM_001250793.2  PREDICTED: Bos taurus similar to small 
nuclear ribonucleoprotein polypeptide G 
(SNRPG), mRNA 
0.0330865 -5.65 
NM_001075623.1  Bos taurus ATP synthase mitochondrial F1 
complex assembly factor 2 (ATPAF2), 
nuclear gene encoding mitochondrial 
protein, mRNA 
0.0451120 -2.16 
NM_001098022.1  Bos taurus ATPase, H+ transporting, 
lysosomal accessory protein 2 (ATP6AP2), 
mRNA 
0.0292548 -3.26 
XM_001790089.1  PREDICTED: Bos taurus similar to 
endonuclease reverse transcriptase 
(LOC100140273), mRNA 
0.0033505 -4.26 
NM_001075515.1  Bos taurus 5'-nucleotidase, cytosolic III-like 
(NT5C3L), mRNA 
0.0276110 -4.72 
NM_001083515.1  Bos taurus transmembrane protein 87A 
(TMEM87A), mRNA 
0.0126441 -4.78 
XM_602857.3  PREDICTED: Bos taurus similar to 
ubiquitin specific protease 25 (USP25), 
mRNA 
0.0058494 -4.93 
NM_001012682.1  Bos taurus ribosomal protein, large, P0 
(RPLP0), mRNA 
0.0456545 -2.54 
XM_611700.4  PREDICTED: Bos taurus similar to SET 
domain containing 5, transcript variant 2 
(SETD5), mRNA 
0.0405884 -2.20 
NM_174062.3  Bos taurus ferritin, heavy polypeptide 1 
(FTH1), mRNA 
0.0382741 -4.23 
XM_865029.3  PREDICTED: Bos taurus similar to splicing 
factor 3b, subunit 1, transcript variant 2 
(SF3B1), mRNA 
0.0013511 -2.11 
XM_864599.3  PREDICTED: Bos taurus similar to splicing 
factor, arginine/serine-rich 12, transcript 





NM_001109807.1  Bos taurus peptidylprolyl isomerase G 
(cyclophilin G) (PPIG), mRNA 
0.0203114 -2.78 
XM_865383.3  PREDICTED: Bos taurus similar to Protein 
strawberry notch homolog 1 (Monocyte 
protein 3) (MOP-3), transcript variant 2 
(SBNO1), mRNA 
0.0167606 -13.50 
XM_594174.3  PREDICTED: Bos taurus NOL1/NOP2/Sun 
domain family, member 2 (NSUN2), mRNA 
0.0009117 -2.78 
XR_027542.2  PREDICTED: Bos taurus misc_RNA 
(LOC538959), miscRNA 
0.0128684 -3.74 
NM_175814.2  Bos taurus succinate dehydrogenase 
complex, subunit C, integral membrane 
protein, 15kDa (SDHC), nuclear gene 
encoding mitochondrial protein, mRNA 
0.0054062 -2.48 
NM_001014860.2  Bos taurus heterogeneous nuclear 
ribonucleoprotein F (HNRNPF), mRNA 
0.0051763 -5.45 
NM_001045935.2  Bos taurus CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) small 
phosphatase 2 (CTDSP2), mRNA 
0.0435216 -6.39 
NM_001046520.1  Bos taurus YTH domain containing 1 
(YTHDC1), mRNA 
0.0437184 -5.99 
NM_001034335.1  Bos taurus KIAA0174 (KIAA0174), mRNA 0.0484906 -3.71 
XR_042975.1  PREDICTED: Bos taurus misc_RNA 
(LOC784058), miscRNA 
0.0398500 -5.21 
NM_001080301.1  Bos taurus LUC7-like (S. cerevisiae) 
(LUC7L), mRNA 
0.0169183 -6.86 
XM_583514.4  PREDICTED: Bos taurus 
phosphoglucomutase 2 (PGM2), mRNA 
0.0324241 -5.44 
NM_001083726.1  Bos taurus SET domain and mariner 
transposase fusion gene (SETMAR), mRNA 
0.0178443 -3.77 
NM_001031760.1  Bos taurus solute carrier family 38, member 
11 (SLC38A11), mRNA 
0.0141571 -3.98 
NM_001083466.1  Bos taurus heterogeneous nuclear 
ribonucleoprotein U-like 1 (HNRNPUL1), 
mRNA 
0.0406447 -6.60 
XM_001788653.1  PREDICTED: Bos taurus similar to 
endonuclease reverse transcriptase 
(LOC100138878), mRNA 
0.0146295 -4.67 
XM_001787703.1  PREDICTED: Bos taurus similar to 
endonuclease reverse transcriptase 
(LOC100137861), mRNA 
0.0155975 -5.87 
NM_001046044.1  Bos taurus cytidine monophosphate (UMP-
CMP) kinase 1, cytosolic (CMPK1), mRNA 
0.0002082 -2.16 
XM_001249987.2  PREDICTED: Bos taurus similar to 
eukaryotic translation elongation factor 1 






XM_864796.3  PREDICTED: Bos taurus adenylosuccinate 
synthase, transcript variant 3 (ADSS), 
mRNA 
0.0152255 -2.39 
XR_042755.1  PREDICTED: Bos taurus misc_RNA 
(FBL), miscRNA 
0.0489360 -6.01 
NM_001098013.1  Bos taurus COX10 homolog, cytochrome c 
oxidase assembly protein, heme A: 
farnesyltransferase (yeast) (COX10), nuclear 
gene encoding mitochondrial protein, 
mRNA 
0.0302652 -3.84 
NM_001076209.1  Bos taurus SMAD family member 4 
(SMAD4), mRNA 
0.0179492 -6.40 
NM_001046142.1  Bos taurus general transcription factor IIB 
(GTF2B), mRNA 
0.0260409 -3.12 
NM_001076155.1  Bos taurus interleukin 1 receptor accessory 
protein (IL1RAP), mRNA 
0.0056952 -2.21 
NM_001035272.1  Bos taurus splicing factor, arginine/serine-
rich 6 (SFRS6), mRNA 
0.0403233 -4.00 
NM_001040479.1  Bos taurus periostin, osteoblast specific 
factor (POSTN), mRNA 
0.0040323 -4.93 
NM_001075788.1  Bos taurus damage-specific DNA binding 
protein 2, 48kDa (DDB2), mRNA 
0.0243865 -7.41 
NM_001038153.1  Bos taurus eukaryotic translation initiation 
factor 5B (EIF5B), mRNA 
0.0245873 -3.06 
XM_589161.4  PREDICTED: Bos taurus synaptotagmin 
binding, cytoplasmic RNA interacting 
protein (SYNCRIP), mRNA 
0.0297002 -7.71 
XR_028112.2  PREDICTED: Bos taurus misc_RNA 
(LOC784517), miscRNA 
0.0442164 -2.21 
NM_001076070.1  Bos taurus 3-oxoacid CoA transferase 1 
(OXCT1), nuclear gene encoding 
mitochondrial protein, mRNA 
0.0280594 -2.52 
XM_001790233.1  PREDICTED: Bos taurus similar to 
endonuclease reverse transcriptase 
(LOC100139370), mRNA 
0.0155737 -3.28 
XM_582135.4  PREDICTED: Bos taurus neurofilament, 
medium polypeptide (NEF3), mRNA 
0.0034747 -19.72 
XR_027849.2  PREDICTED: Bos taurus misc_RNA 
(LOC538561), miscRNA 
0.0046641 -4.40 
NM_001015533.1  Bos taurus signal sequence receptor, beta 
(translocon-associated protein beta) (SSR2), 
mRNA 
0.0434364 -3.15 
XM_001249745.2  PREDICTED: Bos taurus similar to 





factor, transcript variant 1 (BPTF), mRNA 
NM_001075947.1  Bos taurus F-box and leucine-rich repeat 
protein 14 (FBXL14), mRNA 
0.0274017 -7.08 
NM_001098006.1  Bos taurus BUD13 homolog (S. cerevisiae) 
(BUD13), mRNA 
0.0099689 -7.60 
XM_594391.4  PREDICTED: Bos taurus similar to G-
protein signaling modulator 3 (AGS3-like, 
C. elegans) (GPSM3), mRNA 
0.0334115 -4.70 
NM_001099022.1  Bos taurus Era G-protein-like 1 (E. coli) 
(ERAL1), mRNA 
0.0341951 -3.27 
XM_001250989.2  PREDICTED: Bos taurus similar to 
heterogeneous nuclear ribonucleoprotein A3 
(HNRPA3), mRNA 
0.0346428 -3.21 
NM_001082422.1  Bos taurus ribosomal protein S4, Y-linked 1 
(RPS4Y1), mRNA 
0.0202760 -5.89 
XM_001249365.2  PREDICTED: Bos taurus similar to 
C6orf49-like protein (LOC781350), mRNA 
0.0146829 -3.88 
NM_001035068.1  Bos taurus acyl-CoA synthetase family 
member 3 (ACSF3), mRNA 
0.0375326 -3.03 
NM_001102264.1  Bos taurus cystinosis, nephropathic 
(CTNS), mRNA 
0.0404995 -3.45 
NM_001083725.1  Bos taurus heterogeneous nuclear 
ribonucleoprotein D-like (HNRPDL), 
mRNA 
0.0004144 -4.72 
NM_001034279.2  Bos taurus chromosome 1 open reading 
frame 50 ortholog (C3H1ORF50), mRNA 
0.0056109 -3.99 
XM_001787372.1  PREDICTED: Bos taurus PTK2 protein 
tyrosine kinase 2 (PTK2), mRNA 
0.0288371 -2.29 
XM_001253928.2  PREDICTED: Bos taurus similar to major 
histocompatibility complex, class II, DR 
beta 3 (LOC786695), mRNA 
0.0106522 -2.58 
XM_001254849.2  PREDICTED: Bos taurus similar to 
fibrillin3 (FBN3), mRNA 
0.0354642 -2.33 
NM_001076941.1  Bos taurus ring finger protein 220 
(RNF220), mRNA 
0.0478160 -2.25 
XM_001252331.1  PREDICTED: Bos taurus similar to 
serine/arginine repetitive matrix 1, transcript 
variant 1 (SRRM1), mRNA 
0.0374443 -2.56 
NM_001075585.1  Bos taurus RIB43A domain with coiled-
coils 1 (RIBC1), mRNA 
0.0345273 -4.80 
NM_001103287.1  Bos taurus zinc finger protein 64 homolog 
(mouse) (ZFP64), mRNA 
0.0160239 -2.57 
XM_001255563.2  PREDICTED: Bos taurus similar to 
pericentrin (kendrin) (PCNT), mRNA 
0.0402414 -2.67 




NM_001075649.1  Bos taurus N-acetyltransferase 15 (GCN5-
related, putative) (NAT15), mRNA 
0.0343933 -3.63 
NM_001034399.1  Bos taurus FXYD domain containing ion 
transport regulator 6 (FXYD6), mRNA 
0.0416590 -4.19 
XM_592234.3  PREDICTED: Bos taurus similar to nuclear 
receptor binding SET domain protein 1 
(NSD1), partial mRNA 
0.0030047 -3.54 
XM_001790611.1  PREDICTED: Bos taurus similar to ferritin 
L subunit, transcript variant 2 (LOC785987), 
mRNA 
0.0395119 -2.47 
NM_001024532.2  Bos taurus proteasome (prosome, 
macropain) 26S subunit, non-ATPase, 13 
(PSMD13), mRNA 
0.0202117 -3.58 
NM_001075748.1  Bos taurus CCCTC-binding factor (zinc 
finger protein) (CTCF), mRNA 
0.0443230 -2.11 
XM_588351.4  PREDICTED: Bos taurus similar to ring 
finger protein 26 (RNF26), mRNA 
0.0438387 -2.99 
NM_001083745.1  Bos taurus GTF2I repeat domain containing 
2 (GTF2IRD2), mRNA 
0.0165003 -5.51 
NM_174099.2  Bos taurus lactate dehydrogenase A 
(LDHA), mRNA 
0.0396655 -2.31 
NM_001034694.1  Bos taurus COP9 constitutive 
photomorphogenic homolog subunit 4 
(Arabidopsis) (COPS4), mRNA 
0.0288877 -3.29 
NM_001034342.1  Bos taurus activating transcription factor 4 
(tax-responsive enhancer element B67) 
(ATF4), mRNA 
0.0344535 -4.48 
NM_001038092.1  Bos taurus chromosome 17 open reading 
frame 49 ortholog (C19H17orf49), mRNA 
0.0455655 -2.94 
XR_042834.1  PREDICTED: Bos taurus misc_RNA 
(LOC786009), partial miscRNA 
0.0392252 -6.14 
XM_616885.4  PREDICTED: Bos taurus similar to 
membrane metallo endopeptidase (MME), 
mRNA 
0.0383563 -3.12 
NM_001083439.1  Bos taurus suppressor of Ty 5 homolog (S. 
cerevisiae) (SUPT5H), mRNA 
0.0223104 -3.44 
NM_001081717.1  Bos taurus EGF-containing fibulin-like 
extracellular matrix protein 1 (EFEMP1), 
mRNA 
0.0186095 -2.43 
XM_583103.4  PREDICTED: Bos taurus similar to Rho 
GTPase activating protein 30, transcript 
variant 1 (ARHGAP30), mRNA 
0.0499581 -2.97 
XM_580963.3  PREDICTED: Bos taurus similar to TBP-
associated factor 1 (TAF1), mRNA 
0.0078859 -3.79 
XM_001251118.1  PREDICTED: Bos taurus similar to 





NM_001040645.1  Bos taurus paired box 6 (PAX6), mRNA 0.0025796 -2.77 
NM_001077113.1  Bos taurus chromosome 6 open reading 
frame 130 ortholog (C23H6orf130), mRNA 
0.0005039 -4.02 
NM_174778.1  Bos taurus ribosomal protein S27a 
(RPS27A), mRNA 
0.0078379 -2.18 
XM_001254701.2  PREDICTED: Bos taurus similar to 
Calponin 3, acidic, transcript variant 1 
(CNN3), mRNA 
0.0001859 -4.57 
XM_587683.3  PREDICTED: Bos taurus similar to Six2 
(SIX2), mRNA 
0.0121558 -3.20 
XM_581880.4  PREDICTED: Bos taurus similar to 
cartilage intermediate layer protein (CILP), 
mRNA 
0.0173826 -4.49 
NM_001100344.1  Bos taurus zinc finger protein 192 
(ZNF192), mRNA 
0.0223472 -2.66 
NM_001077830.1  Bos taurus ribosomal protein S14 (RPS14), 
mRNA 
0.0083007 -2.77 
XM_583748.3  PREDICTED: Bos taurus similar to T-box 
transcription factor TBX21 (T-box protein 
21) (Transcription factor TBLYM) (T-cell-
specific T-box transcription factor T-bet) 
(TBX21), mRNA 
0.0385482 -2.40 
NM_001098929.1  Bos taurus splicing factor, arginine/serine-
rich 5 (SFRS5), mRNA 
0.0498861 -3.64 
XM_590872.4  PREDICTED: Bos taurus similar to antigen 
identified by monoclonal antibody Ki-67 
(MKI67), mRNA 
0.0245835 -2.59 
XM_001790641.1  PREDICTED: Bos taurus dishevelled, dsh 
homolog 2 (Drosophila) (DVL2), mRNA 
0.0300229 -4.35 
NM_001035280.1  Bos taurus chromosome 14 open reading 
frame 166 ortholog (C10H14ORF166), 
mRNA 
0.0148839 -5.67 
NM_001144095.1  Bos taurus EPH receptor A1 (EPHA1), 
mRNA 
0.0437188 -4.21 
NM_205799.1  Bos taurus lysosomal protein 
transmembrane 4 alpha (LAPTM4A), 
mRNA 
0.0012534 -6.77 
NM_001015628.1  Bos taurus eukaryotic translation initiation 
factor 3, subunit I (EIF3I), mRNA 
0.0372000 -4.12 
XM_001788161.1  PREDICTED: Bos taurus similar to putative 
utrophin (LOC534358), mRNA 
0.0065054 -2.62 
NM_001075992.1  Bos taurus tuberous sclerosis 1 (TSC1), 
mRNA 
0.0476045 -3.51 
XM_590380.4  PREDICTED: Bos taurus similar to ephrin 
receptor EphA2 (EPHA2), mRNA 
0.0311043 -2.50 





NM_001105465.1  Bos taurus hypothetical protein LOC785988 
(LOC785988), mRNA 
0.0206683 -2.15 
NM_001046133.1  Bos taurus poly-U binding splicing factor 
60KDa (PUF60), mRNA 
0.0199270 -3.21 
NM_001045971.1  Bos taurus serine peptidase inhibitor, Kunitz 
type, 2 (SPINT2), mRNA 
0.0024973 -3.45 
NM_001080294.1  Bos taurus solute carrier family 6 (proline 
IMINO transporter), member 20 
(SLC6A20), mRNA 
0.0061160 -2.50 
XR_027681.2  PREDICTED: Bos taurus misc_RNA 
(LOC783022), miscRNA 
0.0347433 -5.16 
NM_001105333.1  Bos taurus ubiquitin specific peptidase 20 
(USP20), mRNA 
0.0404030 -5.73 
XM_589248.3  PREDICTED: Bos taurus similar to renin 
(REN), mRNA 
0.0432776 -3.40 
NM_001078161.2  Bos taurus hypothetical protein LOC777786 
(LOC777786), mRNA 
0.0288931 -3.84 
NM_001076394.1  Bos taurus splicing factor, arginine/serine-
rich 1 (SFRS1), mRNA 
0.0167958 -6.22 
XM_614225.4  PREDICTED: Bos taurus similar to zinc 
finger protein of the cerebellum 3, transcript 
variant 1 (ZIC3), mRNA 
0.0476748 -2.43 
NM_001017947.1  Bos taurus PDZ and LIM domain 7 
(enigma) (PDLIM7), transcript variant 1, 
mRNA 
0.0311574 -2.30 
NM_001105378.1  Bos taurus synaptosomal-associated protein, 
91kDa homolog (mouse) (SNAP91), mRNA 
0.0174253 -2.82 
NM_001035286.2  Bos taurus polymerase (DNA directed), mu 
(POLM), mRNA 
0.0161732 -2.47 
XM_001250804.2  PREDICTED: Bos taurus similar to 
fibroblast growth factor-binding protein 
(LOC783341), mRNA 
0.0296001 -2.61 
XM_001250304.2  PREDICTED: Bos taurus similar to cyclin 
T2 (CCNT2), mRNA 
0.0041832 -2.70 
XM_587361.4  PREDICTED: Bos taurus similar to 
rCG26042, transcript variant 1 (PPM1M), 
mRNA 
0.0316281 -2.36 
NM_001075283.1  Bos taurus poly(rC) binding protein 4 
(PCBP4), mRNA 
0.0143704 -2.76 
XR_027358.1  PREDICTED: Bos taurus misc_RNA 
(LOC781886), miscRNA 
0.0104707 -2.14 
XR_028398.2  PREDICTED: Bos taurus misc_RNA 
(LOC504694), miscRNA 
0.0123232 -2.02 
XM_001255132.1  PREDICTED: Bos taurus similar to 






XM_615600.4  PREDICTED: Bos taurus similar to patatin-
like phospholipase domain containing 8 
(PNPLA8), mRNA 
0.0380442 -2.24 
NM_001014901.1  Bos taurus RNA binding motif protein 14 
(RBM14), mRNA 
0.0306348 -2.34 
XM_864691.3  PREDICTED: Bos taurus similar to 
cytoplasmic polyadenylation element 
binding protein 1, transcript variant 2 
(CPEB1), mRNA 
0.0220921 -2.34 
NM_001077094.1  Bos taurus cytohesin 2 (CYTH2), mRNA 0.0017351 -3.54 
NM_001034498.1  Bos taurus translocase of inner 
mitochondrial membrane 22 homolog (yeast) 
(TIMM22), nuclear gene encoding 
mitochondrial protein, mRNA 
0.0423327 -3.18 
XM_864142.3  PREDICTED: Bos taurus similar to 
Eukaryotic translation initiation factor 1A, 
X-chromosomal (eIF-1A X isoform) (eIF-
4C), transcript variant 1 (LOC613487), 
mRNA 
0.0339264 -5.24 
NM_001015533.1  Bos taurus signal sequence receptor, beta 
(translocon-associated protein beta) (SSR2), 
mRNA 
0.0162902 -3.12 
NM_001034360.1  Bos taurus dolichyl-phosphate 
mannosyltransferase polypeptide 3 (DPM3), 
mRNA 
0.0259220 -2.07 
NM_174715.1  Bos taurus ribosomal protein L3 (Rpl3), 
mRNA 
0.0331080 -12.45 
NM_001035302.1  Bos taurus ARV1 homolog (S. cerevisiae) 
(ARV1), mRNA 
0.0225546 -4.83 
NM_001046128.1  Bos taurus phosphorylase kinase, gamma 2 
(testis) (PHKG2), mRNA 
0.0203012 -11.50 
NM_001075154.1  Bos taurus ral guanine nucleotide 
dissociation stimulator-like 2 (RGL2), 
mRNA 
0.0397883 -3.74 
XM_866334.3  PREDICTED: Bos taurus similar to cell 
division cycle 25B, transcript variant 2 
(CDC25B), mRNA 
0.0291195 -2.43 
XM_001787408.1  PREDICTED: Bos taurus similar to 
astrotactin 2 (LOC781555), partial mRNA 
0.0206163 -3.10 





XM_586902.3  PREDICTED: Bos taurus DEAD (Asp-Glu-






NM_001034285.1  Bos taurus transmembrane protein 208 
(TMEM208), mRNA 
0.0191771 -2.24 
NM_001098910.1  Bos taurus embryonal Fyn-associated 
substrate (EFS), mRNA 
0.0043734 -2.45 
XM_001250964.1  PREDICTED: Bos taurus similar to 
mCG114897 (LOC782315), mRNA 
0.0067955 -2.50 
NM_001034654.1  Bos taurus LSM14A, SCD6 homolog A (S. 








Appendix Table 2:  Transcripts that were differentially expressed in LRECe vs. ECe 





Bovine RefSeq_Description P value Fold 
change* 
NR_001464.2 XIST X (inactive)-specific transcript  0.00028 10.00 
XM_582069.4 Amyloid protein-binding protein 2 (Amyloid beta 
precursor protein-binding protein 2)  
0.03882 5.88 
NM_001046333.1 calcium/calmodulin-dependent protein kinase II 
delta (CAMK2D) 
0.00005 5.88 
NM_001046340.1 H2A histone family, member Y (H2AFY) 0.01908 5.26 
NM_001046498.1 HBS1-like (S. cerevisiae) (HBS1L) 0.04813 4.54 
NM_176659.2 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa (NDUFA3) 
0.04817 4.00 
XM_865587.3 ankyrin repeat domain 12 (ANKARD12) 0.02241 3.84 
NM_001075649.1 N-acetyltransferase 15 (GCN5-related, putative) 
(NAT15) 
0.00795 3.70 
NM_001105433.1 Collagen type XIII alpha-1 chain, partial (31%) 0.02004 3.22 
XM_001788478.1 dishevelled 3 0.03591 3.22 
NM_001103236.1 Acyl-coenzyme A oxidase 3, peroxisomal  
(Pristanoyl-CoA oxidase)  
0.00473 3.12 
NM_001076543.1 Protein regulating cytokinesis 1 (Protein regulator 
of cytokinesis 1) 
0.04865 3.12 
XM_868289.2 Rnpc2 protein  0.02595 3.00 
NM_001076945.1 Torsin B precursor (Torsin family 1 member B) 
(FKSG18 protein) 
0.03605 3.00 
NM_001098069.1 Probable transcriptional regulator, LysR family,  0.01694 3.00 
NM_001078004.1 PELI1 pellino homolog 1 (Drosophila) [ Bos 
taurus ] (PELI1) 
0.04298 2.94 
XM_001250858.2 MON2 MON2 homolog (S. cerevisiae) [ Bos 
taurus ] (MON2) 
0.03747 2.63 
XR_027593.2 similar to Selenoprotein T (SELT) 0.03908 2.56 
NM_001014862.2 Ribosomal protein L29/heparin/heparan sulfate 
interacting protein (Ribosomal protein L29/cell 
surface heparin binding protein HIP) 
0.00830 2.56 
NM_001024473.2 gypsy retrotransposon integrase 1 (GINI) 0.03900 2.50 






NM_001083468.1 Serine/threonine protein phosphatase 2A, 56 kDa 
regulatory subunit, epsilon isoform (PP2A, B 
subunit, B' epsilon isoform) (PP2A, B subunit, 
B56 epsilon isoform) (PP2A, B subunit, PR61 
epsilon isoform) (PP2A, B subunit, R5 epsilon 
isoform 
0.00608 2.43 
NM_001076900.1 Bos taurus heterogeneous nuclear 
ribonucleoprotein L-like (HNRPLL) 
 
0.00849 2.43 
XR_028008.2 SNF related kinase (SNRK) 0.04944 2.43 
NM_001077051.1 Ataxin-10 (Spinocerebellar ataxia type 10 
protein) (Brain protein E46 homolog) 
0.04175 2.43 
NM_001035056.1 transmembrane protein 111 (TMEM11) 0.03288 2.38 
NM_001076835.1 Bos taurus kelch-like 20 (Drosophila) (KLHL20) 
 
0.03386 2.38 
XM_615597.4 Orphan nuclear receptor NR5A2 (Alpha-1-
fetoprotein transcription factor) (Hepatocytic 
transcription factor) (B1-binding factor) (hB1F) 
(CYP7A promoter binding factor) 
0.04533 2.32 




XM_593410.4 PREDICTED: Bos taurus similar to LKB1 
interacting protein (STK11IP) 
 
0.00803 2.27 
XM_587229.4 PREDICTED: Bos taurus similar to serum-
inducible kinase, transcript variant 1 (PLK2) 
 
0.03486 2.22 
NM_001078099.2 DPH2 homolog (S. cerevisiae) (DPH2) 0.04872 2.22 
NM_001078161.2 Bos taurus ataxin 7-like 3B (ATXN7L3B) 
 
0.03461 2.22 
XM_001249400.2 PREDICTED: Bos taurus similar to fibronectin 
type III domain containing 3B, transcript variant 
1 (FNDC3B) 
0.03703 2.04 
NM_174130.2 Ornithine decarboxylase  (ODC)  0.03797 2.04 
NM_001034373.1 Bos taurus cytochrome P450, family 4, subfamily 
V, polypeptide 2 (CYP4V2) 
 
0.03165 2.04 








NM_001192779.1 Bos taurus protein tyrosine phosphatase, non-
receptor type 11 (PTPN11) 
0.00364 2.00 
NM_001075334.1 Bos taurus microtubule-associated protein, 
RP/EB family, member 1 (MAPRE1) 
 
0.00348 2.00 
NM_001040471.1 Glucose-6-phosphate isomerase  (GPI)  0.03622 2.00 
NM_001102183.1 ERG v-ets erythroblastosis virus E26 oncogene 
homolog (avian) [ Bos taurus ] (ERG) 
0.02054 -9.07 
NM_001076842.1 signal transducing adaptor molecule (SH3 domain 
and ITAM motif) 1 (STAM) 
0.03909 -7.66 
XM_001790635.1 HLA-B associated transcript 2-like 2 (BAT2L2) 0.03624 -6.14 
NM_001034697.1 Bos taurus tubulin, beta 4A class IVa (TUBB4A) 
 
0.01665 -6.11 
NM_001114520.1 Bos taurus calcium/calmodulin-dependent protein 
kinase II inhibitor 1 (CAMK2N1) 
0.01249 -5.66 
XR_028749.2 ciliary rootlet coiled-coil, rootletin (CROCC) 0.03916 -5.54 
XM_001251162.2 IQ motif containing GTPase activating protein 1 
(IQGAP1) 
0.04492 -5.47 
NM_001102106.1 coiled-coil domain containing 77 (CCDC77) 0.01134 -5.39 
XM_581758.4 forkhead box N3 (FOXN3) 0.01970 -4.85 
NM_001075317.1 RAB21, member RAS oncogene family (RAB21) 0.04531 -4.55 
XM_001250666.2 FUS interacting protein (serine/arginine-rich) 1 
(FUSIPI) 
0.03230 -4.42 
XM_591540.4 eukaryotic translation initiation factor 3, subunit 
F (EIF3F) 
0.00763 -4.30 
NM_001099155.1 Bos taurus CD177 molecule (CD177) 
 
0.03054 -3.73 
XM_593636.4 Microtubule-associated protein 1A (MAP 1A)  0.04977 -3.59 
NM_001110004.1 Bos taurus HECT, UBA and WWE domain 
containing 1 (HUWE1) 
0.01659 -3.57 
XM_587001.3 PREDICTED: Bos taurus adenylate cyclase 6, 
transcript variant 1 (ADCY6) 
0.03768 -3.50 




XM_001789611.1 PREDICTED: Bos taurus similar to WD repeat-











XM_001787963.1 t-complex 11 (mouse)-like 1 (TCP11L1) 0.04744 -3.12 
NM_001078081.1 chromosome 6 open reading frame 25 (C6orf25) 0.04016 -3.00 
XM_001789698.1 PREDICTED: Bos taurus myeloid/lymphoid or 
mixed-lineage leukemia 5 (trithorax homolog, 
Drosophila), transcript variant 2 (MLL5) 
 
0.02234 -2.93 




NM_001101171.1 Bos taurus abl-interactor 2 (ABI2) 
 
0.02709 -2.88 
XM_001790373.1 similar to Zinc finger protein 583 (Zinc finger 
protein L3-5) (ZFP583) 
0.00629 -2.87 
XM_872705.3 PREDICTED: Bos taurus zinc finger protein 142, 
transcript variant 2 (ZNF142) 
 
0.01362 -2.84 




XM_001256033.2 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily d, 
member 2 (SMARCD2) 
0.00668 -2.78 
XM_615671.3 anaphase promoting complex subunit 1 
(ANAPC1) 
0.01744 -2.78 
NM_001037591.1 chromosome 2 open reading frame 39 ortholog 
(C11H2ORF39) 
0.02215 -2.73 
XM_611789.4 ataxin 2 (ATXN2) 0.02135 -2.69 




NM_001008666.1 Bos taurus solute carrier family 14 (urea 
transporter), member 1 (Kidd blood group) 
(SLC14A1) 
0.01839 -2.61 
NM_001102151.1 Bos taurus enhancer of zeste homolog 1 
(Drosophila) (EZH1) 
0.03810 -2.57 




NM_001046442.1 Bos taurus KH domain containing, RNA binding, 
signal transduction associated 1 (KHDRBS1) 
 
0.04034 -2.55 
XM_882161.2 PREDICTED: Bos taurus procollagen-lysine, 2-







NM_001101060.1 v-yes-1 Yamaguchi sarcoma viral oncogene 
homolog 1 (YES1) 
0.04456 -2.51 
XM_001790627.1 HIV-1 Tat specific factor 1 (HTATSF1) 0.04214 -2.46 
XM_872313.3 PREDICTED: Bos taurus similar to Nucleosome 
assembly protein 1-like 1 (NAP-1-related protein) 
(hNRP), transcript variant 4 (LOC540136) 
 
0.00906 -2.43 
NM_001034521.1 SAR1a gene homolog (SAR1A) 0.03600 -2.42 




XM_866155.3 PREDICTED: Bos taurus similar to proline-
serine-threonine phosphatase interacting protein 
1, transcript variant 2 (PSTPIP1) 
 
0.00129 -2.40 




NM_001105620.1 ankyrin 3, node of Ranvier (ankyrin G) (ANK3) 0.04038 -2.40 
XM_870871.3 PREDICTED: Bos taurus similar to SAPS 
domain family, member 1 (SAPS1) 
 
0.01407 -2.37 
XM_001251703.2 PREDICTED: Bos taurus ribosomal protein S29-
like 
0.03232 -2.36 
NM_001102098.1 Zinc finger protein 304 (ZNF304) 0.04097 -2.33 
NM_001034765.1 Bos taurus Thy-1 cell surface antigen (THY1) 
 
0.03373 -2.33 
NM_001040520.1 Ribosomal protein L7A (RPL7A) 0.04975 -2.31 
NM_001024527.1 Bos taurus FYVE, RhoGEF and PH domain 
containing 3 (FGD3) 
 
0.05003 -2.26 




NM_001109808.1 Bos taurus adaptor-related protein complex 1, 
gamma 2 subunit (AP1G2) 
 
0.02072 -2.26 
NM_001105437.1 Potassium channel tetramerisation domain 
containing 17 (KCTD17) 
0.02854 -2.25 
XM_591190.4 Uncharacterized protein C17orf68 homolog 0.02661 -2.24 






XM_601083.4 PREDICTED: Bos taurus Kruppel-like factor 10 
(KLF10) 
0.04792 -2.20 
NM_001083456.1 Bos taurus KIAA0907 ortholog (KIAA0907) 
 
0.03512 -2.18 




XR_028120.2 PREDICTED: Bos taurus misc_RNA 
(LOC518495) 
0.03913 -2.16 
NM_001114517.1 Cytochrome c oxidase subunit VIII-H 
(heart/muscle) (COX8B) 
0.00111 -2.15 
NM_001192981   
 
Bos taurus low density lipoprotein receptor-
related protein 12 (LRP12) 
0.01258 -2.13 
NM_001034406.1 Bos taurus zinc finger CCCH-type containing 14 
(ZC3H14) 
0.04964 -2.10 
NM_174656.2 Bos taurus solute carrier family 25 (mitochondrial 
carrier; citrate transporter), member 1(SLC25A1), 
nuclear gene encoding mitochondrial protein 
0.01608 -2.08 
XM_606901.4 Protein kinase C, iota (PRKCI) 0.00988 -2.05 
NM_001035428.1 Bos taurus coiled-coil domain containing 47 
(CCDC47) 
0.00534 -2.03 
NM_001046027.1 Bos taurus thromboxane A synthase 1 (platelet) 
(TBXAS1) 
0.03955 -2.02 









Appendix Table 3:  Transcripts that were differentially expressed in LRECb vs. LRECe 




Bovine RefSeq_Description P value Fold 
change* 
NM_001046430.1  Bos taurus ubiquitin specific peptidase 15 
(USP15), mRNA 
0.00052 16.67 
NM_001081611.1  Bos taurus F-box protein 34 (FBXO34), mRNA 0.00392 16.67 
XM_001254067.2  PREDICTED: Bos taurus similar to 
trichohyalin, putative (LOC786372), mRNA 
0.02744 14.28 
NM_001098874.1  Bos taurus ribosomal protein S7 (RPS7), mRNA 0.04479 12.50 
NM_001015655.1  Bos taurus cofilin 1 (non-muscle) (CFL1), 
mRNA 
0.04363 8.33 
XM_594080.4  PREDICTED: Bos taurus similar to RNA 
polymerase I-specific transcription initiation 
factor RRN3 (Transcription initiation factor IA) 
(TIF-IA) (RRN3), mRNA 
0.03211 7.14 
NM_174520.2  Bos taurus collagen, type I, alpha 2 (COL1A2), 
mRNA 
0.02700 7.14 
NM_178317.3  Bos taurus tribbles homolog 2 (Drosophila) 
(TRIB2), mRNA 
0.00146 6.67 
NM_001076027.1  Bos taurus heat shock protein, alpha-crystallin-
related, B6 (HSPB6), mRNA 
0.01972 6.67 
XM_590933.4  PREDICTED: Bos taurus similar to nucleoporin 
153kDa (NUP153), mRNA 
0.02673 6.25 
XM_001251703.2  PREDICTED: Bos taurus similar to mCG7602 
(LOC784384), mRNA 
0.01326 6.25 
XM_001253131.2  PREDICTED: Bos taurus similar to solute 
carrier family 10 (sodium/bile acid cotransporter 
family), member 5 (SLC10A5), mRNA 
0.04262 5.88 
NM_001015543.1  Bos taurus ribosomal protein L13 (RPL13), 
mRNA 
0.00814 5.88 
XM_611689.4  PREDICTED: Bos taurus similar to Laminin 
subunit gamma-1 precursor (Laminin B2 chain) 
(LAMC1), mRNA 
0.02142 5.88 
NM_001040479.1  Bos taurus periostin, osteoblast specific factor 
(POSTN), mRNA 
0.03043 5.55 
NM_001034765.1  Bos taurus Thy-1 cell surface antigen (THY1), 
mRNA 
0.00330 5.55 
NM_001038582.1  Bos taurus electron-transfer-flavoprotein, beta 
polypeptide (ETFB), mRNA 
0.01836 5.00 
NM_001076331.1  Bos taurus MAX interactor 1 (MXI1), mRNA 0.02888 5.00 






XM_615405.4  PREDICTED: Bos taurus WD-repeat protein 33 
(WDR33), mRNA 
0.01603 5.00 
XR_043027.1  PREDICTED: Bos taurus misc_RNA 
(LOC789346), miscRNA 
0.00720 4.76 
XM_872002.3  PREDICTED: Bos taurus similar to APG16 
autophagy 16-like, transcript variant 5 
(ATG16L1), mRNA 
0.00737 4.76 
NR_024614.1  Bos taurus ribosomal protein S27 (RPS27), 
transcript variant 3, transcribed RNA 
0.01351 4.76 
NM_001040487.1  Bos taurus eukaryotic translation elongation 
factor 1 gamma (EEF1G), mRNA 
0.00711 4.76 
NM_001075946.1  Bos taurus cell adhesion molecule 3 (CADM3), 
mRNA 
0.01029 4.34 
NM_001078157.1  Bos taurus ADP-ribosylation factor-like 6 
interacting protein 1 (ARL6IP1), mRNA 
0.02483 4.34 
XM_001790104.1  PREDICTED: Bos taurus NFKB activating 
protein, transcript variant 1 (NKAP), mRNA 
0.01801 4.34 
NM_001081616.1  Bos taurus VMA21 vacuolar H+-ATPase 
homolog (S. cerevisiae) (VMA21), mRNA 
0.00728 4.34 
XM_615786.4  PREDICTED: Bos taurus peptidylprolyl 
isomerase (cyclophilin)-like 4, transcript variant 
1 (PPIL4), mRNA 
0.00801 4.16 
NM_001101894.1  Bos taurus F-box protein 11 (FBXO11), mRNA 0.04165 4.00 
NM_175801.2  Bos taurus follistatin (FST), mRNA 0.01199 4.00 
XM_603300.3  PREDICTED: Bos taurus similar to nuclear 
receptor interacting protein 1 (NRIP1), mRNA 
0.01573 4.00 
NM_001080314.1  Bos taurus GTP-binding protein 10 (putative) 
(GTPBP10), mRNA 
0.04093 4.00 
XM_588451.4  PREDICTED: Bos taurus similar to NFBD1 
(MDC1), mRNA 
0.03057 4.00 
XM_612368.4  PREDICTED: Bos taurus similar to RAN 
binding protein 17 (LOC533085), mRNA 
0.03247 3.84 
NM_001076468.1  Bos taurus HLA-B associated transcript 4 
(BAT4), mRNA 
0.03791 3.84 
NM_001035272.1  Bos taurus splicing factor, arginine/serine-rich 6 
(SFRS6), mRNA 
0.00604 3.84 
XM_614458.4  PREDICTED: Bos taurus CAP-GLY domain 
containing linker protein 1, transcript variant 1 
(CLIP1), mRNA 
0.01541 3.84 
NM_001034684.1  Bos taurus cisplatin resistance-associated 
overexpressed protein (CROP), mRNA 
0.04997 3.84 
NM_001015551.1  Bos taurus aminoadipate aminotransferase 
(AADAT), mRNA 
0.02881 3.70 
XM_614308.4  PREDICTED: Bos taurus coiled-coil domain 





NM_001075601.1  Bos taurus monocyte to macrophage 
differentiation-associated (MMD), mRNA 
0.01548 3.70 
XM_866635.2  PREDICTED: Bos taurus similar to Echinoderm 
microtubule-associated protein-like 4 (EMAP-4) 
(Restrictedly overexpressed proliferation-
associated protein) (Ropp 120), transcript variant 
3 (EML4), mRNA 
0.01380 3.70 
XM_867978.3  PREDICTED: Bos taurus chromosome 9 open 
reading frame 16 ortholog (C11H9orf16), 
mRNA 
0.00067 3.70 
XM_868974.2  PREDICTED: Bos taurus THAP domain 
containing 9 (THAP9), mRNA 
0.02239 3.57 
XM_611908.4  PREDICTED: Bos taurus similar to mutS 
homolog 6, transcript variant 1 (MSH6), mRNA 
0.04898 3.57 
NM_001035432.1  Bos taurus CCR4-NOT transcription complex, 
subunit 4 (CNOT4), mRNA 
0.01503 3.57 
NM_001083643.1  Bos taurus NIMA (never in mitosis gene a)-
related kinase 3 (NEK3), mRNA 
0.00078 3.44 
NM_174564.2  Bos taurus NADH dehydrogenase (ubiquinone) 
1, subcomplex unknown, 1, 6kDa (NDUFC1), 
mRNA 
0.00282 3.44 
NM_001034555.2  Bos taurus S100 calcium binding protein B 
(S100B), mRNA 
0.01983 3.44 
NM_174033.3  Bos taurus CYB5 protein (CYB5), mRNA 0.00081 3.44 
NM_001046143.1  Bos taurus CDKN2A interacting protein 
(CDKN2AIP), mRNA 
0.01020 3.44 
NM_174301.3  Bos taurus chemokine (C-X-C motif) receptor 4 
(CXCR4), mRNA 
0.03667 3.44 
NM_001075297.1  Bos taurus interleukin 33 (IL33), mRNA 0.00711 3.33 
NM_001076023.1  Bos taurus chromosome 12 open reading frame 
49 ortholog (C9H12orf49), mRNA 
0.03312 3.33 
XM_600235.4  PREDICTED: Bos taurus myeloid/lymphoid or 
mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 3 (MLLT3), mRNA 
0.03043 3.33 
NM_174387.2  Bos taurus mannosidase, beta A, lysosomal 
(MANBA), mRNA 
0.01136 3.33 
NM_001114082.1  Bos taurus angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8) (AGT), mRNA 
0.00681 3.33 
XM_597427.4  PREDICTED: Bos taurus similar to 
phosphatidylinositol glycan class V (PIGV), 
mRNA 
0.02774 3.33 
NM_001102259.1  Bos taurus chromosome 10 open reading frame 
6 ortholog (C26H10ORF6), mRNA 
0.03744 3.33 
NM_174043.2  Bos taurus dopamine receptor D2 (DRD2), 
mRNA 
0.04227 3.33 





NM_174087.3  Bos taurus insulin-like growth factor 2 
(somatomedin A) (IGF2), mRNA 
0.00711 3.22 
NM_001002887.1  Bos taurus paternally expressed 3 (PEG3), 
mRNA 
0.01719 3.22 
XM_001787646.1  PREDICTED: Bos taurus similar to 
phospholipase C-like 1 (LOC537873), partial 
mRNA 
0.00028 3.22 
NM_001046461.1  Bos taurus TRIM6-TRIM34 readthrough 
transcript (TRIM6-TRIM34), mRNA 
0.00422 3.22 
XR_042825.1  PREDICTED: Bos taurus misc_RNA 
(MAML3), partial miscRNA 
0.02367 3.22 
XM_001249464.2  PREDICTED: Bos taurus similar to intersectin 1 
long form (ITSN1), mRNA 
0.03861 3.22 
NM_001077991.1  Bos taurus RecQ protein-like (DNA helicase 
Q1-like) (RECQL), mRNA 
0.01667 3.22 
XM_606010.4  PREDICTED: Bos taurus similar to solute 
carrier family 35, member B3 (SLC35B3), 
mRNA 
0.03799 3.22 
NM_001034591.1  Bos taurus zinc finger, C3HC-type containing 1 
(ZC3HC1), mRNA 
0.00205 3.22 
XM_588427.3  PREDICTED: Bos taurus similar to cell division 
cycle 2-like 5, transcript variant 3 (CDC2L5), 
mRNA 
0.00594 3.12 
XM_582124.3  PREDICTED: Bos taurus similar to GC-rich 
promoter binding protein 1-like 1, transcript 
variant 1 (GPBP1L1), mRNA 
0.01704 3.12 
NM_001080289.1  Bos taurus hypothetical LOC526913 
(MGC148942), mRNA 
0.00460 3.12 
XM_001790627.1  PREDICTED: Bos taurus HIV-1 Tat specific 
factor 1 (HTATSF1), mRNA 
0.03675 3.12 
XM_614320.4  PREDICTED: Bos taurus similar to Dmx-like 1 
(DMXL1), mRNA 
0.02635 3.12 
NM_001015565.1  Bos taurus poly(rC) binding protein 1 (PCBP1), 
mRNA 
0.04980 3.12 
NM_001076320.1  Bos taurus ADP-ribosylation factor-like 10 
(ARL10), mRNA 
0.01185 3.12 
XM_582283.3  PREDICTED: Bos taurus similar to huntingtin 
interacting protein 1 (HIP1), mRNA 
0.01904 3.12 
NM_203323.2  Bos taurus spermidine/spermine N1-
acetyltransferase family member 2 (SAT2), 
mRNA 
0.01429 3.00 
NM_001099033.1  Bos taurus guanine nucleotide binding protein 





XM_001787807.1  PREDICTED: Bos taurus similar to Leucine-
rich PPR motif-containing protein, mitochondrial 
precursor (130 kDa leucine-rich protein) (LRP 
130) (GP130) (LOC509995), mRNA 
0.00516 3.00 
XM_001251924.2  PREDICTED: Bos taurus similar to enhancer of 
rudimentary homolog (LOC783761), mRNA 
0.03672 3.00 
XM_864250.3  PREDICTED: Bos taurus similar to DNA repair 
and recombination protein RAD54B (RAD54 
homolog B), transcript variant 2 (RAD54B), 
mRNA 
0.04770 3.00 
NM_001078069.1  Bos taurus protein tyrosine phosphatase, non-
receptor type 18 (brain-derived) (PTPN18), 
mRNA 
0.04115 3.00 
NM_001035428.1  Bos taurus coiled-coil domain containing 47 
(CCDC47), mRNA 
0.01911 3.00 
XM_593991.4  PREDICTED: Bos taurus similar to 
transmembrane 6 superfamily member 2 
(TM6SF2), mRNA 
0.02394 2.94 
XR_027597.2  PREDICTED: Bos taurus misc_RNA 
(LOC532189), miscRNA 
0.00015 2.94 
XR_028749.2  PREDICTED: Bos taurus misc_RNA 
(LOC530641), miscRNA 
0.00281 2.94 
NM_001046517.1  Bos taurus lymphocyte antigen 96 (LY96), 
mRNA 
0.03013 2.94 
XM_591415.4  PREDICTED: Bos taurus similar to 
Uncharacterized protein C1orf160 
(LOC513687), mRNA 
0.01677 2.94 
NM_001034673.1  Bos taurus chromosome 12 open reading frame 
23 ortholog (C5H12orf23), mRNA 
0.03579 2.94 
NM_001103319.1  Bos taurus phospholamban (PLN), mRNA 0.00565 2.85 
XM_584232.4  PREDICTED: Bos taurus hypothetical 
LOC539014, transcript variant 1 (LOC539014), 
mRNA 
0.02942 2.85 
XR_043032.1  PREDICTED: Bos taurus misc_RNA (AOC3), 
miscRNA 
0.01480 2.85 
XM_584266.4  PREDICTED: Bos taurus similar to partner and 
localizer of BRCA2 (PALB2), mRNA 
0.01058 2.85 
NM_001099710.1  Bos taurus muscleblind-like 2 (Drosophila) 
(MBNL2), mRNA 
0.01823 2.85 
NM_001109795.1  Bos taurus alpha-2-macroglobulin (A2M), 
mRNA 
0.01895 2.85 
NM_001105341.1  Bos taurus TRAF and TNF receptor associated 
protein (TTRAP), mRNA 
0.00817 2.85 
NM_001034583.1  Bos taurus component of oligomeric golgi 





XM_601617.4  PREDICTED: Bos taurus topoisomerase I 
binding, arginine/serine-rich (TOPORS), mRNA 
0.01047 2.77 
XM_598625.4  PREDICTED: Bos taurus similar to calmodulin 
regulated spectrin-associated protein 1-like 1 
(LOC520385), mRNA 
0.02197 2.77 
XR_028796.2  PREDICTED: Bos taurus misc_RNA 
(LOC615883), miscRNA 
0.03802 2.77 
NM_001098038.1  Bos taurus kinesin family member 23 (KIF23), 
mRNA 
0.01480 2.77 
NM_001083469.1  Bos taurus transmembrane protein 156 
(TMEM156), mRNA 
0.04739 2.77 
NM_001078131.1  Bos taurus nuclear receptor binding factor 2 
(NRBF2), mRNA 
0.04746 2.77 
NM_001101843.1  Bos taurus collectin sub-family member 12 
(COLEC12), mRNA 
0.04699 2.77 
NM_001076414.1  Bos taurus transmembrane BAX inhibitor motif 
containing 6 (TMBIM6), mRNA 
0.01504 2.77 
XM_869402.2  PREDICTED: Bos taurus similar to MYST 
histone acetyltransferase (monocytic leukemia) 3 
(LOC529373), mRNA 
0.04771 2.77 
XM_585792.4  PREDICTED: Bos taurus similar to Oxysterol-
binding protein-related protein 7 (OSBP-related 
protein 7) (ORP-7), transcript variant 1 
(OSBPL7), mRNA 
0.03672 2.70 
NM_001035361.1  Bos taurus RNA binding motif, single stranded 
interacting protein 1 (RBMS1), mRNA 
0.02621 2.70 
XM_879087.2  PREDICTED: Bos taurus similar to 
transcriptional repressor 
BSR/RACK7/PRKCBP1, transcript variant 7 
(ZMYND8), mRNA 
0.04257 2.70 
NM_001037463.1  Bos taurus WW domain containing E3 ubiquitin 
protein ligase 1 (WWP1), mRNA 
0.00585 2.70 
XM_611206.4  PREDICTED: Bos taurus similar to adducin 1 
(alpha) (ADD1), mRNA 
0.03464 2.70 
NM_001101925.1  Bos taurus transmembrane and coiled-coil 
domain family 1 (TMCC1), mRNA 
0.04075 2.70 
NM_001083468.1  Bos taurus protein phosphatase 2, regulatory 
subunit B', epsilon isoform (PPP2R5E), mRNA 
0.00087 2.70 
NM_001098122.1  Bos taurus synovial sarcoma translocation, 
chromosome 18 (SS18), mRNA 
0.02415 2.70 
NM_001099209.1  Bos taurus hypothetical protein LOC788754 
(MGC152484), mRNA 
0.03043 2.70 
XM_863836.2  PREDICTED: Bos taurus microtubule-






XR_042701.1  PREDICTED: Bos taurus misc_RNA 
(LOC786759), miscRNA 
0.01586 2.63 
NM_001143867.1  Bos taurus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6 (DDX6), mRNA 
0.04126 2.63 
XM_600663.4  PREDICTED: Bos taurus nestin (NES), mRNA 0.00303 2.63 
NM_001034629.1  Bos taurus epoxide hydrolase 1, microsomal 
(xenobiotic) (EPHX1), mRNA 
0.00935 2.63 
XM_584315.4  PREDICTED: Bos taurus similar to 
chromosome 14 open reading frame 106 
(LOC507661), mRNA 
0.02230 2.63 
XM_585218.4  PREDICTED: Bos taurus similar to 
bromodomain adjacent to zinc finger domain, 1B 
(BAZ1B), mRNA 
0.04863 2.63 
XM_604909.4  PREDICTED: Bos taurus similar to crooked 
neck-like 1 protein (CRNKL1), partial mRNA 
0.01894 2.63 
NM_001035362.1  Bos taurus tetraspanin 13 (TSPAN13), mRNA 0.00244 2.63 
XM_584555.4  PREDICTED: Bos taurus similar to nuclear 
pore complex-associated protein TPR, transcript 
variant 1 (TPR), mRNA 
0.00608 2.63 
NM_001101898.1  Bos taurus inter-alpha (globulin) inhibitor H3 
(ITIH3), mRNA 
0.03844 2.63 
NM_194465.2  Bos taurus murine retrovirus integration site 1 
homolog (MRVI1), transcript variant 2, mRNA 
0.03526 2.63 
NM_001102502.1  Bos taurus CDC42 binding protein kinase 
gamma (CDC42BPG), mRNA 
0.00869 2.63 
XM_592333.4  PREDICTED: Bos taurus similar to 
transcriptional regulator ATRX (ATRX), mRNA 
0.04112 2.63 
NM_001076846.1  Bos taurus far upstream element (FUSE) 
binding protein 1 (FUBP1), mRNA 
0.02223 2.63 
NM_174028.1  Bos taurus colony stimulating factor 3 
(granulocyte) (CSF3), mRNA 
0.04807 2.56 
XM_864645.3  PREDICTED: Bos taurus similar to 
alkylglycerone phosphate synthase, transcript 
variant 2 (AGPS), mRNA 
0.00919 2.56 
NM_001100313.1  Bos taurus dehydrogenase/reductase (SDR 
family) member 12 (DHRS12), mRNA 
0.02334 2.56 
XR_028142.1  PREDICTED: Bos taurus misc_RNA 
(LOC535967), miscRNA 
0.04114 2.56 
NM_001011681.3  Bos taurus growth factor receptor-bound protein 
14 (GRB14), mRNA 
0.02877 2.56 
NM_001014883.1  Bos taurus nuclear receptor subfamily 1, group 
H, member 2 (NR1H2), mRNA 
0.03541 2.56 
NM_001034515.1  Bos taurus G protein-coupled receptor, family 





XM_001256832.2  PREDICTED: Bos taurus similar to Pre-mRNA-
splicing factor SYF2 (CCNDBP1-interactor) 
(p29) (LOC790322), partial mRNA 
0.00113 2.56 
NM_001075641.1  Bos taurus myotubularin related protein 7 
(MTMR7), mRNA 
0.01876 2.56 
NM_001102325.1  Bos taurus activating transcription factor 7 
interacting protein (ATF7IP), mRNA 
0.00789 2.56 
NM_001075366.2  Bos taurus HLA-B associated transcript 3 
(BAT3), mRNA 
0.03587 2.56 
NM_001076334.1  Bos taurus small nuclear ribonucleoprotein 
polypeptide C (SNRPC), mRNA 
0.01243 2.56 
NM_001078001.1  Bos taurus hypothetical LOC534560 
(MGC152232), mRNA 
0.04503 2.50 
XM_864293.3  PREDICTED: Bos taurus similar to 
Transcription cofactor vestigial-like protein 1 
(Vgl-1) (Protein TONDU), transcript variant 4 
(VGLL1), mRNA 
0.03602 2.50 
NM_001077980.1  Bos taurus polycomb group ring finger 5 
(PCGF5), mRNA 
0.03170 2.50 
XM_865593.3  PREDICTED: Bos taurus similar to Midasin 
(MIDAS-containing protein), transcript variant 2 
(MDN1), mRNA 
0.03172 2.44 
NM_001101096.1  Bos taurus nudix (nucleoside diphosphate linked 
moiety X)-type motif 9 (NUDT9), mRNA 
0.04002 2.44 
NM_001046314.1  Bos taurus ubiquitin-fold modifier 1 (UFM1), 
mRNA 
0.04398 2.44 
XM_871152.2  PREDICTED: Bos taurus similar to TRD@ 
protein (LOC618831), mRNA 
0.04936 2.44 
NM_001034524.1  Bos taurus heat shock 70kDa protein 9 
(mortalin) (HSPA9), nuclear gene encoding 
mitochondrial protein, mRNA 
0.04059 2.44 
XM_594786.4  PREDICTED: Bos taurus similar to RIKEN 
cDNA 1110067D22 (LOC516629), mRNA 
0.03133 2.44 
XM_001251030.1  PREDICTED: Bos taurus cutC copper 
transporter homolog (E. coli), transcript variant 1 
(CUTC), partial mRNA 
0.03286 2.44 
NM_001037629.1  Bos taurus translocase of inner mitochondrial 
membrane 8 homolog B (yeast) (TIMM8B), 
nuclear gene encoding mitochondrial protein, 
mRNA 
0.00489 2.44 
XM_001787477.1  PREDICTED: Bos taurus similar to dedicator of 
cytokinesis 10 (LOC539421), mRNA 
0.02126 2.38 
NM_001103096.1  Bos taurus nucleoporin 43kDa (NUP43), mRNA 0.02101 2.38 
NM_174087.3  Bos taurus insulin-like growth factor 2 
(somatomedin A) (IGF2), mRNA 
0.03194 2.38 




NM_001101170.2  Bos taurus sine oculis binding protein homolog 
(Drosophila) (SOBP), mRNA 
0.00167 2.38 
XM_868213.3  PREDICTED: Bos taurus similar to 
Transcobalamin-1 precursor (Transcobalamin I) 
(TCI) (TC I) (TCN1), mRNA 
0.04905 2.38 
NM_174712.2  Bos taurus rhesus-like protein (LOC282685), 
mRNA 
0.04955 2.38 
NM_001100293.1  Bos taurus chemokine (C-C motif) receptor 4 
(CCR4), mRNA 
0.03768 2.38 
NM_001102082.1  Bos taurus zinc finger CCCH-type containing 
18 (ZC3H18), mRNA 
0.01653 2.38 
NM_001034714.1  Bos taurus chromosome 2 open reading frame 
42 ortholog (C11H2orf42), mRNA 
0.01792 2.38 
NM_177945.3  Bos taurus peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha 
(PPARGC1A), mRNA 
0.03376 2.38 
XM_614758.4  PREDICTED: Bos taurus similar to 
Thrombospondin type-1 domain-containing 
protein 4 (LOC534844), mRNA 
0.03417 2.32 
NM_174587.1  Bos taurus protein kinase C, beta (PRKCB), 
mRNA 
0.01678 2.32 
XM_615405.4  PREDICTED: Bos taurus WD-repeat protein 33 
(WDR33), mRNA 
0.04315 2.32 
XM_001256289.2  PREDICTED: Bos taurus similar to mucin 2 
(LOC789571), partial mRNA 
0.00945 2.32 
XM_591968.4  PREDICTED: Bos taurus similar to aurora 
borealis, transcript variant 1 (LOC514162), 
mRNA 
0.03991 2.32 
XM_582828.3  PREDICTED: Bos taurus similar to exonuclease 
1 (EXO1), mRNA 
0.01591 2.32 
NM_174715.1  Bos taurus ribosomal protein L3 (Rpl3), mRNA 0.04690 2.32 
NM_001105258.1  Bos taurus kinesin family member 20B 
(KIF20B), mRNA 
0.01761 2.32 
NM_001075823.1  Bos taurus sulfotransferase family, cytosolic, 
1B, member 1 (SULT1B1), mRNA 
0.01267 2.32 
XM_867682.3  PREDICTED: Bos taurus hypothetical 
LOC615784 (LOC615784), mRNA 
0.03488 2.32 
XM_592611.4  PREDICTED: Bos taurus fibroblast growth 
factor 10, transcript variant 2 (FGF10), mRNA 
0.04468 2.32 
NM_001038543.1  Bos taurus sperm associated antigen 7 (SPAG7), 
mRNA 
0.03018 2.27 
XM_591440.3  PREDICTED: Bos taurus similar to Importin-7 
(Imp7) (Ran-binding protein 7) (RanBP7) 
(IPO7), mRNA 
0.04102 2.27 
NM_001078013.1  Bos taurus RAB7B, member RAS oncogene 





XM_865774.3  PREDICTED: Bos taurus similar to Heat shock 
70 kDa protein 4L (Osmotic stress protein 94) 
(Heat shock 70-related protein APG-1), 
transcript variant 3 (HSPA4L), mRNA 
0.03347 2.27 
NM_001098885.1  Bos taurus golgi SNAP receptor complex 
member 2 (GOSR2), mRNA 
0.03655 2.27 
XM_617171.4  PREDICTED: Bos taurus similar to cytidine 
monophosphate-N-acetylneuraminic acid 
hydroxylase, transcript variant 1 (LOC537017), 
mRNA 
0.01249 2.27 
XM_001252878.1  PREDICTED: Bos taurus similar to 
LOC522191 protein (MTERF), mRNA 
0.02951 2.27 
XR_043028.1  PREDICTED: Bos taurus misc_RNA 
(LOC100138100), miscRNA 
0.00517 2.27 
XM_001790491.1  PREDICTED: Bos taurus IQ motif containing 
with AAA domain (IQCA), mRNA 
0.03127 2.27 
NM_001045999.1  Bos taurus hypothetical LOC508280 
(MGC127461), mRNA 
0.01102 2.22 
XM_001790095.1  PREDICTED: Bos taurus coiled-coil domain 
containing 76 (CCDC76), mRNA 
0.00272 2.22 
XM_001256605.1  PREDICTED: Bos taurus similar to pregnancy-
associated glycoprotein 8 (LOC790008), partial 
mRNA 
0.01145 2.22 
XM_582594.4  PREDICTED: Bos taurus similar to zinc finger 
protein 77 (pT1) (LOC506181), partial mRNA 
0.03953 2.22 
NM_001080357.1  Bos taurus anaphase promoting complex subunit 
10 (ANAPC10), mRNA 
0.01297 2.22 
XR_042974.1  PREDICTED: Bos taurus misc_RNA 
(METTL10), miscRNA 
0.02732 2.22 
XM_001253151.2  PREDICTED: Bos taurus similar to von 
Willebrand factor C and EGF domains (VWCE), 
mRNA 
0.02884 2.22 
XM_581757.3  PREDICTED: Bos taurus similar to cytochrome 
P450 2C92 (LOC505468), mRNA 
0.01054 2.22 
NM_174056.3  Bos taurus fibroblast growth factor 2 (basic) 
(FGF2), mRNA 
0.04033 2.22 
NM_001077928.1  Bos taurus plexin domain containing 2 
(PLXDC2), mRNA 
0.02503 2.22 
NM_001015642.2  Bos taurus carboxypeptidase X (M14 family), 
member 1 (CPXM1), mRNA 
0.04359 2.17 
NM_001083500.1  Bos taurus hypothetical LOC541171 
(MGC143035), mRNA 
0.03365 2.17 
NM_001103224.1  Bos taurus annexin A6 (ANXA6), mRNA 0.04137 2.17 
XM_610845.4  PREDICTED: Bos taurus serum deprivation 
response (phosphatidylserine binding protein) 





XM_870123.2  PREDICTED: Bos taurus similar to Amiloride-
sensitive sodium channel subunit gamma 
(Epithelial Na(+) channel subunit gamma) 
(Gamma-ENaC) (Nonvoltage-gated sodium 
channel 1 subunit gamma) (SCNEG) (Gamma-
NaCH) (SCNN1G), mRNA 
0.00310 2.17 
XM_882441.2  PREDICTED: Bos taurus hypothetical 
LOC617028 (LOC617028), mRNA 
0.04925 2.17 
NM_001083503.1  Bos taurus ubiquitin-conjugating enzyme E2M 
(UBC12 homolog, yeast) (UBE2M), mRNA 
0.02430 2.17 
NM_001103224.1  Bos taurus annexin A6 (ANXA6), mRNA 0.04495 2.17 
XM_587287.4  PREDICTED: Bos taurus proline-rich cyclin 
A1-interacting protein (PROCA1), mRNA 
0.03110 2.17 
XM_615597.4  PREDICTED: Bos taurus similar to nuclear 
receptor subfamily 5, group A, member 2, 
transcript variant 1 (NR5A2), mRNA 
0.04968 2.17 
XM_616144.4  PREDICTED: Bos taurus desmocollin 3 
(DSC3), mRNA 
0.04708 2.17 
XM_592197.3  PREDICTED: Bos taurus similar to 
Desmoplakin (DP) (250/210 kDa paraneoplastic 
pemphigus antigen), transcript variant 1 (DSP), 
mRNA 
0.01086 2.17 
XR_042741.1  PREDICTED: Bos taurus misc_RNA 
(LOC785805), miscRNA 
0.04058 2.12 
XM_001788305.1  PREDICTED: Bos taurus similar to calcium 
activated chloride channel 2 (LOC534256), 
mRNA 
0.01044 2.12 
NM_001076427.1  Bos taurus cytochrome P450, family 2, 
subfamily C, polypeptide 87 (CYP2C87), 
mRNA 
0.02339 2.12 
NM_001034447.1  Bos taurus fructose-1,6-bisphosphatase 1 
(FBP1), mRNA 
0.04555 2.12 
XM_592304.4  PREDICTED: Bos taurus similar to Protein 
flightless-1 homolog, transcript variant 1 (FLII), 
mRNA 
0.00334 2.12 
NM_001101213.1  Bos taurus isochorismatase domain containing 1 
(ISOC1), mRNA 
0.04217 2.12 
NM_001046332.1  Bos taurus cell division cycle 42 (GTP binding 
protein, 25kDa) (CDC42), mRNA 
0.04187 2.12 
XM_588697.4  PREDICTED: Bos taurus similar to tumor 
necrosis factor, alpha-induced protein 1, 
transcript variant 1 (TNFAIP1), mRNA 
0.01922 2.12 
XR_027344.2  PREDICTED: Bos taurus misc_RNA 
(LOC781850), miscRNA 
0.03912 2.12 
NM_001076136.1  Bos taurus GINS complex subunit 3 (Psf3 





NM_001102004.1  Bos taurus URB2 ribosome biogenesis 2 
homolog (S. cerevisiae) (URB2), mRNA 
0.02762 2.12 
XM_865933.2  PREDICTED: Bos taurus similar to KIAA1946 
(LOC614438), mRNA 
0.04601 2.12 
XM_001253129.2  PREDICTED: Bos taurus similar to 
programmed cell death protein 7 (PDCD7), 
mRNA 
0.00648 2.08 
XM_582278.4  PREDICTED: Bos taurus chromosome 6 open 
reading frame 115 ortholog (H9C6ORF115), 
mRNA 
0.03368 2.08 
XM_001788143.1  PREDICTED: Bos taurus similar to 
transmembrane protein with EGF-like and two 
follistatin-like domains 1 (LOC100139803), 
mRNA 
0.03039 2.08 
XM_001787893.1  PREDICTED: Bos taurus similar to echinoderm 
microtubule associated protein like 5 
(LOC537305), partial mRNA 
0.02931 2.08 
NM_174386.2  Bos taurus microfibrillar associated protein 5 
(MFAP5), mRNA 
0.01789 2.08 
XM_614691.3  PREDICTED: Bos taurus topoisomerase (DNA) 
I (TOP1), mRNA 
0.02338 2.08 
XM_001250628.2  PREDICTED: Bos taurus similar to ATP 
synthase subunit epsilon, mitochondrial 
(LOC782270), mRNA 
0.04762 2.08 
NM_173942.2  Bos taurus cleavage and polyadenylation 
specific factor 4, 30kDa (CPSF4), mRNA 
0.01118 2.08 
XM_583652.3  PREDICTED: Bos taurus similar to pleckstrin 
homology domain containing, family A 
(phosphoinositide binding specific) member 8 
(PLEKHA8), mRNA 
0.04434 2.04 
XM_580330.4  PREDICTED: Bos taurus similar to nadrin 
(ARHGAP17), mRNA 
0.01185 2.04 
NM_174399.1  Bos taurus neural cell adhesion molecule 1 
(NCAM1), mRNA 
0.03915 2.04 
XM_597858.4  PREDICTED: Bos taurus similar to myosin 
18A, transcript variant 2 (MYO18A), mRNA 
0.01654 2.04 
XM_614586.4  PREDICTED: Bos taurus similar to histone 
cluster 2, H2aa4 (LOC541108), mRNA 
0.02442 2.04 
NM_001035074.1  Bos taurus acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member B 
(ANP32B), mRNA 
0.01055 2.04 
NM_001034469.1  Bos taurus mesoderm development candidate 2 
(MESDC2), mRNA 
0.01206 2.04 






XM_001249810.2  PREDICTED: Bos taurus similar to LON 
peptidase N-terminal domain and RING finger 
protein 3, transcript variant 1 (LONRF3), mRNA 
0.01397 2.04 
NM_001076926.1  Bos taurus neuronal guanine nucleotide 
exchange factor (NGEF), mRNA 
0.04147 2.00 
XR_042959.1  PREDICTED: Bos taurus misc_RNA (TAF5), 
miscRNA 
0.01026 2.00 
XM_592026.4  PREDICTED: Bos taurus caspase 1, apoptosis-
related cysteine peptidase (interleukin 1, beta, 
convertase), transcript variant 1 (CASP1), 
mRNA 
0.04651 2.00 
NM_001081526.1  Bos taurus protein-L-isoaspartate (D-aspartate) 
O-methyltransferase domain containing 1 
(PCMTD1), mRNA 
0.02648 2.00 
NM_001035490.1  Bos taurus chromosome 8 open reading frame 4 
ortholog (C27H8orf4), mRNA 
0.01950 2.00 
NM_001038117.1  Bos taurus coiled-coil domain containing 52 
(CCDC52), mRNA 
0.00121 2.00 
NM_001098929.1  Bos taurus splicing factor, arginine/serine-rich 5 
(SFRS5), mRNA 
0.03955 -3.68 
NR_001464.2  Bos taurus X (inactive)-specific transcript 
(XIST), non-coding RNA 
0.01175 -5.59 
NM_001078161.2  Bos taurus hypothetical protein LOC777786 
(LOC777786), mRNA 
0.00770 -2.98 
NM_001038092.1  Bos taurus chromosome 17 open reading frame 
49 ortholog (C19H17orf49), mRNA 
0.01536 -3.93 
XM_587229.4  PREDICTED: Bos taurus similar to serum-
inducible kinase, transcript variant 1 (PLK2), 
mRNA 
0.02743 -2.52 
NM_001075347.1  Bos taurus THAP domain containing, apoptosis 
associated protein 3 (THAP3), mRNA 
0.01731 -3.66 
NM_174212.2  Bos taurus UDP-glucose pyrophosphorylase 2 
(UGP2), mRNA 
0.01212 -3.35 
XM_865719.3  PREDICTED: Bos taurus chromosome X open 
reading frame 15 ortholog, transcript variant 3 
(HXCXORF15), mRNA 
0.02060 -2.58 
NM_001040471.1  Bos taurus glucose phosphate isomerase (GPI), 
mRNA 
0.00658 -2.51 
XM_864691.3  PREDICTED: Bos taurus similar to cytoplasmic 
polyadenylation element binding protein 1, 
transcript variant 2 (CPEB1), mRNA 
0.01679 -2.97 
NM_001024488.2  Bos taurus solute carrier family 3 (activators of 
dibasic and neutral amino acid transport), 
member 2 (SLC3A2), mRNA 
0.04640 -3.27 






NM_001102306.1  Bos taurus eukaryotic translation initiation 
factor 4E family member 3 (EIF4E3), mRNA 
0.01196 -3.27 
NM_001046333.1  Bos taurus calcium/calmodulin-dependent 
protein kinase II delta (CAMK2D), mRNA 
0.01793 -3.27 
NM_001035302.1  Bos taurus ARV1 homolog (S. cerevisiae) 
(ARV1), mRNA 
0.04777 -2.55 
XM_867976.2  PREDICTED: Bos taurus similar to ankyrin 
repeat and sterile alpha motif domain containing 
3, transcript variant 2 (ANKS3), mRNA 
0.03831 -2.55 
XM_864973.3  PREDICTED: Bos taurus SLAM family 
member 9 (SLAMF9), mRNA 
0.00261 -2.04 
NM_001034606.1  Bos taurus syntaxin 17 (STX17), mRNA 0.04349 -2.40 
XM_593410.4  PREDICTED: Bos taurus similar to LKB1 
interacting protein (STK11IP), mRNA 
0.01437 -3.66 
NM_001034784.1  Bos taurus fission 1 (mitochondrial outer 
membrane) homolog (S. cerevisiae) (FIS1), 
nuclear gene encoding mitochondrial protein, 
mRNA 
0.03793 -2.09 
XM_001790641.1  PREDICTED: Bos taurus dishevelled, dsh 
homolog 2 (Drosophila) (DVL2), mRNA 
0.03482 -2.86 
XM_586727.4  PREDICTED: Bos taurus similar to zinc finger 
protein 74 (ZNF74), mRNA 
0.02021 -2.25 
NM_001045945.1  Bos taurus RCAN family member 3 (RCAN3), 
mRNA 
0.01413 -2.57 
NM_001102266.1  Bos taurus A kinase (PRKA) anchor protein 7 
(AKAP7), mRNA 
0.03703 -2.36 
NM_001034670.1  Bos taurus anterior pharynx defective 1 
homolog A (C. elegans) (APH1A), mRNA 
0.03605 -2.22 
XM_001251118.1  PREDICTED: Bos taurus similar to dynamin 
binding protein (DNMBP), mRNA 
0.04047 -2.13 
NM_001046376.1  Bos taurus ubiquitin specific peptidase 21 
(USP21), mRNA 
0.02988 -2.15 
XM_614921.4  PREDICTED: Bos taurus similar to 60S 
ribosomal protein L26-like 1, transcript variant 1 
(RPL26L1), mRNA 
0.01993 -2.05 
XM_600364.4  PREDICTED: Bos taurus similar to additional 
sex combs like 1 (ASXL1), mRNA 
0.03269 -2.19 







Appendix Table 4:  Transcripts that were differentially expressed in ECb vs. ECe 




Bovine RefSeq_Description P value Fold 
change* 
XM_612798.4  PREDICTED: Bos taurus similar to protein 
inhibitor of activated STAT X, transcript variant 
1 (PIAS2), mRNA 
0.00247 25.00 
XM_588088.4  PREDICTED: Bos taurus similar to delangin 
(NIPBL), mRNA 
0.03253 20.00 
XM_001250465.1  PREDICTED: Bos taurus similar to ubiquitin 
specific peptidase 54 (LOC784739), mRNA 
0.01715 16.67 
NM_174345.3  Bos taurus heat shock 70kDa protein 8 
(HSPA8), mRNA 
0.00069 16.67 
NM_001034039.1  Bos taurus collagen, type I, alpha 1 (COL1A1), 
mRNA 
0.00135 16.67 
XM_001788124.1  PREDICTED: Bos taurus similar to cleavage 
stimulation factor subunit 3 (LOC613678), 
mRNA 
0.00230 16.67 
XR_028410.2  PREDICTED: Bos taurus misc_RNA 
(LOC614926), miscRNA 
0.00291 16.67 
XM_582135.4  PREDICTED: Bos taurus neurofilament, 
medium polypeptide (NEF3), mRNA 
0.01724 14.28 
NM_174715.1  Bos taurus ribosomal protein L3 (Rpl3), mRNA 0.00002 14.28 
XR_028569.2  PREDICTED: Bos taurus misc_RNA 
(LOC535649), miscRNA 
0.00318 14.28 
NM_001035014.1  Bos taurus ribosomal protein L23 (RPL23), 
mRNA 
0.02095 12.50 
NM_176645.3  Bos taurus ras homolog gene family, member A 
(RHOA), mRNA 
0.00002 12.50 
NR_001464.2  Bos taurus X (inactive)-specific transcript 
(XIST), non-coding RNA 
0.02390 12.50 
NM_174464.2  Bos taurus secreted protein, acidic, cysteine-rich 
(osteonectin) (SPARC), mRNA 
0.02412 12.50 
NM_001105045.1  Bos taurus neuronal protein 3.1 
(LOC100125763), mRNA 
0.01061 12.50 
XM_001255132.1  PREDICTED: Bos taurus similar to ribosomal 
protein S6-like (LOC787914), mRNA 
0.00373 11.11 
NM_174568.2  Bos taurus poly(A) binding protein, cytoplasmic 
1 (PABPC1), mRNA 
0.02252 11.11 






NM_174780.3  Bos taurus brain abundant, membrane attached 
signal protein 1 (BASP1), mRNA 
0.03227 11.11 
XM_589161.4  PREDICTED: Bos taurus synaptotagmin 
binding, cytoplasmic RNA interacting protein 
(SYNCRIP), mRNA 
0.01538 11.11 
XM_001250700.1  PREDICTED: Bos taurus similar to 
Serine/threonine-protein phosphatase 2A 55 kDa 
regulatory subunit B gamma isoform (PP2A, 
subunit B, B-gamma isoform) (PP2A, subunit B, 
B55-gamma isoform) (PP2A, subunit B, PR55-
gamma isoform) (PP2A, subunit B, R2-gamma 
isoform) (IMYPNO1) (PPP2R2C), mRNA 
0.02041 10.00 
XM_001255541.2  PREDICTED: Bos taurus similar to metastasis 
suppressor 1 (LOC788499), mRNA 
0.04351 10.00 
XR_028031.2  PREDICTED: Bos taurus misc_RNA 
(LOC536267), miscRNA 
0.01138 10.00 
NM_001012670.1  Bos taurus heat shock 90kD protein 1, alpha 
(HSPCA), mRNA 
0.00861 9.00 
NM_001046347.1  Bos taurus RAB3A interacting protein (rabin3) 
(RAB3IP), mRNA 
0.04279 9.00 
NM_174464.2  Bos taurus secreted protein, acidic, cysteine-rich 
(osteonectin) (SPARC), mRNA 
0.03973 9.00 
NM_174062.3  Bos taurus ferritin, heavy polypeptide 1 (FTH1), 
mRNA 
0.04736 9.00 
NM_001101886.1  Bos taurus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 31 (DDX31), mRNA 
0.00165 8.33 
XM_582135.4  PREDICTED: Bos taurus neurofilament, 
medium polypeptide (NEF3), mRNA 
0.04293 8.33 
NM_001111103.1  Bos taurus polymerase I and transcript release 
factor (PTRF), transcript variant 2, mRNA 
0.02888 8.33 
NM_001034500.1  Bos taurus emopamil binding protein (sterol 
isomerase) (EBP), mRNA 
0.00682 8.33 
NM_174386.2  Bos taurus microfibrillar associated protein 5 
(MFAP5), mRNA 
0.00176 8.33 
NM_174053.1  Bos taurus fibrillin 1 (FBN1), mRNA 0.00607 7.69 
NM_001080347.1  Bos taurus hypothetical protein LOC783068 
(MGC151567), mRNA 
0.01231 7.69 
NM_174815.2  Bos taurus Y box binding protein 1 (YBX1), 
mRNA 
0.02221 7.69 
NM_174333.3  Bos taurus protein disulfide isomerase family A, 





XM_598984.4  PREDICTED: Bos taurus similar to Mediator of 
RNA polymerase II transcription subunit 1 
(Mediator complex subunit 1) (Peroxisome 
proliferator-activated receptor-binding protein) 
(PBP) (PPAR-binding protein) (Thyroid 
hormone receptor-associated protein complex 
220 kDa com, transcript variant 1 (MED1), 
mRNA 
0.00075 7.14 
NM_001034039.1  Bos taurus collagen, type I, alpha 1 (COL1A1), 
mRNA 
0.01894 7.14 
NM_001035497.1  Bos taurus ubiquitin-conjugating enzyme E2 
variant 1 (UBE2V1), mRNA 
0.00758 7.14 
NM_001035306.1  Bos taurus ribosomal protein L5 (RPL5), mRNA 0.00458 7.14 
NM_001025339.1  Bos taurus ribosomal protein S24 (RPS24), 
mRNA 
0.01487 7.14 
XM_001252331.1  PREDICTED: Bos taurus similar to 
serine/arginine repetitive matrix 1, transcript 
variant 1 (SRRM1), mRNA 
0.02549 7.14 
NM_001076067.1  Bos taurus proteasome (prosome, macropain) 
26S subunit, non-ATPase, 14 (PSMD14), mRNA 
0.04760 6.66 
NM_001101162.1  Bos taurus hypothetical LOC535277 
(LOC535277), mRNA 
0.00887 6.66 
NM_001098006.1  Bos taurus BUD13 homolog (S. cerevisiae) 
(BUD13), mRNA 
0.00653 6.66 
NM_001083466.1  Bos taurus heterogeneous nuclear 
ribonucleoprotein U-like 1 (HNRNPUL1), 
mRNA 
0.00492 6.66 
XR_027885.2  PREDICTED: Bos taurus misc_RNA 
(LOC613460), miscRNA 
0.01760 6.66 
NM_001079637.1  Bos taurus heat shock 90kDa protein 1, beta 
(HSP90AB1), mRNA 
0.00413 6.25 
NM_001075515.1  Bos taurus 5'-nucleotidase, cytosolic III-like 
(NT5C3L), mRNA 
0.00166 6.25 
NM_174464.2  Bos taurus secreted protein, acidic, cysteine-rich 
(osteonectin) (SPARC), mRNA 
0.01074 6.25 
NM_001114192.1  Bos taurus heat shock 70kDa protein 4 
(HSPA4), mRNA 
0.00451 5.88 
NM_174663.2  Bos taurus platelet-activating factor 
acetylhydrolase, isoform Ib, alpha subunit 45kDa 
(PAFAH1B1), mRNA 
0.00093 5.88 
NM_001014388.1  Bos taurus tumor protein, translationally-
controlled 1 (TPT1), mRNA 
0.00153 5.88 
NM_001037468.1  Bos taurus cell division cycle 7 homolog (S. 
cerevisiae) (CDC7), mRNA 
0.03038 5.88 
XM_883110.3  PREDICTED: Bos taurus similar to Histone 






NM_001038558.1  Bos taurus cell adhesion molecule 1 (CADM1), 
mRNA 
0.00104 5.88 
NM_001015533.1  Bos taurus signal sequence receptor, beta 
(translocon-associated protein beta) (SSR2), 
mRNA 
0.01524 5.88 
NM_001034614.1  Bos taurus BCL2/adenovirus E1B 19kDa 
interacting protein 3-like (BNIP3L), mRNA 
0.00843 5.55 
NM_001007806.2  Bos taurus prostaglandin E synthase 3 
(cytosolic) (PTGES3), mRNA 
0.02171 5.55 
NM_001014388.1  Bos taurus tumor protein, translationally-
controlled 1 (TPT1), mRNA 
0.01722 5.55 
NM_174087.3  Bos taurus insulin-like growth factor 2 
(somatomedin A) (IGF2), mRNA 
0.00028 5.55 
XR_027849.2  PREDICTED: Bos taurus misc_RNA 
(LOC538561), miscRNA 
0.03222 5.55 
NM_001015522.1  Bos taurus vacuolar protein sorting 16 homolog 
(S. cerevisiae) (VPS16), mRNA 
0.01103 5.55 
NM_001076831.1  Bos taurus collagen, type III, alpha 1 
(COL3A1), mRNA 
0.04352 5.26 
XM_602857.3  PREDICTED: Bos taurus similar to ubiquitin 
specific protease 25 (USP25), mRNA 
0.02442 5.26 
XM_867454.3  PREDICTED: Bos taurus similar to 
transmembrane anterior posterior transformation 
1 (TAPT1), mRNA 
0.00546 5.26 
NM_001080301.1  Bos taurus LUC7-like (S. cerevisiae) (LUC7L), 
mRNA 
0.01602 5.26 
XM_614281.4  PREDICTED: Bos taurus similar to Probable E3 
ubiquitin-protein ligase MYCBP2 (Myc-binding 
protein 2) (Protein associated with Myc) 
(Pam/highwire/rpm-1 protein) (MYCBP2), 
mRNA 
0.04158 5.26 
NM_001101931.1  Bos taurus hypothetical protein LOC510660 
(LOC510660), mRNA 
0.01724 5.00 
XM_879644.2  PREDICTED: Bos taurus RNA binding motif 
protein 25, transcript variant 5 (RBM25), mRNA 
0.03258 5.00 
NM_174062.3  Bos taurus ferritin, heavy polypeptide 1 (FTH1), 
mRNA 
0.03393 5.00 
NM_001077928.1  Bos taurus plexin domain containing 2 
(PLXDC2), mRNA 
0.03094 4.76 
XM_589795.4  PREDICTED: Bos taurus similar to coiled-coil 
domain containing 15 (CCDC15), mRNA 
0.04905 4.76 
NM_001075436.1  Bos taurus heterochromatin protein 1, binding 





XM_867461.3  PREDICTED: Bos taurus similar to ubiquitin-
conjugating enzyme E2E 1, transcript variant 2 
(UBE2E1), mRNA 
0.00409 4.76 
XM_590860.4  PREDICTED: Bos taurus similar to zinc finger, 
CCHC domain containing 6, transcript variant 1 
(ZCCHC6), mRNA 
0.00807 4.76 
NM_174763.2  Bos taurus peroxiredoxin 2 (PRDX2), nuclear 
gene encoding mitochondrial protein, mRNA 
0.01602 4.54 
XM_609842.3  PREDICTED: Bos taurus similar to BTB and 
CNC homology 1 (BACH1), mRNA 
0.00056 4.54 
NM_001075788.1  Bos taurus damage-specific DNA binding 
protein 2, 48kDa (DDB2), mRNA 
0.00302 4.54 
NM_001081510.1  Bos taurus splicing factor 3a, subunit 1, 120kDa 
(SF3A1), mRNA 
0.03436 4.54 
NM_001075649.1  Bos taurus N-acetyltransferase 15 (GCN5-
related, putative) (NAT15), mRNA 
0.00341 4.54 
XR_028633.2  PREDICTED: Bos taurus misc_RNA 
(LOC788293), miscRNA 
0.04815 4.54 
XM_001254709.2  PREDICTED: Bos taurus similar to 
topoisomerase (DNA) II beta 180kDa (TOP2B), 
mRNA 
0.01366 4.34 
NM_001075402.1  Bos taurus TatD DNase domain containing 1 
(TATDN1), mRNA 
0.02649 4.34 
XM_001249987.2  PREDICTED: Bos taurus similar to eukaryotic 
translation elongation factor 1 alpha 1, transcript 
variant 1 (EEF1A1), mRNA 
0.00999 4.34 
NM_001040487.1  Bos taurus eukaryotic translation elongation 
factor 1 gamma (EEF1G), mRNA 
0.04782 4.34 
XM_867149.3  PREDICTED: Bos taurus similar to Poly [ADP-
ribose] polymerase 4 (PARP-4) (Vault 
poly(ADP-ribose) polymerase) (VPARP) (193 
kDa vault protein) (PARP-related/IalphaI-related 
H5/proline-rich) (PH5P) (PARP4), mRNA 
0.01237 4.34 
XM_597007.4  PREDICTED: Bos taurus similar to F-box/LRR-
repeat protein 7 (F-box and leucine-rich repeat 
protein 7) (F-box protein FBL6/FBL7) (FBXL7), 
mRNA 
0.02811 4.34 
NM_001037468.1  Bos taurus cell division cycle 7 homolog (S. 
cerevisiae) (CDC7), mRNA 
0.03266 4.16 
XM_592234.3  PREDICTED: Bos taurus similar to nuclear 
receptor binding SET domain protein 1 (NSD1), 
partial mRNA 
0.00032 4.16 
NM_001045883.1  Bos taurus 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 (mitochondrial) 
(HMGCS2), nuclear gene encoding 





XM_001250706.2  PREDICTED: Bos taurus similar to 60S 
ribosomal protein L9, transcript variant 1 
(LOC782631), mRNA 
0.01374 4.16 
XM_001249528.2  PREDICTED: Bos taurus similar to Histone 
H3.3B CG8989-PA (LOC781224), mRNA 
0.04295 4.16 
NM_001033762.1  Bos taurus GDP dissociation inhibitor 2 (GDI2), 
mRNA 
0.01586 4.16 
NM_001035008.1  Bos taurus ribosomal protein L37a (RPL37A), 
mRNA 
0.02059 4.16 
NM_001101933.1  Bos taurus TSR1, 20S rRNA accumulation, 
homolog (S. cerevisiae) (TSR1), mRNA 
0.01696 4.16 
NM_001034484.1  Bos taurus eukaryotic translation initiation 
factor 3, subunit D (EIF3D), mRNA 
0.00217 4.16 
XR_027807.2  PREDICTED: Bos taurus misc_RNA 
(LOC614207), miscRNA 
0.00606 4.16 
NM_174004.3  Bos taurus caveolin 1, caveolae protein, 22kDa 
(CAV1), mRNA 
0.00648 4.16 
XM_865029.3  PREDICTED: Bos taurus similar to splicing 
factor 3b, subunit 1, transcript variant 2 (SF3B1), 
mRNA 
0.00144 4.00 
NM_001024535.1  Bos taurus KIAA0141 protein (KIAA0141), 
mRNA 
0.04788 4.00 
XM_001250706.2  PREDICTED: Bos taurus similar to 60S 
ribosomal protein L9, transcript variant 1 
(LOC782631), mRNA 
0.01001 4.00 
NM_001015533.1  Bos taurus signal sequence receptor, beta 
(translocon-associated protein beta) (SSR2), 
mRNA 
0.04078 4.00 
NM_205799.1  Bos taurus lysosomal protein transmembrane 4 
alpha (LAPTM4A), mRNA 
0.01650 4.00 
XM_602832.4  PREDICTED: Bos taurus similar to ribosomal 
protein S19 (LOC524507), mRNA 
0.02472 4.00 
NM_001098874.1  Bos taurus ribosomal protein S7 (RPS7), mRNA 0.03551 4.00 
XM_864796.3  PREDICTED: Bos taurus adenylosuccinate 
synthase, transcript variant 3 (ADSS), mRNA 
0.00346 3.84 
NM_001105374.1  Bos taurus protein arginine methyltransferase 5 
(PRMT5), mRNA 
0.02074 3.84 
NM_001046454.1  Bos taurus casein kinase 2, beta polypeptide 
(CSNK2B), mRNA 
0.04487 3.84 
NM_001083725.1  Bos taurus heterogeneous nuclear 
ribonucleoprotein D-like (HNRPDL), mRNA 
0.02938 3.84 
XM_001249610.1  PREDICTED: Bos taurus similar to mitogen-
activated protein kinase kinase kinase kinase 5, 
transcript variant 1 (MAP4K5), mRNA 
0.00753 3.84 
XM_867454.3  PREDICTED: Bos taurus similar to 





1 (TAPT1), mRNA 
XM_606667.4  PREDICTED: Bos taurus similar to jumonji, AT 
rich interactive domain 2 protein, transcript 
variant 6 (JARID2), mRNA 
0.04826 3.84 
NM_001083515.1  Bos taurus transmembrane protein 87A 
(TMEM87A), mRNA 
0.00219 3.84 
NM_001075294.1  Bos taurus chromosome 20 open reading frame 
149 ortholog (C13H20orf149), mRNA 
0.03967 3.84 
NM_001035008.1  Bos taurus ribosomal protein L37a (RPL37A), 
mRNA 
0.01029 3.70 
NM_001076070.1  Bos taurus 3-oxoacid CoA transferase 1 
(OXCT1), nuclear gene encoding mitochondrial 
protein, mRNA 
0.01278 3.70 
NM_001035445.1  Bos taurus ribosomal protein S4, Y-linked 2 
(RPS4Y2), mRNA 
0.01743 3.70 
XM_589329.4  PREDICTED: Bos taurus similar to 
Chromosome 7 open reading frame 43 
(LOC511902), mRNA 
0.03715 3.57 
NM_001101231.1  Bos taurus splicing factor, arginine/serine-rich 4 
(SFRS4), mRNA 
0.01625 3.57 
NM_001081587.1  Bos taurus ring finger protein 20 (RNF20), 
mRNA 
0.01993 3.57 
NM_174788.3  Bos taurus ribosomal protein, large, P2 
(RPLP2), mRNA 
0.01368 3.57 
XM_616885.4  PREDICTED: Bos taurus similar to membrane 
metallo endopeptidase (MME), mRNA 
0.02783 3.44 
XM_869402.2  PREDICTED: Bos taurus similar to MYST 
histone acetyltransferase (monocytic leukemia) 3 
(LOC529373), mRNA 
0.02918 3.44 
NM_001079777.1  Bos taurus hypothetical protein LOC526597 
(LOC526597), mRNA 
0.02754 3.44 
NM_001017950.2  Bos taurus follistatin-like 1 (FSTL1), mRNA 0.01569 3.44 
NM_001046526.1  Bos taurus methionine adenosyltransferase II, 
beta (MAT2B), mRNA 
0.02552 3.44 
NM_001078043.1  Bos taurus zinc finger protein 75 (D8C6) 
(ZNF75), mRNA 
0.04206 3.44 
NM_001076448.1  Bos taurus similar to HEAT repeat containing 
protein 1 (Protein BAP28) (LOC617204), 
mRNA 
0.02203 3.33 
NM_001012673.1  Bos taurus signal transducer and activator of 
transcription 5A (STAT5A), mRNA 
0.00350 3.33 
NM_001037595.1  Bos taurus tetraspanin 31 (TSPAN31), mRNA 0.02073 3.33 
XR_042784.1  PREDICTED: Bos taurus misc_RNA 
(LOC100141269), miscRNA 
0.01680 3.33 





NM_001014928.1  Bos taurus ribosomal protein L7 (RPL7), mRNA 0.04903 3.33 
NM_001034502.1  Bos taurus actin, alpha 2, smooth muscle, aorta 
(ACTA2), mRNA 
0.00339 3.33 
XM_594391.4  PREDICTED: Bos taurus similar to G-protein 
signaling modulator 3 (AGS3-like, C. elegans) 
(GPSM3), mRNA 
0.04637 3.22 
NM_001015533.1  Bos taurus signal sequence receptor, beta 
(translocon-associated protein beta) (SSR2), 
mRNA 
0.01268 3.22 
NM_001015608.1  Bos taurus chloride intracellular channel 1 
(CLIC1), mRNA 
0.02809 3.22 
NM_001105629.1  Bos taurus transmembrane and tetratricopeptide 
repeat containing 4 (TMTC4), mRNA 
0.00638 3.22 
NM_001025339.1  Bos taurus ribosomal protein S24 (RPS24), 
mRNA 
0.04503 3.22 
NM_001076831.1  Bos taurus collagen, type III, alpha 1 
(COL3A1), mRNA 
0.02176 3.22 
XM_870555.3  PREDICTED: Bos taurus similar to Splicing 
factor, proline- and glutamine-rich 
(Polypyrimidine tract-binding protein-associated-
splicing factor) (PTB-associated-splicing factor) 
(PSF) (DNA-binding p52/p100 complex, 100 
kDa subunit) (100 kDa DNA-pairing protein) 
(hPOMp100 (SFPQ), mRNA 
0.02566 3.22 
NM_001035280.1  Bos taurus chromosome 14 open reading frame 
166 ortholog (C10H14ORF166), mRNA 
0.01719 3.12 
XM_874550.3  PREDICTED: Bos taurus ubiquitin C, transcript 
variant 12 (UBC), mRNA 
0.03275 3.12 
NM_001076000.1  Bos taurus dihydropyrimidinase-like 2 
(DPYSL2), mRNA 
0.00757 3.12 
NM_001034666.1  Bos taurus AHA1, activator of heat shock 
90kDa protein ATPase homolog 1 (yeast) 
(AHSA1), mRNA 
0.04169 3.12 
NM_001077114.1  Bos taurus HIG1 domain family, member 1D 
(HIGD1D), mRNA 
0.00319 3.12 
NM_001034335.1  Bos taurus KIAA0174 (KIAA0174), mRNA 0.01399 3.12 
XM_588094.4  PREDICTED: Bos taurus spectrin, beta, non-
erythrocytic 1, transcript variant 1 (SPTBN1), 
mRNA 
0.03598 3.12 
XM_001251796.1  PREDICTED: Bos taurus similar to Zinc finger 
X-linked protein ZXDB (LOC783265), mRNA 
0.00169 3.12 
XM_882704.3  PREDICTED: Bos taurus hypothetical 
LOC617275 (CCDC72), mRNA 
0.00325 3.00 






NM_001034746.1  Bos taurus coiled-coil-helix-coiled-coil-helix 
domain containing 9 (CHCHD9), mRNA 
0.03301 3.00 
NM_001046593.1  Bos taurus coactosin-like 1 (Dictyostelium) 
(COTL1), mRNA 
0.03799 3.00 
NM_001034222.1  Bos taurus nucleoporin 88kDa (NUP88), mRNA 0.02062 3.00 
XM_600663.4  PREDICTED: Bos taurus nestin (NES), mRNA 0.01881 3.00 
XM_001788124.1  PREDICTED: Bos taurus similar to cleavage 
stimulation factor subunit 3 (LOC613678), 
mRNA 
0.00864 3.00 
NM_174368.2  Bos taurus integrin, beta 1 (fibronectin receptor, 
beta polypeptide, antigen CD29 includes MDF2, 
MSK12) (ITGB1), mRNA 
0.02471 3.00 
XM_605970.4  PREDICTED: Bos taurus similar to tripartite 
motif protein TRIM4, transcript variant 1 
(TRIM4), partial mRNA 
0.00422 2.94 
NM_174591.1  Bos taurus RAB guanine nucleotide exchange 
factor (GEF) 1 (RABGEF1), mRNA 
0.00449 2.94 
NM_001034373.1  Bos taurus cytochrome P450, family 4, 
subfamily V, polypeptide 2 (CYP4V2), mRNA 
0.00741 2.94 
NM_001099206.1  Bos taurus myeloid cell leukemia sequence 1 
(BCL2-related) (MCL1), mRNA 
0.04033 2.94 
NM_001098070.1  Bos taurus O-linked N-acetylglucosamine 
(GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) (OGT), mRNA 
0.03993 2.94 
XM_001788858.1  PREDICTED: Bos taurus centrosomal protein 
170kDa (CEP170), mRNA 
0.03040 2.94 
XM_615128.3  PREDICTED: Bos taurus similar to Myosin-VI 
(Unconventional myosin VI) (MYO6), mRNA 
0.00205 2.94 
NM_174310.3  Bos taurus eukaryotic translation initiation 
factor 4E (EIF4E), mRNA 
0.00111 2.85 
NM_001105474.1  Bos taurus prenylcysteine oxidase 1 (PCYOX1), 
mRNA 
0.02639 2.85 
NM_174133.2  Bos taurus polyubiquitin (LOC281370), mRNA 0.00251 2.85 
NM_001080738.1  Bos taurus leucine-rich repeats and calponin 
homology (CH) domain containing 4 (LRCH4), 
mRNA 
0.02023 2.85 
XM_864796.3  PREDICTED: Bos taurus adenylosuccinate 
synthase, transcript variant 3 (ADSS), mRNA 
0.03269 2.85 
XM_585215.4  PREDICTED: Bos taurus similar to CG2943 
CG2943-PA (LOC508439), mRNA 
0.04330 2.85 
NM_001075135.1  Bos taurus similar to Putative ubiquitin-
conjugating enzyme E2 D3-like protein 
(UBE2D3P), mRNA 
0.00318 2.85 
NM_001077113.1  Bos taurus chromosome 6 open reading frame 





XR_042605.1  PREDICTED: Bos taurus misc_RNA 
(CSF2RA), miscRNA 
0.02525 2.77 
NM_001034277.1  Bos taurus splicing factor, arginine/serine-rich 7, 
35kDa (SFRS7), mRNA 
0.02041 2.77 
XM_584927.4  PREDICTED: Bos taurus SLAM family 
member 6 (SLAMF6), mRNA 
0.03793 2.77 
XM_879302.3  PREDICTED: Bos taurus eukaryotic translation 
initiation factor 3, subunit A, transcript variant 4 
(EIF3A), mRNA 
0.04119 2.77 
NM_174019.2  Bos taurus chondroadherin (CHAD), mRNA 0.03660 2.77 
NM_001102122.1  Bos taurus signal sequence receptor, alpha 
(SSR1), mRNA 
0.03922 2.70 
NM_001098982.1  Bos taurus coiled-coil domain containing 80 
(CCDC80), mRNA 
0.03248 2.70 
XR_027685.2  PREDICTED: Bos taurus misc_RNA 
(LOC540561), miscRNA 
0.04354 2.70 
NM_001099133.1  Bos taurus lactamase, beta (LACTB), nuclear 
gene encoding mitochondrial protein, mRNA 
0.01701 2.70 
NM_001083792.1  Bos taurus tetratricopeptide repeat domain 9C 
(TTC9C), mRNA 
0.00364 2.63 
NM_001015567.2  Bos taurus serine/threonine kinase receptor 
associated protein (STRAP), mRNA 
0.00971 2.63 
NM_001033624.1  Bos taurus ribosomal protein S16 (RPS16), 
mRNA 
0.02779 2.63 
NM_001076970.1  Bos taurus G protein-coupled receptor 89 
(GPR89), mRNA 
0.04322 2.63 
XM_582017.4  PREDICTED: Bos taurus similar to la related 
protein (LARP1), mRNA 
0.03818 2.63 
NM_001035428.1  Bos taurus coiled-coil domain containing 47 
(CCDC47), mRNA 
0.00910 2.63 
NM_001098956.1  Bos taurus sorting nexin family member 27 
(SNX27), mRNA 
0.03458 2.56 
NM_001113727.1  Bos taurus cationic trypsin (LOC780933), 
mRNA 
0.04485 2.56 
XM_615298.4  PREDICTED: Bos taurus similar to Exportin-T 
(tRNA exportin) (Exportin(tRNA)) (XPOT), 
mRNA 
0.01987 2.56 
XM_866612.3  PREDICTED: Bos taurus similar to Rab5B, 
transcript variant 3 (RAB5B), mRNA 
0.01137 2.56 
NM_001045878.1  Bos taurus glycine amidinotransferase (L-
arginine:glycine amidinotransferase) (GATM), 
nuclear gene encoding mitochondrial protein, 
mRNA 
0.02772 2.56 
NM_174244.1  Bos taurus ATP synthase, H+ transporting, 
mitochondrial F1 complex, O subunit (ATP5O), 






XM_866403.3  PREDICTED: Bos taurus homeobox and leucine 
zipper encoding, transcript variant 1 (HOMEZ), 
mRNA 
0.01811 2.56 
NM_001014389.2  Bos taurus H3 histone, family 3A (H3F3A), 
mRNA 
0.01167 2.50 
XM_869563.3  PREDICTED: Bos taurus similar to karyopherin 
beta 1, transcript variant 2 (KPNB1), mRNA 
0.01118 2.50 
NM_174663.2  Bos taurus platelet-activating factor 
acetylhydrolase, isoform Ib, alpha subunit 45kDa 
(PAFAH1B1), mRNA 
0.01787 2.50 
XR_042975.1  PREDICTED: Bos taurus misc_RNA 
(LOC784058), miscRNA 
0.04409 2.50 
XM_597797.4  PREDICTED: Bos taurus similar to PDZ 
domain containing 8 (PDZD8), mRNA 
0.02648 2.50 
NM_001103278.1  Bos taurus splicing factor 4 (SF4), mRNA 0.02864 2.50 
XM_001251494.2  PREDICTED: Bos taurus similar to Protein 
jagged-1 precursor (Jagged1) (hJ1) (CD339 
antigen) (JAG1), mRNA 
0.00193 2.50 
NM_001081727.1  Bos taurus chloride intracellular channel 2 
(CLIC2), mRNA 
0.02756 2.50 
NM_001076867.1  Bos taurus ubiquitin specific peptidase 16 
(USP16), mRNA 
0.02283 2.41 
XM_001254235.2  PREDICTED: Bos taurus similar to Tubulin, 
alpha 1, transcript variant 1 (LOC787568), 
mRNA 
0.02604 2.41 
NM_001098131.1  Bos taurus ribosomal protein L22-like 1 
(RPL22L1), mRNA 
0.04917 2.41 
NM_001102531.1  Bos taurus RAP2B, member of RAS oncogene 
family (RAP2B), mRNA 
0.01492 2.41 
XM_584555.4  PREDICTED: Bos taurus similar to nuclear pore 
complex-associated protein TPR, transcript 
variant 1 (TPR), mRNA 
0.04555 2.41 
XM_580963.3  PREDICTED: Bos taurus similar to TBP-
associated factor 1 (TAF1), mRNA 
0.01076 2.41 
NM_001034398.1  Bos taurus solute carrier family 29 (nucleoside 
transporters), member 1 (SLC29A1), nuclear 
gene encoding mitochondrial protein, mRNA 
0.04353 2.41 
NM_001075121.1  Bos taurus eukaryotic translation elongation 
factor 2 (EEF2), mRNA 
0.01478 2.41 
NM_001046594.1  Bos taurus pituitary tumor-transforming 1 





XM_864599.3  PREDICTED: Bos taurus similar to splicing 
factor, arginine/serine-rich 12, transcript variant 
2 (SFRS12), mRNA 
0.00418 2.41 
NM_001034528.1  Bos taurus transmembrane protein 86B 
(TMEM86B), mRNA 
0.04554 2.38 
XM_001249420.1  PREDICTED: Bos taurus similar to jumonji 
domain containing 1C, transcript variant 2 
(JMJD1C), mRNA 
0.02585 2.38 
XM_001250793.2  PREDICTED: Bos taurus similar to small 
nuclear ribonucleoprotein polypeptide G 
(SNRPG), mRNA 
0.04243 2.38 
NM_001100319.1  Bos taurus ubiquitin specific peptidase 4 (proto-
oncogene) (USP4), mRNA 
0.03189 2.38 
NM_001034504.1  Bos taurus high mobility group nucleosomal 
binding domain 3 (HMGN3), mRNA 
0.01764 2.38 
NM_001076219.1  Bos taurus Yip1 domain family, member 3 
(YIPF3), mRNA 
0.03889 2.32 
NM_001076104.1  Bos taurus nuclear factor I/B (NFIB), mRNA 0.00833 2.32 
NM_001101198.1  Bos taurus chromobox homolog 3 (HP1 gamma 
homolog, Drosophila) (CBX3), mRNA 
0.02541 2.32 
NM_174778.1  Bos taurus ribosomal protein S27a (RPS27A), 
mRNA 
0.02806 2.32 
XM_617685.4  PREDICTED: Bos taurus similar to tousled-like 
kinase 1 (TLK1), mRNA 
0.02889 2.32 
NM_001038647.1  Bos taurus transmembrane protein 57 
(TMEM57), mRNA 
0.00809 2.27 
NM_001037142.1  Bos taurus catenin, beta interacting protein 1 
(CTNNBIP1), mRNA 
0.04481 2.27 
NM_001034674.1  Bos taurus ribosomal protein L14 (RPL14), 
mRNA 
0.01643 2.27 
NM_205799.1  Bos taurus lysosomal protein transmembrane 4 
alpha (LAPTM4A), mRNA 
0.03764 2.27 
NM_001002883.2  Bos taurus ST3 beta-galactoside alpha-2,3-
sialyltransferase 6 (ST3GAL6), mRNA 
0.03361 2.27 
XM_001788161.1  PREDICTED: Bos taurus similar to putative 
utrophin (LOC534358), mRNA 
0.00966 2.22 
XM_865008.3  PREDICTED: Bos taurus similar to Protein 
LAP2 (Erbb2-interacting protein) (Erbin) 
(Densin-180-like protein), transcript variant 3 
(ERBB2IP), mRNA 
0.00857 2.17 
XM_594174.3  PREDICTED: Bos taurus NOL1/NOP2/Sun 
domain family, member 2 (NSUN2), mRNA 
0.01622 2.12 
XM_590469.4  PREDICTED: Bos taurus similar to RAS 






XM_591153.4  PREDICTED: Bos taurus similar to pleckstrin 
homology domain containing, family B 
(evectins) member 2 (LOC513469), mRNA 
0.02690 2.12 
NM_001046142.1  Bos taurus general transcription factor IIB 
(GTF2B), mRNA 
0.01959 2.12 
NM_001076113.1  Bos taurus ribosomal modification protein 
rimK-like family member B (RIMKLB), mRNA 
0.01976 2.08 
NM_001034360.1  Bos taurus dolichyl-phosphate 
mannosyltransferase polypeptide 3 (DPM3), 
mRNA 
0.04680 2.08 
NM_001099859.1  Bos taurus eukaryotic translation initiation 
factor 4 gamma, 2 (EIF4G2), mRNA 
0.03340 2.04 
NM_001034421.1  Bos taurus RAB5-interacting protein (RIP5), 
mRNA 
0.03586 2.04 
NM_001075982.1  Bos taurus MAPK scaffold protein 1 
(MAPKSP1), mRNA 
0.02002 2.04 
XR_027860.2  PREDICTED: Bos taurus misc_RNA 
(LOC510487), miscRNA 
0.02833 2.00 
NM_001040516.1  Bos taurus ribosomal protein L19 (RPL19), 
mRNA 
0.03902 2.00 
NM_001015640.2  Bos taurus myosin regulatory light chain 
MRCL3 (MRCL3), mRNA 
0.01077 2.00 
NM_001075983.1  Bos taurus matrix metallopeptidase 19 
(MMP19), mRNA 
0.00020 -2.12 
XR_028120.2  PREDICTED: Bos taurus misc_RNA 
(LOC518495), miscRNA 
0.00054 -2.08 
XM_866155.3  PREDICTED: Bos taurus similar to proline-
serine-threonine phosphatase interacting protein 
1, transcript variant 2 (PSTPIP1), mRNA 
0.00105 -2.26 
NM_001075540.1  Bos taurus hydroxyacylglutathione hydrolase-
like (HAGHL), mRNA 
0.00182 -2.24 
NM_001035088.1  Bos taurus dehydrogenase/reductase (SDR 
family) member 11 (DHRS11), mRNA 
0.00284 -2.02 
NM_001045884.2  Bos taurus adaptor-related protein complex 1, 
mu 1 subunit (AP1M1), mRNA 
0.00341 -2.27 
XR_027682.2  PREDICTED: Bos taurus misc_RNA 
(LOC509550), miscRNA 
0.00343 -2.06 
NM_001024514.1  Bos taurus zinc finger, CCCH-type with G patch 
domain (ZGPAT), mRNA 
0.00368 -2.18 
XM_001250409.1  PREDICTED: Bos taurus similar to Eukaryotic 
translation initiation factor 4E type 2 (eIF4E type 
2) (eIF-4E type 2) (mRNA cap-binding protein 
type 3) (Eukaryotic translation initiation factor 
4E-like 3) (Eukaryotic translation initiation 






NM_001101280.1  Bos taurus TNF receptor-associated factor 4 
(TRAF4), mRNA 
0.00430 -2.12 
XM_864253.3  PREDICTED: Bos taurus similar to erythroid 
differentiation-related factor 1, transcript variant 
2 (LOC534065), mRNA 
0.00525 -2.61 
XM_618409.4  PREDICTED: Bos taurus similar to glycine N-
methyltransferase, transcript variant 1 (GNMT), 
mRNA 
0.00530 -2.29 
XM_001254499.2  PREDICTED: Bos taurus similar to NCK 
interacting protein with SH3 domain, transcript 
variant 1 (NCKIPSD), mRNA 
0.00785 -2.24 
XM_001253142.1  PREDICTED: Bos taurus similar to Kinase 
suppressor of Ras 2 (hKSR2) (LOC784995), 
mRNA 
0.00861 -2.05 
NM_001075134.1  Bos taurus glycine C-acetyltransferase (2-
amino-3-ketobutyrate coenzyme A ligase) 
(GCAT), nuclear gene encoding mitochondrial 
protein, mRNA 
0.00875 -2.07 
NM_001080288.1  Bos taurus solute carrier family 13 (sodium-
dependent dicarboxylate transporter), member 3 
(SLC13A3), mRNA 
0.00929 -2.00 
XM_001788131.1  PREDICTED: Bos taurus similar to cytochrome 
P450, family 2, subfamily J (LOC100140018), 
mRNA 
0.01023 -2.21 
XM_580939.4  PREDICTED: Bos taurus similar to solute 
carrier family 25, member 28 (LOC538529), 
mRNA 
0.01047 -2.42 
NM_001103286.1  Bos taurus glyceronephosphate O-
acyltransferase (GNPAT), mRNA 
0.01157 -2.13 
XM_001790246.1  PREDICTED: Bos taurus obscurin-like 1 
(OBSL1), mRNA 
0.01448 -2.09 
NM_001075629.1  Bos taurus procollagen C-endopeptidase 
enhancer 2 (PCOLCE2), mRNA 
0.01504 -2.46 
NM_001083394.1  Bos taurus lipolysis stimulated lipoprotein 
receptor (LSR), mRNA 
0.01515 -2.04 
NM_001024487.1  Bos taurus peptidase inhibitor 16 (PI16), mRNA 0.01537 -2.11 
XM_864270.2  PREDICTED: Bos taurus similar to Interferon-
inducible protein (LOC613464), mRNA 
0.01577 -2.20 
XM_587039.3  PREDICTED: Bos taurus complement 
component 1, q subcomponent, C chain, 
transcript variant 1 (C1QC), mRNA 
0.01715 -2.32 
XM_001789528.1  PREDICTED: Bos taurus similar to 
Serine/threonine-protein kinase LMTK3 
precursor (Lemur tyrosine kinase 3) 
(LOC100140306), partial mRNA 
0.01734 -2.04 




XM_618475.4  PREDICTED: Bos taurus similar to Src 
homology 2 domain containing adaptor protein B 
(SHB), mRNA 
0.01810 -2.53 
XM_591615.4  PREDICTED: Bos taurus similar to TBC1 
domain family, member 10B, transcript variant 1 
(TBC1D10B), mRNA 
0.01869 -2.25 
NM_001076830.1  Bos taurus Rho GTPase activating protein 10 
(ARHGAP10), mRNA 
0.01914 -2.18 
XM_867736.3  PREDICTED: Bos taurus similar to EPB41L1 
protein, transcript variant 2 (EPB41L1), mRNA 
0.02015 -2.32 
NM_001114976.1  Bos taurus selenoprotein N, 1 (SEPN1), mRNA 0.02158 -2.01 
XM_864753.3  PREDICTED: Bos taurus similar to Potassium-
transporting ATPase subunit beta (Proton pump 
beta chain) (Gastric H(+)/K(+) ATPase subunit 
beta) (gp60-90), transcript variant 1 (ATP4B), 
mRNA 
0.02162 -2.32 
NM_001102351.1  Bos taurus butyrophilin-like 2 (MHC class II 
associated) (BTNL2), mRNA 
0.02321 -2.48 
NM_001110445.1  Bos taurus Purkinje cell protein 4 like 1 
(PCP4L1), mRNA 
0.02385 -2.15 
NM_001040486.1  Bos taurus solute carrier family 38, member 3 
(SLC38A3), mRNA 
0.02393 -2.03 
NM_181028.2  Bos taurus cellular retinoic acid binding protein 
1 (CRABP1), mRNA 
0.02453 -2.66 
NM_001075598.2  Bos taurus DDHD domain containing 2 
(DDHD2), mRNA 
0.02515 -2.58 
NM_001034697.1  Bos taurus tubulin, beta 4 (TUBB4), mRNA 0.02585 -2.97 
XM_617909.4  PREDICTED: Bos taurus similar to PHD finger 
protein 2 (PHF2), mRNA 
0.02640 -2.82 
XR_028567.2  PREDICTED: Bos taurus misc_RNA 
(LOC615842), miscRNA 
0.02667 -2.17 
XR_028705.2  PREDICTED: Bos taurus misc_RNA 
(LOC507766), miscRNA 
0.02709 -2.00 
NM_001143862.1  Bos taurus LSM7 homolog, U6 small nuclear 
RNA associated (S. cerevisiae) (LSM7), mRNA 
0.02782 -2.23 
NM_174251.1  Bos taurus biliverdin reductase B (flavin 
reductase (NADPH)) (BLVRB), mRNA 
0.02817 -3.11 
NM_001046021.1  Bos taurus CD1b molecule (CD1B), mRNA 0.02830 -3.04 
NM_001102295.1  Bos taurus transmembrane 6 superfamily 
member 1 (TM6SF1), mRNA 
0.02853 -2.37 
NM_175808.2  Bos taurus cleavage and polyadenylation 
specific factor 2, 100kDa (CPSF2), mRNA 
0.02982 -2.54 
NM_001102212.1  Bos taurus triple functional domain (PTPRF 
interacting) (TRIO), mRNA 
0.02988 -2.01 
NM_001103183.1  Bos taurus polymerase (DNA-directed), delta 





NM_001098972.1  Bos taurus G patch domain containing 3 
(GPATCH3), mRNA 
0.03019 -2.53 
NM_001100337.1  Bos taurus exostoses (multiple)-like 1 (EXTL1), 
mRNA 
0.03020 -2.19 
NM_174277.2  Bos taurus clathrin, light polypeptide B (light 
chain B) (CLTLB), mRNA 
0.03088 -2.18 
NM_001114513.1  Bos taurus chromosome 10 open reading frame 
116 ortholog (C28H10ORF116), mRNA 
0.03138 -2.04 
NM_001024549.2  Bos taurus Ras association (RalGDS/AF-6) 
domain family (N-terminal) member 8 
(RASSF8), mRNA 
0.03163 -2.46 
NM_001098037.1  Bos taurus RecQ protein-like 4 (RECQL4), 
mRNA 
0.03181 -2.05 
XM_873628.2  PREDICTED: Bos taurus similar to UDP 
glucuronosyltransferase 2 family, polypeptide 
B4, transcript variant 2 (UGT2B4), mRNA 
0.03263 -2.02 
XM_870302.2  PREDICTED: Bos taurus similar to interleukin 
21 receptor (IL21R), mRNA 
0.03277 -2.36 
NM_001110004.1  Bos taurus HECT, UBA and WWE domain 
containing 1 (HUWE1), mRNA 
0.03281 -2.57 
NM_001079649.1  Bos taurus cysteine-rich protein 2 (CRIP2), 
mRNA 
0.03336 -2.08 
NM_001081609.1  Bos taurus transmembrane emp24 protein 
transport domain containing 3 (TMED3), mRNA 
0.03466 -2.56 
NM_001144082.1  Bos taurus DAB2 interacting protein (DAB2IP), 
mRNA 
0.03508 -2.38 
NM_173991.2  Bos taurus apolipoprotein E (APOE), mRNA 0.03818 -2.03 
NM_001102068.1  Bos taurus phosphodiesterase 7B (PDE7B), 
mRNA 
0.03837 -2.52 
XM_875593.2  PREDICTED: Bos taurus similar to chloride 
channel 3, transcript variant 4 (CLCN3), mRNA 
0.04025 -2.01 
XM_865879.2  PREDICTED: Bos taurus myosin, heavy chain 
8, skeletal muscle, perinatal, transcript variant 2 
(MYH8), mRNA 
0.04045 -3.12 
XR_027344.2  PREDICTED: Bos taurus misc_RNA 
(LOC781850), miscRNA 
0.04137 -2.16 
NM_001034792.1  Bos taurus suppressor of Ty 4 homolog 1 (S. 
cerevisiae) (SUPT4H1), mRNA 
0.04173 -2.05 
NM_001075302.1  Bos taurus heat shock 105kDa/110kDa protein 1 
(HSPH1), mRNA 
0.04238 -3.11 
NM_001045877.1  Bos taurus bone morphogenetic protein 4 
(BMP4), mRNA 
0.04262 -2.26 
NM_001075834.1  Bos taurus nicotinamide nucleotide 
adenylyltransferase 1 (NMNAT1), mRNA 
0.04279 -2.20 
NM_001046552.1  Bos taurus chromosome 20 open reading frame 





NM_001083525.1  Bos taurus GTPase activating Rap/RanGAP 
domain-like 1 (GARNL1), mRNA 
0.04535 -2.01 
XM_604345.4  PREDICTED: Bos taurus matrix 
metallopeptidase 16 (membrane-inserted) 
(MMP16), mRNA 
0.04552 -2.02 
NM_174627.1  Bos taurus TYRO protein tyrosine kinase 
binding protein (TYROBP), mRNA 
0.04845 -3.13 
XM_588427.3  PREDICTED: Bos taurus similar to cell division 
cycle 2-like 5, transcript variant 3 (CDC2L5), 
mRNA 
0.04958 -3.13 
XM_871071.2  PREDICTED: Bos taurus similar to deleted in 






Appendix Table 5.  The 387 genes (partial list) enriched in LRECb vs. ECb and their 





Cancer (75) ABP1, ADH1C, ATP8B1, BAMBI, BRAF, CASP1, CCR4, CD33, 
CD3E, CD8A, CDK6, CPA4, CXCR4, DNM1L, DPYD, DRD2, EXO1, 
FAM134B, FAM149B1, FGF1, FGF2, FGF10, FLII, FST, FXYD3, 
GCH1, GRINL1A, HAVCR1, HDAC7, HIF1A, HNF4A, HPGD, HRH1, 
HSD17B6, IGFBP1, ISOC1, KIF20B, KLHL20, KNG1, LAMC2, 
LMBRD1, MAPK8, MAPT, MORC2, MRVI1, MSH6, MSMB, 
MYD88, NLGN1, NRIP1, NUP107, OSMR, PLAT, PLG, PPP1R3C, 
PPPDE1, PRKCB, PSAT1, RBM15, REV3L, RGS1, RGS4, RPS11, 
RTN1, SAT2, SDPR, SERPINA3, SOSTDC1, TCN1, TERF1, TNNT3, 
TUBE1, UBE2D1, WEE1, ZC3H13 
Inflammatory 
disease (82) 
ACTA1, AGPS, AK5, ASB7, ATP8B1, AUH, C12ORF35, C13ORF34, 
C1QTNF6, C1QTNF7, C9ORF150, CASP1, CCDC11, CCL8, CCR4, 
CD33, CD3E, CD8A, CDK6, CELA2A, COL4A3, CTNS, CXCR4, 
CYFIP1, DPYD, DRD2, EAF1, ESD, F5, FAM69A, FETUB, FGF2, 
FGF10, GBA3, GCA, GLIPR2, GLRB, HAVCR1, HDAC7, HLA-
DQA2, HPGD, HRH1, JARID2, KIAA0247, KLHL20, KLRB1, KNG1, 
KYNU, LAMC2, LUZP2, MAGI1, MAN2A1, MAPT, MBOAT1, 
MYD88, NLGN1, NMT2, NR5A2, NT5C3, NUP153, OSMR, PAM, 
PLAT, PLEKHA2, PLG, PLXDC2, PPA1, PRKCB, PWP1, RAMP1, 
RSBN1, S100A12, SERPINA3, SLC25A24, SPAG1, TAOK3, TCF12, 





AGPS, ATP5A1, BRAF, CASP1, CASR, CD33, CD3E, CD8A, CDK6, 
COL4A3, CRTAM, CXCR4, CYP2C9, DRD2, FGF1, FGF2, FGF10, 
FST, GCNT1, GNE, GRB14, HAVCR1, HDAC7, HIF1A, HNF4A, 
HPGD, HRH1, IGFBP1, IL22RA1, KNG1, LATS1, MAPK8, MAPT, 
MSMB, MYD88, MYH14, NFE2, NRIP1, NT5C3, PLAT, PLG, 
PRKCB, RGS4, RGS16, SIRT1, SIRT2, SYNM, TCF12, TERF1 
Organism 
Survival (30) 
ADH1C, BRAF, BRD4, CASP1, CASR, CCR4, CD3E, CD8A, CDK6, 
COL4A3, CXCR4, DRD2, FGF2, FLII, GCH1, HIF1A, HRH1, LTBP2, 
MAN2A1, MAPK8, MEF2C, MSH6, MYD88, NCAPG2, NFE2, 
NR5A2, PLAT, PLG, REV3L, TCF12 
Cell Cycle 
(29) 
ASPM, BRAF, BRD4, CD320, CD3E, CDK6, CKAP2, CLIP1, CSE1L, 
DNM1L, FGF1, FGF2, FGF10, HAVCR1, HIF1A, HPGD, JARID2, 
KIF20B, KNG1, LATS1, MAPK8, MYH14, PLG, PPP2R3A, PRKCB, 





CASP1, CD33, CD3E, CD8A, CDK6, CLPX, CSRP2BP, DUSP11, 
DUSP12, ERCC8, FGF1, FGF2, KNG1, MAPT, MTMR7, NMT2, 
PAM, PLAT, PPEF1, SIRT1, SIRT2, ST3GAL6, SULT1B1, UBE2D1, 
WWP1 




(16) HNF4A, KNG1, MAPT, MRVI1, PLG, PRKCB, RGS1 
Angiogenesis 
(14) 
COL4A3, CXCR4, DRD2, FGF1, FGF2, FGF10, GCH1, HIF1A, 
KLHL20, KNG1, MEF2C, PLAT, PLG, RBM15 















Appendix Figure 2.  IPA figure legend 







Appendix Table 6. Transcripts of cell surface protein that were upregulated in LRECb 
vs. ECb 
(*All genes listed are expressed at higher level in LRECb) 
 
Symbol Gene name Fold 
change* 
SAT2 Spermidine/spermine N1-acetyltransferase family 
member 2  
4.34 
IL22RA1 Interleukin 22 receptor, alpha 1 4.34 
CXCR4 Chemokine (C-X-C motif) receptor 4 4 
SDPR Serum deprivation response 3.57 
RTP3 Receptor (chemosensory) transporter protein 3 3.44 
RGS1 Regulator of G-protein signaling 1 3.33 
CRB1 Crumbs homolog 1 (Drosophila) 3.22 
CASR Calcium-sensing receptor 3.12 
DRD2 Dopamine receptor D2 3.12 
HAVCR1 Hepatitis A virus cellular receptor 1 3.12 
GNGT1 Guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 1 
2.94 
RARRES1 Retinoic acid receptor responder (tazarotene induced) 1 2.94 
CCR4 Chemokine (C-C motif) receptor 4 2.77 
FXYD3 FXYD domain containing ion transport regulator 3 2.7 
GRB14 Growth factor receptor-bound protein 14 2.63 
GLRB Glycine receptor, beta 2.56 
F5 Coagulation factor V (proaccelerin, labile factor) 2.56 
ATP8B1 ATPase, class I, type 8B, member 1 2.56 
CD8A CD8A molecule 2.5 
MAGI1 Membrane associated guanylate kinase, WW and PDZ 
domain containing 1 
2.43 
NLGN1 Neuroligin 1 2.38 
P2RY14 Purinergic receptor P2Y, G-protein coupled, 14 2.38 
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